Gaucher Disease

🏷

Classifications

Lysosomal Storage

ICIMD (Inherited Metabolic Disorders)

📘

Definitions

1

Orphanet disease definition

Orphanet defines Gaucher disease as a lysosomal storage disorder spanning three main forms plus fetal and cardiac-involvement variants.

OTHER Orphanet structured disease record for ORPHA:355

Show evidence (1 reference)

ORPHA:355 SUPPORT Other

"Gaucher disease (GD) is a lysosomal storage disorder encompassing three main forms (types 1, 2 and 3), a fetal form and a variant with cardiac involvement (Gaucher disease - ophthalmoplegia - cardiovascular calcification or Gaucher-like disease)."

Orphanet defines Gaucher disease as a lysosomal storage disorder with the major clinical forms represented in this entry.

👪

Inheritance

1

Autosomal recessive HP:0000007

When both parents are heterozygous for pathogenic GBA1 variants, each pregnancy has a 25% affected, 50% heterozygous, and 25% noncarrier probability; these figures do not apply unchanged when a parent is biallelic.

Autosomal recessive

Show evidence (2 references)

ORPHA:355 SUPPORT Other

"Autosomal recessive"

Orphanet lists autosomal recessive inheritance for Gaucher disease.

PMID:20301446 SUPPORT Human Clinical

"If both parents are known to be heterozygous for a GBA1 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being a heterozygote, and a 25% chance of inheriting neither of the familial GBA1 pathogenic variants."

Specifies the parental-genotype condition for Mendelian recurrence probabilities.

◆

Subtypes

5

Type 1 (Non-neuronopathic) MONDO:0009265

GBA1 hgnc:4177

Non-neuronopathic form, comprising about 90% of diagnosed cases in Europe and the USA but a smaller fraction in some other regions. Visceral, hematologic, and skeletal severity varies greatly; absence of primary childhood CNS disease does not exclude later Parkinson disease risk.

Show evidence (1 reference)

PMID:28218669 SUPPORT

"Type-1 Gaucher disease, which affects the majority of patients (90% in Europe and USA, but less in other regions), is characterized by effects on the viscera"

Review confirms Type 1 is the most common form with visceral manifestations.

Type 2 (Acute neuronopathic) MONDO:0009266

GBA1 hgnc:4177

Acute neuronopathic form with primary CNS disease beginning before age two years, limited psychomotor development, and rapid progression. Death commonly occurs by age two to four years; systemic ERT does not correct the CNS disease.

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"Type 2 GD is characterized by primary central nervous system disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years."

GeneReviews defines the broader onset and survival range; onset before six months and death by two years are not universal.

Type 3 (Chronic neuronopathic) MONDO:0009267

GBA1 hgnc:4177

Chronic neuronopathic form with both systemic and neurological involvement. Onset in childhood with slower neurological progression than Type 2. Hallmark feature is horizontal supranuclear gaze palsy. May also develop myoclonic epilepsy and cognitive decline. Survival into adulthood.

Show evidence (1 reference)

PMID:28218669 SUPPORT

"types 2 and 3 are also associated with neurological impairment, either severe in type 2 or variable in type 3"

Review confirms Type 3 has variable neurological involvement distinct from severe Type 2.

Perinatal lethal MONDO:0011945

GBA1 hgnc:4177

Perinatal presentation with skin-barrier disease and/or nonimmune hydrops fetalis.

Show evidence (3 references)

PMID:42165577 SUPPORT BACKGROUND Human Clinical

"Gaucher disease is a rare lysosomal storage disease caused by mutations in the GBA gene, resulting in the accumulation of glucosylceramides in macrophages. The perinatal/lethal form, also including fetal Gaucher disease, is a distinct and severe variant"

Places the perinatal/lethal form inside GBA-caused Gaucher disease, supporting the GBA1 gene binding on this subtype row. The quoted sentences are the series' background framing rather than its own finding.

PMID:42165577 SUPPORT PRIMARY RESULT Human Clinical

"Further reporting of genotype-phenotype correlations is necessary in cases of fetal/perinatal Gaucher disease."

Sources the note above that no perinatal-lethal-specific genotype is established, rather than asserting an absence this entry never searched.

PMID:20301446 SUPPORT Human Clinical

"The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis."

GeneReviews recognizes this clinical form in addition to types 1–3.

Cardiovascular MONDO:0009268

GBA1 hgnc:4177

Cardiovascular form, often associated with p.Asp448His (legacy D409H), featuring valvular calcification, corneal opacity, and supranuclear ophthalmoplegia.

Show evidence (2 references)

PMID:8544197 SUPPORT PRIMARY RESULT Human Clinical

"Genotype analysis indicated that the patient was homozygous for the D409H mutation. It is tempting to relate the phenotype of severe cardiac involvement to the D409H/D409H genotype, although further cases will be needed before this association can be confirmed."

The sib series that tied the cardiovascular form to homozygous GBA1 D409H, and states its own hedge, which is why this row says "often associated with" rather than asserting the genotype defines the form.

PMID:20301446 SUPPORT Human Clinical

"The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia."

GeneReviews recognizes this clinical form in addition to types 1–3.

◈

Mechanistic Hypotheses

3

Canonical GBA1 Glucocerebroside Lysosomal Storage Model

canonical_gba1_glucocerebroside_lysosomal_storage_model CANONICAL

Evidence balance 2 support

Biallelic GBA1 pathogenic variants reduce lysosomal glucocerebrosidase activity and impair glucosylceramide and glucosylsphingosine degradation. Macrophage lipid storage, inflammatory amplification, and altered skeletal remodeling contribute to visceral, hematologic, and skeletal disease. Neuronopathic forms additionally involve neuronal and glial lipid homeostasis and injury; their CNS biology is not explained by macrophage infiltration alone. ERT and substrate reduction strongly support the systemic storage pathway, while individual toxic intermediates and CNS mechanisms require separate evidence.

The OpenScientist report is assessed twice beside the report, in assessments/openscientist-assessment-by-codex.yaml (overall PARTIALLY_SUPPORTED) and assessments/openscientist-assessment-by-claude-opus-5.yaml (overall SUPPORTED); both endorse keeping CANONICAL for the core axis, and the verdicts differ on how much of the report beyond that core is carried. Retain CANONICAL for the GBA1 enzyme/substrate axis. Glucosylsphingosine, complement signaling, bone-cell interactions, and lipid-reactive gammopathy refine that axis. Biomarker association does not prove that glucosylsphingosine is the dominant toxin, and therapy response does not identify every intervening mechanism. GBA1-associated Parkinson disease is a risk branch distinct from acute/chronic neuronopathic Gaucher disease. ER stress predominance and comparative CNS treatment efficacy remain unresolved.

Deep research

OpenScientist citations 25 citations 2026-05-23T16:21:07.173425

Show evidence (2 references)

PMID:10464619 SUPPORT Human Clinical

"the presence of a single N370S allele is diagnostic of the type 1 or nonneuronopathic"

Canonical mechanism review used as the seed reference for the hypothesis-search deep-research run.

PMID:36739645 SUPPORT INDIRECT Human Clinical

"Organ volumes and hematologic parameters improved in parallel with reductions in plasma glucosylsphingosine during eliglustat treatment in both trials."

Treatment-linked substrate and clinical responses support the canonical pathway without proving mediator-specific causation.

Complement amplification of lipid storage

complement_amplification EMERGING

Evidence balance 1 support

A C5a/C5aR1-dependent inflammatory and substrate-synthesis feedback circuit extends the canonical storage mechanism. Intervention support comes from experimental systems, and therapeutic benefit in Gaucher patients remains unestablished.

Pathograph links

Glucocerebroside Accumulation in Macrophages -> Complement C5aR1 Activation INDIRECT KNOWN INTERMEDIATES Stored lipid and lipid-reactive antibodies can activate complement in experimental Gaucher disease. Intermediates: lipid-reactive IgG; complement cleavage and C5a generation

Complement C5aR1 Activation -> Increased Glucosylceramide Synthesis DIRECT C5aR1 signaling increases glucosylceramide synthase production.

Complement C5aR1 Activation -> Macrophage Inflammatory Mediator Release INDIRECT UNKNOWN INTERMEDIATES Complement signaling enhances inflammatory-cell recruitment and cytokine production.

Increased Glucosylceramide Synthesis -> Glucocerebroside Accumulation in Macrophages INDIRECT KNOWN INTERMEDIATES Increased substrate synthesis adds to accumulation when degradation is deficient. Intermediates: synthesis exceeds residual lysosomal clearance

Show evidence (1 reference)

PMID:28225753 SUPPORT Model Organism

"Marked local and systemic complement activation occurred in GCase-deficient mice or after pharmacological inhibition of GCase and was associated with GC storage, tissue inflammation and proinflammatory cytokine production."

Both genetic and pharmacological mouse systems support complement activation; this does not demonstrate clinical efficacy of complement inhibition.

Innate immune activation by stored glucosylceramide

stored_lipid_immune_activation EMERGING

Evidence balance 1 support

Stored or released glucosylceramide can activate Mincle-dependent myeloid inflammation. Experimental receptor and ligand results support a mechanism beyond passive storage, without establishing human clinical effect sizes.

Pathograph links

Glucocerebroside Accumulation in Macrophages -> Mincle-Dependent Lipid Sensing INDIRECT KNOWN INTERMEDIATES Exposed glucosylceramide can act as an endogenous Mincle ligand in experimental myeloid systems. Intermediates: release or exposure of cellular glucosylceramide

Mincle-Dependent Lipid Sensing -> Macrophage Inflammatory Mediator Release DIRECT Mincle-dependent myeloid signaling induces inflammatory cytokine production in vitro.

Show evidence (1 reference)

PMID:28373578 SUPPORT In Vitro

"Synthetic β-GlcCer activated myeloid cells and induced production of inflammatory cytokines; this production was abrogated in Mincle-deficient cells."

Ligand and receptor-loss assays support Mincle-dependent cytokine induction; human Gaucher contribution is not established.

?

Discussions and Knowledge Gaps

3

Which lipid-dependent and secondary processes determine neuronal, vascular, skin, and malignant complications?

KNOWLEDGE GAP unresolved_tissue_injury

Attached to

pathophysiology#Glucosylsphingosine Accumulation phenotypes#Multiple Myeloma phenotypes#Lung Disease has_subtypes#Perinatal lethal has_subtypes#Cardiovascular

The canonical substrate defect is established, but circulating GlcSph associations do not prove dominant tissue toxicity. Gammopathy and cancer associations do not establish the entire malignant-transformation chain. Perinatal skin/hydrops, valvular calcification, and pulmonary vascular versus infiltrative disease are represented clinically without unsupported mechanistic arrows. Prospective substrate-guided skeletal studies, lipid/ER-stress measurements in cell-resolved models, and longitudinal B-cell clonality studies would discriminate candidate explanations.

Show evidence (2 references)

PMID:37249220 SUPPORT Human Clinical

"There was a significant correlation between GlcSph levels and AVN."

Correlation motivates mechanistic and prospective testing, rather than proving direct mediation.

PMID:36054609 SUPPORT Human Clinical

"The 10-year cumulative incidence of MM after diagnosis of MGUS was 7.9%, comparable to the general population."

Increased gammopathy prevalence is distinguishable from an increased MGUS-to-myeloma progression rate.

How does lipid storage relate to the ALPS-like lymphocyte/apoptosis phenotype in a subset of patients?

KNOWLEDGE GAP selected_alps_like_immune_phenotype

Attached to

pathophysiology#Lysolipid-Reactive B-Cell Stimulation pathophysiology#Macrophage Inflammatory Mediator Release

In a 41-patient cohort, 10 had ALPS-like immune features and seven of those ten showed defective FAS-induced apoptosis. This selected subgroup supports an additional immune phenotype but does not establish universal FAS dysfunction or the missing lipid-to-apoptosis mechanism.

Show evidence (1 reference)

PMID:32702516 SUPPORT In Vitro

"FAS-induced apoptosis and caspase activation were further evaluated in these 10 patients and were found to be defective in 7 of them."

The measured apoptosis defect is conditional on the selected ALPS-like subgroup.

Does glucosylceramide or glucosylsphingosine actually accumulate in the brains of people with GBA1-associated Parkinson disease, or is that branch driven by misfolded GCase protein independently of substrate storage?

KNOWLEDGE GAP OPEN gap_gd_brain_substrate_in_gba1_parkinson

Attached to

pathophysiology#GBA1-Associated Alpha-Synuclein Proteostasis pathophysiology#Neuronal Glycosphingolipid Accumulation

This entry models the Parkinson disease branch as flowing from reduced GCase activity and mutant GCase handling through impaired alpha-synuclein turnover, in parallel with the substrate accumulation that drives the other branches. Reviewers of the GBA1-Parkinson literature report that substrate accumulation has not been convincingly demonstrated in GBA1-Parkinson brains, and propose instead that misfolded GCase induces endoplasmic reticulum stress and an unfolded protein response that impairs the autophagy-lysosomal pathway. If that is right, the branch is a gain-of-function proteotoxicity operating alongside rather than downstream of the storage chain, and it predicts different therapeutic priorities: chaperone stabilization over substrate reduction. The absence is scoped to GBA1-Parkinson brains and does not transfer to neuronopathic types 2 and 3, where neuronal glucosylsphingosine accumulation is documented. This is the ER-stress question left unresolved in the canonical hypothesis notes. The stronger reading, that this absence proves gain-of-function predominance, is rejected in the codex assessment of the OpenScientist report: bulk-brain absence does not prove absence in the relevant cells, and heterozygous GBA1-Parkinson disease cannot be conflated with biallelic neuronopathic Gaucher disease. What remains is the open question recorded here.

Proposed experiments

Region-resolved brain lipidomics in GBA1-associated Parkinson disease

exp_gd_gba1pd_brain_lipidomics

Mass spectrometry imaging of glucosylceramide and glucosylsphingosine in post-mortem GBA1-Parkinson brain, stratified by variant severity, region (substantia nigra, cortex, cerebellum) and disease stage, with paired endoplasmic reticulum stress markers and cell-type-resolved measurement separating neurons from glia.

Would support

pathophysiology#Neuronal Glycosphingolipid Accumulation

Supporting outcome

Glucosylceramide and glucosylsphingosine are elevated in affected regions and track alpha-synuclein pathology, placing the Parkinson branch downstream of substrate accumulation as the storage chain predicts.

Refuting outcome

Lipids are normal or minimally raised while endoplasmic reticulum stress markers are elevated, which would weaken the substrate-driven reading of this branch without by itself establishing that protein misfolding is the predominant mechanism.

No entity is listed in would_refute. The refuting outcome bears on whether neuronal glycosphingolipid accumulation extends to the Parkinson branch, which is the node already named in would_support; it does not refute the alpha-synuclein proteostasis node, whose description covers mutant GCase handling as well as reduced activity and is therefore compatible with an endoplasmic reticulum stress result.

Posed 2026-09-17T00:00:00Z

Show evidence (2 references)

PMID:37080432 SUPPORT Human Clinical

"Preclinical evidence also shows that products of GCase activity can promote accumulation of α-synuclein, however there is no convincing evidence of substrate accumulation in GBA1-PD brains."

States the absence directly for GBA1-Parkinson brains, and sets it against the preclinical evidence that would predict the opposite.

PMID:37080432 SUPPORT Human Clinical

"Misfolded GCase proteins induce endoplasmic reticulum stress and subsequent unfolded protein response and impair the autophagy-lysosomal pathway."

Names the competing gain-of-function mechanism that would explain the branch without substrate storage.

⚙

Pathophysiology

21

GBA1 Mutation

Biallelic GBA1 pathogenic variants reduce lysosomal glucocerebrosidase activity through catalytic loss, protein misfolding, or impaired delivery to the lysosome. Genotype severity helps shape the clinical path: at least one N370S allele is associated with non-neuronopathic disease, while L444P homozygosity is strongly associated with neuronopathic disease.

GBA1 hgnc:4177

Downstream

Glucocerebrosidase Deficiency GBA1 mutations reduce or abolish glucocerebrosidase enzyme activity.

Show evidence (1 reference)

PMID:10464619 SUPPORT Human Clinical

"the presence of a single N370S allele is diagnostic of the type 1 or nonneuronopathic variant, whereas the L444P/L444P genotype is highly associated with neuronopathic variants in the Caucasian population."

This genotype-phenotype review supports the mutation severity branch used in the pathograph.

Glucocerebrosidase Deficiency

Deficient beta-glucocerebrosidase (glucosylceramidase) enzyme activity resulting from GBA1 mutations.

GBA1 hgnc:4177

glucocerebrosidase activity GO:0004348 ↓ DECREASED

Downstream

Impaired Sphingolipid Catabolism Loss of glucocerebrosidase activity impairs lysosomal degradation of glucosylceramide.

Neuronal Glycosphingolipid Accumulation Very low residual GCase activity in severe genotypes permits neuronal glycosphingolipid storage.

GBA1-Associated Alpha-Synuclein Proteostasis Reduced GCase activity impairs lysosomal protein degradation and increases alpha-synuclein in experimental neuronal systems; this supports a possible Parkinson-risk mechanism rather than universal neuronopathic Gaucher pathology.

Stromal Inflammatory Secretome GCase-deficient stromal cells show lipid accumulation and altered mediator secretion in vitro.

Show evidence (1 reference)

PMID:28218669 SUPPORT

"It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages."

Review confirms glucocerebrosidase deficiency causes glucosylceramide accumulation in macrophages.

Impaired Sphingolipid Catabolism

Deficient glucocerebrosidase cannot degrade glucocerebroside (glucosylceramide) in lysosomes, leading to substrate accumulation.

Sphingolipid Catabolism GO:0030149 ↓ DECREASED

Downstream

Glucocerebroside Accumulation in Macrophages Undegraded glucosylceramide accumulates primarily in macrophages.

Glucosylsphingosine Accumulation GCase deficiency favors alternative conversion of glucosylceramide to glucosylsphingosine.

Glucocerebroside Accumulation in Macrophages

Glucocerebroside accumulates primarily in macrophages due to their role in phagocytosis and membrane turnover.

Complement amplification of lipid storage Innate immune activation by stored glucosylceramide

Macrophage CL:0000235

Downstream

Gaucher Cell Formation Lipid-laden macrophages become Gaucher cells.

Complement C5aR1 Activation Stored lipid and lipid-reactive antibodies can activate complement in experimental Gaucher disease.

Mincle-Dependent Lipid Sensing Exposed glucosylceramide can act as an endogenous Mincle ligand in experimental myeloid systems.

Gaucher Cell Formation

Lipid-laden macrophages (Gaucher cells) accumulate in spleen, liver, bone marrow, and other organs. These cells have characteristic crinkled tissue paper appearance and cause organ dysfunction through infiltration and inflammatory cytokine release.

Macrophage CL:0000235

Macrophage Activation GO:0042116 ↑ INCREASED

Downstream

Visceral Reticuloendothelial Infiltration Gaucher cells infiltrate spleen and liver, causing reticuloendothelial organ enlargement.

Bone Marrow Infiltration Gaucher cell infiltration of marrow disrupts hematopoietic space and contributes to cytopenias.

Macrophage Inflammatory Mediator Release Gaucher and activated monocyte/macrophage populations release cytokines, chemokines, chitotriosidase, and CCL18.

Bone Infarction Marrow Gaucher-cell accumulation may contribute to focal ischemic injury through vascular compression. This is a proposed route; inflammatory and mechanical factors may also contribute.

Show evidence (1 reference)

PMID:28218669 SUPPORT

"The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."

Review confirms Gaucher cell infiltration causes the major clinical manifestations.

Visceral Reticuloendothelial Infiltration

Gaucher cells accumulate in reticuloendothelial organs, especially spleen and liver, producing splenomegaly and hepatomegaly.

spleen UBERON:0002106 liver UBERON:0002107

Downstream

Hepatomegaly Liver infiltration by Gaucher cells enlarges the liver.

Splenomegaly Spleen infiltration by Gaucher cells enlarges the spleen.

Failure to Thrive Systemic disease burden may limit growth and weight gain in Type 1 disease.

Splenic Sequestration Enlarged, infiltrated spleen contributes to sequestration of blood cells.

Bone Marrow Infiltration

Gaucher macrophages occupy bone marrow and disturb the hematopoietic microenvironment. Marrow suppression and splenic sequestration both contribute to cytopenias; marrow involvement alone does not explain all hematologic disease.

hemopoiesis GO:0030097 ↓ DECREASED

bone marrow UBERON:0002371

Downstream

Thrombocytopenia Marrow infiltration and splenic involvement reduce circulating platelet counts.

Anemia Marrow infiltration contributes to reduced red-cell output and anemia.

Fatigue Cytopenias and systemic Gaucher disease burden can manifest as fatigue.

Macrophage Inflammatory Mediator Release

Gaucher disease includes activated monocyte/macrophage states and elevated inflammatory mediators, with chitotriosidase and CCL18 reflecting Gaucher cell burden and cytokines contributing to hematologic and skeletal disease.

Macrophage CL:0000235

inflammatory response GO:0006954 ↑ INCREASED macrophage activation GO:0042116 ↑ INCREASED

Downstream

Bone Remodeling Imbalance Inflammatory mediators stimulate bone resorption and contribute to skeletal disease.

Glucosylsphingosine Accumulation

GCase deficiency favors formation and accumulation of glucosylsphingosine (Lyso-Gb1), a soluble bioactive sphingolipid that contributes to neuronopathic toxicity and may also affect bone.

Sphingolipid Catabolism GO:0030149 ↓ DECREASED

Downstream

Neuronal Dysfunction and Loss Glucosylsphingosine is a candidate contributor to neuronal toxicity; the intervening injury processes and its relative importance versus other lipids remain incompletely established.

Bone Remodeling Imbalance Sphingolipid imbalance, including sphingosine generated from glucosylsphingosine metabolism, contributes to skeletal toxicity.

Lysolipid-Reactive B-Cell Stimulation Accumulated lysolipid can provide chronic antigenic stimulation.

Bone Remodeling Imbalance

Bone formation and resorption are imbalanced in Gaucher disease. Macrophage-derived mediators can enhance osteoclast differentiation and reduce osteoblast mineralization in experimental systems; structural infarction is modeled separately.

bone remodeling GO:0046849 ↕ DYSREGULATED

bone marrow UBERON:0002371

Experimental models

CBE-treated murine macrophage conditioned-medium model PRIMARY CELL CULTURE

Downstream

Bone Pain Skeletal infiltration, bone crises, and infarction cause recurrent bone pain.

Osteopenia Dysregulated Gaucher skeletal remodeling lowers bone mass and produces osteopenia.

Pathologic Fractures Low bone mass and disordered remodeling increase pathological fracture risk.

Erlenmeyer Flask Deformity Abnormal skeletal remodeling produces the characteristic distal femur deformity.

Show evidence (1 reference)

PMID:24076352 SUPPORT In Vitro

"In conclusion, these results suggest implication of changes in both bone formation and bone resorption and are consistent with the idea that both sides of the homeostatic balance are affected in GD."

A chemical murine cell model supports a remodeling mechanism, with translation to patient skeletal disease qualified.

Neuronal Glycosphingolipid Accumulation

In neuronopathic Gaucher disease, low GCase activity permits neuronal/glial glucosylceramide and glucosylsphingosine accumulation. Their relative contributions to neuronal injury are unresolved; CNS storage is not equivalent to visceral Gaucher-cell infiltration.

Neuron CL:0000540

brain UBERON:0000955

Downstream

Neuroinflammation Neuronal lipid storage and injury are accompanied by microgliosis and astrogliosis.

Neuronal Dysfunction and Loss Neuronal lipid toxicity causes neuronal dysfunction and death, producing oculomotor, bulbar, pyramidal, seizure, and developmental phenotypes.

Show evidence (2 references)

PMID:9497857 SUPPORT

"Severe deficiency of glucocerebrosidase caused by disabling mutations is additionally associated with neurological manifestations that in part reflect a failure to degrade endogenous neuronal glycosphingolipids"

Review explains that neuronopathic disease reflects failure to degrade neuronal glycosphingolipids.

PMID:28218669 SUPPORT

"the accumulation of glucosylsphingosine may cause neuronal dysfunction and death, leading mainly to GD-related neurological symptoms"

Review confirms glucosylsphingosine accumulation causes neuronal dysfunction and death.

Neuroinflammation

Microglial activation and neuroinflammation contribute to neurodegeneration in neuronopathic Gaucher disease.

Microglial cell CL:0000129

Neuroinflammatory Response GO:0150076 ↑ INCREASED

Animal models

Gba1 D409V with progranulin deficiency Mouse partially recapitulates

Downstream

Neuronal Dysfunction and Loss Activated microglia phagocytose impaired neurons in the Gba1 D409V/progranulin-null mouse model; the contribution to ordinary human neuronopathic disease remains qualified by the sensitized model.

Show evidence (1 reference)

PMID:30315684 SUPPORT

"A common feature appears to be microgliosis and subsequent astrogliosis and neuronal loss, particularly in hippocampal regions"

Review of postmortem and mouse model studies confirms microgliosis and astrogliosis as common neuropathological features in neuronopathic Gaucher disease.

Neuronal Dysfunction and Loss

Neuronopathic Gaucher disease progresses through neuronal dysfunction and loss in vulnerable CNS regions, producing supranuclear gaze palsy, bulbar dysfunction, pyramidal or extrapyramidal signs, seizures, myoclonus, and developmental impairment.

Neuron CL:0000540

brain UBERON:0000955

Downstream

Oculomotor Apraxia Dysfunction of neuronal circuits controlling saccades contributes to oculomotor apraxia in chronic neuronopathic disease; the clinical cohort does not identify the intervening circuit lesion.

Horizontal Supranuclear Gaze Palsy Chronic neuronopathic disease commonly affects horizontal supranuclear gaze.

Seizures Progressive neuronal dysfunction produces seizures and myoclonic epilepsy.

Myoclonus Chronic neuronopathic disease may progress to myoclonus epilepsy.

Dysphagia Bulbar dysfunction in acute neuronopathic disease causes swallowing impairment.

Spasticity Pyramidal tract involvement produces progressive spasticity and rigidity.

Global Developmental Delay Early neuronopathic injury alters psychomotor development.

Strabismus Oculomotor pathway involvement may present as bilateral fixed strabismus.

GBA1-Associated Alpha-Synuclein Proteostasis

Reduced GCase activity and mutant GCase handling perturb autophagy and alpha-synuclein turnover, creating a GBA1-linked Parkinson disease risk branch that overlaps with but is distinct from classic neuronopathic Gaucher disease.

Neuron CL:0000540

Sphingolipid Catabolism GO:0030149 ↓ DECREASED

brain UBERON:0000955

Downstream

Parkinsonism Impaired alpha-synuclein proteostasis increases Parkinson disease risk and can manifest clinically as parkinsonism.

Show evidence (1 reference)

PMID:21700325 SUPPORT In Vitro

"functional loss of GD-linked glucocerebrosidase (GCase) in primary cultures or human iPS neurons compromises lysosomal protein degradation, causes accumulation of α-synuclein (α-syn), and results in neurotoxicity through aggregation-dependent mechanisms."

Primary neuronal cultures and human iPS neurons support this mechanistic branch; clinical penetrance remains incomplete.

Splenic Sequestration

Hypersplenic pooling and destruction of blood cells contribute to thrombocytopenia and anemia alongside marrow disease.

Downstream

Anemia Hypersplenism contributes to anemia.

Thrombocytopenia Splenic sequestration contributes to low platelet counts.

Show evidence (1 reference)

PMID:28218669 SUPPORT INDIRECT Human Clinical

"The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."

Clinical review links reticuloendothelial organ involvement to cytopenias.

Complement C5aR1 Activation

Mechanism confidence: Provisional

Complement C5a signaling through C5aR1 amplifies inflammation in experimental Gaucher disease. Human complement and antibody findings support relevance, but intervention evidence remains preclinical.

Complement amplification of lipid storage

Downstream

Increased Glucosylceramide Synthesis C5aR1 signaling increases glucosylceramide synthase production.

Macrophage Inflammatory Mediator Release Complement signaling enhances inflammatory-cell recruitment and cytokine production.

Show evidence (1 reference)

PMID:28225753 SUPPORT Model Organism

"Marked local and systemic complement activation occurred in GCase-deficient mice or after pharmacological inhibition of GCase and was associated with GC storage, tissue inflammation and proinflammatory cytokine production."

Both genetic and pharmacological mouse systems support complement activation; this does not demonstrate clinical efficacy of complement inhibition.

Increased Glucosylceramide Synthesis

Mechanism confidence: Provisional

C5aR1-dependent glucosylceramide synthase upregulation increases substrate supply and amplifies storage in experimental Gaucher disease.

Complement amplification of lipid storage

Downstream

Glucocerebroside Accumulation in Macrophages Increased substrate synthesis adds to accumulation when degradation is deficient.

Show evidence (1 reference)

PMID:28225753 SUPPORT Model Organism

"Subsequent C5aR1 activation controlled UDP-glucose ceramide glucosyltransferase production, thereby tipping the balance between GC formation and degradation."

Experimental evidence supports a C5aR1-dependent substrate-synthesis amplification mechanism.

Lysolipid-Reactive B-Cell Stimulation

Mechanism confidence: Provisional

Lysolipid-reactive clonal immunoglobulin and substrate-responsive murine gammopathy support antigen-driven B-cell/plasma-cell stimulation. Additional changes required for malignant transformation remain unresolved.

Downstream

Monoclonal Gammopathy Chronic antigenic stimulation can contribute to clonal gammopathy.

Show evidence (1 reference)

PMID:26863356 SUPPORT Model Organism

"Substrate reduction ameliorates Gaucher's disease-associated gammopathy in mice."

Experimental reduction of substrate supports a lipid-dependent contribution to gammopathy; it does not establish prevention of human myeloma.

Bone Infarction

Focal skeletal ischemia produces bone infarcts and epiphyseal avascular necrosis. The relative roles of marrow infiltration, vascular compromise, and inflammatory or mechanical factors remain incompletely established.

Downstream

Osteonecrosis Epiphyseal ischemic bone injury manifests as avascular osteonecrosis.

Bone Pain Bone infarction can produce severe bone crises.

Show evidence (1 reference)

PMID:28218669 SUPPORT Other

"The painful bone crises are probably associated with ischemic vaso-occlusive phenomena. It seems that they may be reversible and do not show up as lesions in medical imaging. However, they usually cause abnormalities referred to as bone infarcts on long bones (metaphyses or diaphyses) and flat..."

This narrative-review synthesis describes ischemic skeletal events and their anatomic manifestations; it is not a primary cohort result and qualifies the link between painful crises and vaso-occlusion.

Mincle-Dependent Lipid Sensing

Mechanism confidence: Provisional

Mincle recognizes glucosylceramide and stimulates inflammatory myeloid-cell responses in ligand assays and mouse genetic systems. This is a preclinical extension; the magnitude of its contribution to human Gaucher disease remains unknown.

Innate immune activation by stored glucosylceramide

Downstream

Macrophage Inflammatory Mediator Release Mincle-dependent myeloid signaling induces inflammatory cytokine production in vitro.

Show evidence (1 reference)

PMID:28373578 SUPPORT In Vitro

"Synthetic β-GlcCer activated myeloid cells and induced production of inflammatory cytokines; this production was abrogated in Mincle-deficient cells."

Ligand and receptor-loss assays support Mincle-dependent cytokine induction; human Gaucher contribution is not established.

Stromal Inflammatory Secretome

Mechanism confidence: Provisional

Bone marrow stromal cells from one patient showed an altered inflammatory secretome despite preserved osteogenic differentiation. Its contribution to human skeletal disease remains a model-supported possibility.

Experimental models

GD1 patient bone marrow stromal cells PRIMARY CELL CULTURE

Downstream

Bone Remodeling Imbalance Stromal inflammatory mediators may influence local bone-cell homeostasis.

Show evidence (1 reference)

PMID:19587377 SUPPORT In Vitro

"In conclusion, Gaucher disease MSCs display an altered secretome that could contribute to skeletal disease and immune disease manifestations in a manner distinct and additive to Gaucher macrophages themselves."

The source identifies a distinct stromal inflammatory contribution, with uncertainty about clinical magnitude.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

28

Blood 4

Thrombocytopenia FREQUENT HP:0001873

Due to splenic sequestration and bone marrow infiltration

Show evidence (2 references)

PMID:19047232 SUPPORT

"More than 50% of patients had platelet counts of <100000 platelets per mm3 at baseline, but >95% had platelet counts above this level after 8 years of treatment."

Study documents thrombocytopenia as a common baseline finding in Gaucher disease patients.

ORPHA:355 SUPPORT Other

"HP:0001873 | Thrombocytopenia | Frequent (79-30%)"

Orphanet's curated HPO annotation supports classifying thrombocytopenia as frequent in Gaucher disease.

Anemia VERY_FREQUENT HP:0001903

Contributions include marrow involvement and splenic sequestration; the cited pediatric cohort and Orphanet frequency classes use different ascertainment frames.

Show evidence (2 references)

PMID:19047232 SUPPORT

"Anemia, although not severe, was present in >50% of patients at baseline and resolved for all patients after 8 years of treatment."

Study confirms anemia as a common finding in over half of Gaucher disease patients.

ORPHA:355 SUPPORT Other

"HP:0001903 | Anemia | Very frequent (99-80%)"

Orphanet's curated HPO annotation independently classifies anemia as very frequent in Gaucher disease.

Monoclonal Gammopathy Paraproteinemia HP:0031047

The bound HPO paraproteinemia term covers circulating monoclonal immunoglobulin; MGUS is specified in the clinical description.

Sequelae: Multiple Myeloma

Show evidence (1 reference)

PMID:36054609 SUPPORT Human Clinical

"Age-specific incidence rates of MGUS were unexpectedly high among younger patients."

Large international registry supports the clinical gammopathy association.

Multiple Myeloma HP:0006775

Show evidence (1 reference)

PMID:36054609 SUPPORT Human Clinical

"compared to the general population: non-Hodgkin lymphoma was approximately three times higher; MM was approximately nine times higher."

The registry compares myeloma risk with the general US population.

Cardiovascular 2

Splenomegaly VERY_FREQUENT HP:0001744

Often massive. Splenectomy is reserved for selected severe complications because it can worsen other Gaucher manifestations.

Show evidence (2 references)

PMID:28218669 SUPPORT

"The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."

Review confirms splenomegaly as a major manifestation caused by Gaucher cell infiltration.

ORPHA:355 SUPPORT Other

"HP:0001744 | Splenomegaly | Very frequent (99-80%)"

Orphanet's curated HPO annotation independently classifies splenomegaly as very frequent in Gaucher disease.

Valvular Calcification Cardiac valve calcification HP:0005146

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia."

GeneReviews describes the cardiovascular clinical form.

Digestive 2

Hepatomegaly VERY_FREQUENT HP:0002240

Often massive, may be first sign. Present across all subtypes.

Show evidence (2 references)

PMID:28218669 SUPPORT

"The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."

Review confirms hepatomegaly as a major manifestation of Gaucher disease.

ORPHA:355 SUPPORT Other

"HP:0002240 | Hepatomegaly | Very frequent (99-80%)"

Orphanet's curated HPO annotation independently classifies hepatomegaly as very frequent in Gaucher disease.

Dysphagia HP:0002015

Bulbar dysfunction with swallowing difficulty in Type 2

Show evidence (1 reference)

PMID:28218669 SUPPORT

"bulbar signs (particularly severe swallowing disorders)"

Review identifies severe swallowing disorders (dysphagia) as part of the Type 2 diagnostic triad.

Eye 4

Oculomotor Apraxia HP:0000657

Oculomotor apraxia is reported in GD3 and should not be equated with fixed strabismus or extraocular muscle paralysis.

Show evidence (1 reference)

PMID:37893235 SUPPORT Human Clinical

"The most frequent neurological abnormalities at onset were psychomotor retardation (14/19) and extrinsic muscle disorders (11/19), including oculomotor apraxia, supranuclear palsy, and strabismus."

The GD3 cohort explicitly reports oculomotor apraxia; the combined 11/19 proportion is not an apraxia-specific frequency.

Horizontal Supranuclear Gaze Palsy HP:0007817

Hallmark neurological feature of Type 3 Gaucher disease

Show evidence (1 reference)

PMID:28218669 SUPPORT

"Some patients present moderate systemic involvement with horizontal ophthalmoplegia as the only neurological symptom"

Review identifies horizontal ophthalmoplegia as the cardinal and sometimes sole neurological sign in Type 3.

Strabismus HP:0000486

Convergent strabismus may be present in neuronopathic forms

Show evidence (1 reference)

PMID:28218669 SUPPORT

"oculomotor paralysis (or bilateral fixed strabismus) is very suggestive of the disease"

Review identifies bilateral fixed strabismus as an alternative presentation of oculomotor involvement in Type 2.

Corneal Opacity HP:0007957

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia."

GeneReviews describes the cardiovascular clinical form.

Integument 1

Ichthyosis HP:0008064

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis."

GeneReviews describes severe perinatal skin and hydrops presentations.

Limbs 1

Erlenmeyer Flask Deformity FREQUENT Erlenmeyer flask deformity of the femurs HP:0004975

Characteristic bone remodeling defect in distal femur

Show evidence (2 references)

PMID:22010032 SUPPORT

"Erlenmeyer flask deformity is a common radiological finding in patients with Gaucher's disease"

Study confirms Erlenmeyer flask deformity is a characteristic radiological finding in Gaucher disease.

ORPHA:355 SUPPORT Other

"HP:0004975 | Erlenmeyer flask deformity of the femurs | Frequent (79-30%)"

Orphanet's curated HPO annotation supports Erlenmeyer flask deformity as frequent in Gaucher disease.

Metabolism 1

Nonimmune Hydrops Fetalis HP:0001790

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis."

GeneReviews describes severe perinatal skin and hydrops presentations.

Musculoskeletal 5

Osteopenia FREQUENT HP:0000938

Orphanet classifies osteopenia as a frequent skeletal phenotype.

Show evidence (1 reference)

ORPHA:355 SUPPORT Other

"HP:0000938 | Osteopenia | Frequent (79-30%)"

Orphanet's curated HPO annotation supports osteopenia as a frequent Gaucher disease phenotype.

Pathologic Fractures HP:0002756

Due to bone disease and osteopenia

Show evidence (1 reference)

PMID:28218669 SUPPORT

"Loss of bone mass occurs earlier and is more severe in patients with GD and may cause pathological fractures (of long bones, vertebrae, etc.)."

Review confirms pathological fractures result from accelerated bone mass loss in Gaucher disease.

Spasticity Progressive spasticity HP:0002191

Progressive spasticity and opisthotonus in Type 2

Show evidence (1 reference)

PMID:28218669 SUPPORT

"hypertonia with pyramidal and possibly extrapyramidal rigidity"

Review confirms pyramidal tract involvement with hypertonia and rigidity in Type 2.

Osteonecrosis Avascular necrosis HP:0010885

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"Type 1 GD is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia, thrombocytopenia, lung disease, and the absence of primary central nervous system disease."

GeneReviews supplies the Type 1 clinical baseline.

Kyphosis Thoracic kyphosis HP:0002942

Show evidence (1 reference)

PMID:40112481 SUPPORT Human Clinical

"Thoracic kyphosis is a common complication of GD types 1 and 3, and there is very limited information regarding the effects of ERT or substrate synthesis inhibition therapy (SSIT) on this condition."

Expert synthesis identifies kyphosis and the treatment-response evidence gap.

Nervous System 4

Seizures HP:0001250

Seizures occur in neuronopathic forms, including progressive myoclonic epilepsy in Type 3; the cited sentence does not support a Type 2 frequency estimate.

Show evidence (1 reference)

PMID:28218669 SUPPORT

"Seizures occurring later manifest as myoclonic epilepsy that is resistant to antiepileptic drugs."

Review confirms seizures as a feature of Type 2, progressing to drug-resistant myoclonic epilepsy.

Myoclonus OCCASIONAL HP:0001336

Progressive myoclonic epilepsy is a feature of Type 3

Show evidence (1 reference)

PMID:28218669 SUPPORT

"others present more severe forms with varying neurological signs including progressive myoclonus epilepsy (16% of patients)"

Review documents progressive myoclonus epilepsy in 16% of Type 3 patients.

Global Developmental Delay HP:0001263

Failure to achieve milestones in Type 2; developmental regression in Type 3

Show evidence (1 reference)

PMID:28218669 SUPPORT

"Psychomotor development is then altered, although some children may still continue to acquire skills."

Review confirms altered psychomotor development as a feature of Type 2.

Parkinsonism HP:0001300

GBA1 mutations increase Parkinson disease risk in Type 1 Gaucher disease patients and carriers, although penetrance is incomplete.

Show evidence (2 references)

PMID:30315684 SUPPORT Human Clinical

"Mutations of the GBA allele are the most significant genetic risk factor for idiopathic PD, found in 5%-20% of idiopathic PD cases depending on ethnicity."

This review supports GBA1 mutation-associated Parkinson disease risk.

PMID:28218669 SUPPORT Human Clinical

"Patients with type-1 GD-but also carriers of GBA1 mutation-have been found to be predisposed to developing Parkinson's disease"

This Gaucher disease review specifically links Type 1 Gaucher disease and GBA1 carrier status to Parkinson disease predisposition.

Constitutional 2

Fatigue VERY_FREQUENT HP:0012378

Orphanet classifies fatigue among the very frequent Gaucher disease phenotypes.

Show evidence (1 reference)

ORPHA:355 SUPPORT Other

"HP:0012378 | Fatigue | Very frequent (99-80%)"

Orphanet's curated HPO annotation supports fatigue as a very frequent phenotype in Gaucher disease.

Bone Pain FREQUENT HP:0002653

Bone crises can be severe

Show evidence (2 references)

PMID:19047232 SUPPORT

"Seventeen percent of patients reported a bone crisis before treatment and in the first 2 years of treatment, but no bone crises were reported after 2 years of enzyme replacement therapy."

Study documents bone crises/pain as a significant manifestation that resolves with treatment.

ORPHA:355 SUPPORT Other

"HP:0002653 | Bone pain | Frequent (79-30%)"

Orphanet's curated HPO annotation supports classifying bone pain as frequent in Gaucher disease.

Growth 1

Failure to Thrive FREQUENT HP:0001508

Show evidence (1 reference)

PMID:28218669 SUPPORT

"Growth retardation (30% of patients) may be the first sign, sometimes associated with cachexia."

The review places this 30% growth-retardation figure in Type 1 disease; it is not a frequency estimate for Type 2.

Other 1

Lung Disease

HPO was searched during review; no single term adequately represents the combined infiltrative and pulmonary vascular involvement. Abnormal lung morphology alone would omit the vascular component.

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"Type 1 GD is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia, thrombocytopenia, lung disease, and the absence of primary central nervous system disease."

GeneReviews supplies the Type 1 clinical baseline.

🧬

Genetic Associations

5

GBA1 (Causative)

Gene: GBA1 hgnc:4177 gene page relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:10464619 SUPPORT

"the presence of a single N370S allele is diagnostic of the type 1 or nonneuronopathic variant"

Grabowski review confirms N370S allele is protective against neuronopathic disease.

CGGV:assertion_fbc5a876-f97e-4f9c-be99-664e2f6c8470-2020-06-24T160000.000Z SUPPORT Other

ClinGen classifies the GBA1-Gaucher disease gene-disease relationship as definitive with autosomal recessive inheritance.

Variants (2)

N370S homozygous

Most common genotype in Ashkenazi Jewish patients. Always non-neuronopathic (Type 1).

N370S/other

Compound heterozygotes with N370S are Type 1.

GBA1 (Causative)

Gene: GBA1 hgnc:4177 gene page relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:10464619 SUPPORT

"the L444P/L444P genotype is highly associated with neuronopathic variants in the Caucasian population"

Grabowski review confirms L444P homozygosity predicts neuronopathic disease.

Variants (1)

L444P homozygous

Highly associated with neuronopathic variants in Caucasian population.

GBA1 (Causative)

Gene: GBA1 hgnc:4177 gene page relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:10464619 SUPPORT Human Clinical

"the L444P/L444P genotype is highly associated with neuronopathic variants in the Caucasian population"

Sources the L444P association with neuronopathic disease stated in this record. The review does not separate Type 2 from Type 3 on this genotype, which is why the record says "typically carry" rather than treating L444P as diagnostic of Type 3.

PMID:8544197 SUPPORT PRIMARY RESULT Human Clinical

"It is tempting to relate the phenotype of severe cardiac involvement to the D409H/D409H genotype, although further cases will be needed before this association can be confirmed."

Sources the D409H-cardiac association stated in this record, including the authors' own caution about it.

Variants (2)

L444P homozygous (Type 3)

May present as Type 3 with slower neurological progression.

D409H homozygous

Associated with cardiac variant with cardiovascular calcification.

GBA1 (Causative)

Gene: GBA1 hgnc:4177 gene page relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:8544197 SUPPORT PRIMARY RESULT Human Clinical

"Tissue was obtained from one of the sibs and fibroblast and liver beta-glucocerebrosidase activity was reduced to 4% and 11% of mean normal values. Genotype analysis indicated that the patient was homozygous for the D409H mutation."

Establishes GBA1 as the gene for the cardiovascular form, with the enzyme deficit and the D409H genotype measured in the same patient.

Variants (1)

D409H homozygous (cardiovascular form)

Gene: GBA1 hgnc:4177

Reported in three sisters with calcification of the ascending aorta and of the aortic and mitral valves, ophthalmoplegia and saccadic eye movements in two of them, and glucocerebrosidase activity reduced to 4% (fibroblast) and 11% (liver) of mean normal values in the one sib sampled.

GBA1 (Risk Factor)

Gene: GBA1 hgnc:4177 gene page relationship_type: RISK_FACTOR variant_origin: GERMLINE

Show evidence (3 references)

PMID:19846850 SUPPORT

"The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers."

Landmark multicenter NEJM study confirms strong GBA-Parkinson association with OR 5.43.

PMID:30315684 SUPPORT

"Mutations of the GBA allele are the most significant genetic risk factor for idiopathic PD, found in 5%-20% of idiopathic PD cases depending on ethnicity."

Review confirms GBA mutations are the most significant genetic risk factor for PD.

PMID:28218669 SUPPORT

"Patients with type-1 GD-but also carriers of GBA1 mutation-have been found to be predisposed to developing Parkinson's disease"

Review confirms both GD patients and GBA1 carriers have increased PD risk.

🗃️

External Assertions

1

Orphanet Gaucher disease record

Orphanet Disease registry record ORPHA:355

Orphanet ORPHA:355 is the structured registry record for Gaucher disease and lists exact MONDO and other disease-code cross-references.

Show evidence (3 references)

ORPHA:355 SUPPORT Other

"MONDO:0018150 | Exact"

Orphanet maps ORPHA:355 exactly to the MONDO term used as the disease anchor in this file.

ORPHA:355 SUPPORT Other

"ICD-10:E75.2 | Narrower"

Orphanet lists ICD-10 E75.2 as a narrower cross-reference under the Gaucher disease record.

ORPHA:355 SUPPORT Other

"OMIM:230800 | Broader"

Orphanet lists OMIM 230800 as one of the broader OMIM cross-references for Gaucher disease.

💊

Medical Actions

11

Enzyme Replacement Therapy

Action: enzyme replacement therapy Ontology label: Protein Replacement Therapy NCIT:C16221

Agent: imiglucerase velaglucerase alfa taliglucerase alfa

Platform: Protein replacement

Imiglucerase, velaglucerase alfa, or taliglucerase alfa restore enzyme activity in systemic tissues. ERT improves hematovisceral manifestations in GD1 and GD3, with variable skeletal response, but does not adequately cross the blood-brain barrier or correct neuronopathic disease.

Mechanism Target:

RESTORES Glucocerebrosidase Deficiency — Recombinant enzyme replacement restores systemic glucocerebrosidase activity upstream of macrophage storage.

Show evidence (1 reference)

PMID:19047232 SUPPORT Human Clinical

"Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal."

Clinical response to enzyme replacement supports correction of the upstream systemic enzyme-deficiency pathway.

Show evidence (3 references)

PMID:19047232 SUPPORT

"Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal."

Long-term study demonstrates effectiveness of enzyme replacement therapy in children with Gaucher disease.

PMID:25755533 SUPPORT

"ERT is of no benefit in type 2 disease."

Review confirms ERT does not help neurological disease in Type 2 due to BBB.

PMID:41821052 SUPPORT Human Clinical

"Despite complex disease burden in GD3, imiglucerase therapy led to marked hematovisceral disease reversal and meaningful growth improvements, closely paralleling responses in GD1."

Large pediatric registry distinguishes systemic efficacy in GD3 from absent proof of CNS rescue.

Substrate Reduction Therapy

Action: substrate reduction therapy Ontology label: Substrate Deprivation Therapy NCIT:C85876

Agent: eliglustat miglustat

Platform: Small molecule

Eliglustat and miglustat reduce glucosylceramide synthesis in selected patients with GD1. Eliglustat selection depends on CYP2D6 metabolism, interactions, and clinical suitability. Miglustat can cross the BBB but has not established neurological efficacy in neuronopathic Gaucher disease.

Mechanism Target:

INHIBITS Glucocerebroside Accumulation in Macrophages — Glucosylceramide synthase inhibition reduces substrate supply upstream of macrophage storage.

Show evidence (1 reference)

PMID:25688781 SUPPORT Human Clinical

"treatment with eliglustat compared with placebo for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count."

Clinical response to eliglustat supports substrate reduction acting upstream of visceral and hematologic manifestations.

Show evidence (2 references)

PMID:25688781 SUPPORT

"treatment with eliglustat compared with placebo for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count."

Phase 3 ENGAGE trial demonstrates eliglustat substrate reduction therapy effectively improves clinical manifestations in Gaucher disease.

PMID:19067373 SUPPORT Human Clinical

"No significant between-group differences in vertical saccadic eye movement velocity or in the other neurological or neuropsychological evaluations were observed."

Randomized GD3 comparison found no established neurological benefit from adjunctive miglustat.

Supportive Care

Action: Supportive Care NCIT:C15747

Pain management, orthopedic interventions, transfusions as needed.

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"orthopedic management of bone disease; analgesics for bone pain; joint replacement surgery for relief from chronic pain and restoration of function;"

GeneReviews supports symptomatic orthopedic and pain care.

Orthopedic Management of Skeletal Disease

Action: orthopedic surgical procedure Ontology label: Orthopedic Surgical Procedure NCIT:C16186

Management of Gaucher-related bone disease, including avascular necrosis (osteonecrosis) of the femoral and humeral heads. Early diagnosis enables joint-preserving surgical intervention, while advanced osteonecrosis with articular collapse may require total joint arthroplasty.

Show evidence (3 references)

PMID:36436966 SUPPORT Human Clinical

"Risk factors for osteonecrosis are numerous and include trauma, corticosteroid therapy, alcohol use, HIV, lymphoma/leukemia, blood dyscrasias, chemotherapy, radiation therapy, Gaucher disease, and Caisson disease"

ACR guideline identifies Gaucher disease as an established risk factor for osteonecrosis warranting imaging-guided orthopedic management.

PMID:36436966 SUPPORT Human Clinical

"to allow for possible early surgical prevention to prevent articular collapse and need for joint replacements"

ACR guideline supports early surgical intervention in osteonecrosis to prevent articular collapse and the need for joint replacement.

PMID:30414226 SUPPORT Human Clinical

"For type 1 disease, seven major signs (splenomegaly, thrombocytopenia, bone-related manifestations, anaemia, hyperferritinaemia, hepatomegaly and gammopathy)"

GED-C consensus identifies bone-related manifestations as a major presenting sign of type 1 Gaucher disease, underpinning the need for skeletal disease management.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Family screening, prenatal diagnosis available.

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"Once the GBA1 pathogenic variants have been identified in an affected family member, molecular genetic carrier testing for at-risk family members, preimplantation genetic testing, and prenatal testing for GD are possible."

GeneReviews supports familial and reproductive testing.

Lentiviral Gene Therapy

Action: gene therapy Ontology label: Gene Therapy NCIT:C15238

Platform: Gene therapy

Autologous transplant of CD34+ hematopoietic stem cells transduced with lentiviral vector carrying functional GBA1 gene. Restores glucocerebrosidase production from transduced cells. First-in-human case demonstrates sustained therapeutic response with maintained enzyme levels, reduced biomarkers (lyso-GB1), and organ volume improvement at 5-year follow-up without need for additional enzyme replacement or substrate reduction therapy.

Mechanism Target:

RESTORES Glucocerebrosidase Deficiency — Transduced CD34+ cells produce functional glucocerebrosidase, restoring systemic enzyme activity.

Show evidence (1 reference)

PMID:42324119 SUPPORT Human Clinical

"At 5 years of follow-up, dried blood spot GCase enzyme levels have remained in the normal range"

Case demonstrates sustained restoration of enzyme activity to normal levels following gene therapy.

Show evidence (1 reference)

PMID:42324119 SUPPORT Human Clinical

"This case shows a sustained response to a single dose of lentiviral gene therapy for Gaucher disease."

Case report demonstrates durable long-term efficacy of lentiviral gene therapy approach in Gaucher disease.

Surveillance and Treatment Precautions

Action: Supportive Care NCIT:C15747

Assess progression at least every six months across hematologic, skeletal, pulmonary, cardiac, psychiatric, and neurologic domains; image liver and spleen periodically. Avoid NSAIDs with moderate-to-severe thrombocytopenia and, if possible, eliglustat during pregnancy.

Show evidence (3 references)

PMID:20301446 SUPPORT Human Clinical

"Clinical assessment of disease progression at least every six months to include hematologic, orthopedic, pulmonary, cardiac, psychiatric, and neurologic assessment;"

GeneReviews provides the surveillance baseline.

PMID:20301446 SUPPORT Human Clinical

"Nonsteroidal anti-inflammatory drugs in individuals with moderate-to-severe thrombocytopenia."

Identifies the medication precaution.

PMID:20301446 SUPPORT Human Clinical

"The lack of studies on the safety of eliglustat use during pregnancy and lactation has led to the recommendation that this medication be avoided during pregnancy, if possible."

Records the reproductive treatment precaution.

Ambroxol Chaperone Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: ambroxol

Platform: Small molecule

Investigational pharmacologic enhancement of residual mutant GCase stability and activity. A 28-patient uncontrolled series found variable systemic improvement and two nonresponders; it does not establish comparative efficacy or a neurological cure. A separate 13-patient GD3 study on stable ERT reported improvement in selected neurologic symptoms; absence of a concurrent control limits inference.

Mechanism Target:

RESTORES Glucocerebrosidase Deficiency — Chaperoning can enhance stability and residual activity for responsive variants.

Show evidence (1 reference)

PMID:37342037 SUPPORT In Vitro

"Ambroxol was identified as an enhancer of stability and residual activity of several misfolded glucocerebrosidase variants in 2009."

The reported chaperone mechanism is variant-dependent.

Show evidence (2 references)

PMID:37342037 SUPPORT Human Clinical

"Two patients with severe symptoms at baseline experienced deterioration of hematologic parameters and biomarkers and were deemed nonresponders; clinical response was observed in the other 26 patients."

Uncontrolled case-series response is preliminary and heterogeneous.

PMID:41901003 SUPPORT Human Clinical

"We evaluated 13 patients with type 3 GD (L444P/L444P homozygotes) who received ambroxol at 10 mg/kg/day for one year as part of a clinical trial."

Additional small uncontrolled GD3 cohort on stable ERT; preliminary benefit signals require comparative confirmation.

Hematopoietic Stem Cell Transplantation

Action: Hematopoietic Cell Transplantation NCIT:C15431

Platform: Cell therapy

Selected severe cases, particularly chronic neuronopathic disease, may be considered for transplantation at specialist centers. This option has substantial treatment risk and should not imply established reversal of CNS injury.

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"Hematopoietic stem cell transplantation may be an option in individuals with severe GD, primarily those with chronic neurologic involvement (type 3 GD)."

GeneReviews recognizes selected-use transplantation.

Venglustat

Action: Substrate Deprivation Therapy NCIT:C85876

Agent: venglustat

Platform: Small molecule

Investigational brain-penetrant glucosylceramide synthase inhibitor. Phase 2 LEAP demonstrated CSF substrate lowering with heterogeneous clinical signals; neurological efficacy must be distinguished from biochemical target engagement. The ongoing Phase 3 LEAP2MONO program compares venglustat with imiglucerase.

Mechanism Target:

INHIBITS Neuronal Glycosphingolipid Accumulation — Reduces glycosphingolipid substrate synthesis and CSF lipid concentrations; clinical neuroprotection is a separate claim.

Show evidence (1 reference)

PMID:36256599 SUPPORT Human Clinical

"After 1 year of treatment, median (inter-quartile range) glucosylceramide decreased 78% (72, 84) in plasma and 81% (77, 83) in CSF; median (inter-quartile range) glucosylsphingosine decreased 56% (41, 60) in plasma and 70% (46, 76) in CSF."

LEAP demonstrates CNS substrate target engagement in 11 adults, not a controlled demonstration of neurological rescue.

Show evidence (2 references)

PMID:36256599 SUPPORT Human Clinical

"After 1 year of treatment, median (inter-quartile range) glucosylceramide decreased 78% (72, 84) in plasma and 81% (77, 83) in CSF; median (inter-quartile range) glucosylsphingosine decreased 56% (41, 60) in plasma and 70% (46, 76) in CSF."

LEAP demonstrates CNS substrate target engagement in 11 adults, not a controlled demonstration of neurological rescue.

PMID:36256599 SUPPORT Human Clinical

"neurocognition, assessed by Vineland II, deteriorated in all domains over time, which illustrates disease progression despite the intervention."

The published phase 2 study includes progression despite marked CSF substrate lowering.

AAV Gene Augmentation

Action: Gene Therapy NCIT:C15238

Platform: Gene therapy

Investigational vector-mediated GBA1 augmentation includes systemic FLT201/PR001 programs and CNS-directed VGN-R08b. Routes, target tissues, eligibility, and evidence differ; these approaches should not be represented as established equivalents to systemic ERT.

Mechanism Target:

RESTORES Glucocerebrosidase Deficiency — Investigational gene addition aims to augment functional GCase rather than repair the inherited alleles.

Show evidence (1 reference)

clinicaltrials:NCT07223944 SUPPORT Other

"The study aims to confirm the efficacy and safety of FLT201 in this population after discontinuation of ERT/SRT."

The registered trial establishes investigation of systemic AAV gene augmentation; efficacy is not inferred from registration.

Show evidence (1 reference)

clinicaltrials:NCT07223944 SUPPORT Other

"The study aims to confirm the efficacy and safety of FLT201 in this population after discontinuation of ERT/SRT."

The registered trial establishes investigation of systemic AAV gene augmentation; efficacy is not inferred from registration.

🔬

Biochemical Markers

4

Beta-glucocerebrosidase Activity (Decreased)

Context: Enzyme activity in leukocytes typically less than 15% of normal

Show evidence (1 reference)

PMID:28218669 SUPPORT

"A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes."

Review confirms diagnosis via enzyme activity measurement in leukocytes.

Chitotriosidase (Elevated)

Context: Macrophage-burden marker; also elevated in other conditions and absent or low in patients with CHIT1 null variants.

Pathograph Readouts

Readout Of Macrophage Inflammatory Mediator Release

Secreted enzyme activity reflects Gaucher macrophage burden, with CHIT1 genotype limitations.

Show evidence (3 references)

PMID:28218669 SUPPORT

"This is the case for chitotriosidase and CCL18, which thus constitute quite specific disease biomarkers"

Review confirms chitotriosidase as a specific biomarker expressed by Gaucher cells.

PMID:25755533 SUPPORT

"Monitoring of patients on ERT involves evaluation of growth, blood counts, liver and spleen size and biomarkers such as chitotriosidase which reflect the disease burden."

Review confirms chitotriosidase is used for monitoring disease burden during ERT.

PMID:36739645 SUPPORT Human Clinical

"Serum chitotriosidase activity, a widely used GD biomarker, is also elevated in many other conditions but is not measurable in 5-10% of individuals due to a common CHIT1 null variant."

This biomarker is neither universal nor specific.

Glucosylsphingosine (Lyso-Gb1) (Elevated)

Context: Diagnostic and pharmacodynamic biomarker. Correlations with burden or response do not establish an independently validated surrogate endpoint or that the metabolite is the dominant tissue toxin.

Pathograph Readouts

Readout Of Glucosylsphingosine Accumulation

Circulating lyso-Gb1 measures substrate-related burden; tissue and clinical effects require separate assessment.

Show evidence (1 reference)

PMID:36739645 SUPPORT Human Clinical

"These clinical trial data add to the growing body of evidence supporting plasma glucosylsphingosine as both a diagnostic and pharmacodynamic/response biomarker for GD1."

Supports biomarker use, without assuming causal mediation.

Show evidence (3 references)

PMID:28218669 SUPPORT

"Glucosylsphingosine is a novel biomarker whose sensitivity and specificity are superior to those of chitotriosidase and CCL18"

Review confirms glucosylsphingosine as superior biomarker to chitotriosidase for GD monitoring.

PMID:39499245 SUPPORT Human Clinical

"glucosylsphingosine (lyso-Gb1), galactosylsphingosine (psychosine), and glucose tetrasaccharide (Glca1-6Glca1-4Glca1-4Glc, Glc4) are biomarkers associated with Fabry, Gaucher, Krabbe, and Pompe disease, respectively"

ACMG technical standard establishes glucosylsphingosine (lyso-Gb1) as the disease-specific biomarker for Gaucher disease.

PMID:36544230 SUPPORT Human Clinical

"chitotriosidase activity, PARC/CCL18 or GlcSph concentrations can be used as a first line test"

IWGGD laboratory-diagnosis guideline recommends GlcSph (lyso-Gb1) among first-line biomarker tests when Gaucher disease is suspected.

Ferritin (Elevated)

Context: Common elevation can reflect inflammatory iron redistribution; ferritin alone does not establish systemic iron overload.

Show evidence (1 reference)

PMID:25153906 SUPPORT Human Clinical

"Gaucher disease induces some metabolic abnormalities so increased serum ferritin appears in more than 60% at diagnosis."

Clinical study introduction documents frequent ferritin elevation.

🔬

Diagnosis

1

Glucocerebrosidase activity and GBA1 testing

Confirm deficient GCase activity in leukocytes or other nucleated cells and/or biallelic pathogenic GBA1 variants. Dried-blood-spot screening requires appropriate confirmatory evaluation; GBA1 testing must account for its homologous pseudogene and recombinant alleles.

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"The diagnosis of GD relies on demonstration of deficient glucocerebrosidase (glucosylceramidase) enzyme activity in peripheral blood leukocytes or other nucleated cells, or by the identification of biallelic pathogenic variants in GBA1 on molecular genetic testing."

Authoritative diagnostic confirmation strategy.

📈

Progression

6

Disease onset

Age: All ages

Orphanet records disease-level onset across all ages, complementing the subtype-specific onset patterns below.

Show evidence (1 reference)

ORPHA:355 SUPPORT Other

"Age of onset: All ages"

Orphanet's natural-history field supports broad all-age onset for Gaucher disease overall.

Onset

Type 1 Age: Childhood-Adulthood

Highly variable onset; some patients remain asymptomatic.

Onset

Type 2 Age: before 2 years

GeneReviews describes early CNS onset and death commonly by two to four years; considerable clinical variability remains.

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"Type 2 GD is characterized by primary central nervous system disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years."

GeneReviews defines the broader onset and survival range; onset before six months and death by two years are not universal.

Death

Type 2 Age: 2-4 years

GeneReviews describes early CNS onset and death commonly by two to four years; considerable clinical variability remains.

Show evidence (1 reference)

PMID:20301446 SUPPORT Human Clinical

"Type 2 GD is characterized by primary central nervous system disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years."

GeneReviews defines the broader onset and survival range; onset before six months and death by two years are not universal.

Onset

Type 3 Age: Childhood

Neurological symptoms appear in childhood with slower progression than Type 2.

Chronic

Type 3

Survival into adulthood with progressive neurological decline and systemic disease.

📊

Prevalence

4

Worldwide

Birth Prevalence 1.0–9.0 per 100,000 1–9 per 100,000 (births)

Orphanet reports worldwide prevalence at birth in the 1-9 per 100,000 class.

Show evidence (1 reference)

ORPHA:355 SUPPORT Other

"1-9 / 100 000 | Worldwide | Prevalence at birth | PMID:23046562"

Orphanet provides a worldwide prevalence-at-birth class for Gaucher disease.

Europe

Point Prevalence 1.0–9.0 per 100,000 1–9 per 100,000

Orphanet reports both European annual incidence and point prevalence in the 1-9 per 100,000 class.

Show evidence (1 reference)

ORPHA:355 SUPPORT Other

"1-9 / 100 000 | Europe | Point prevalence | EXPERT"

Orphanet provides a European point-prevalence class for Gaucher disease.

Global

Type 1

Incidence estimates depend on population; the cited review reports approximately 1/40,000–1/60,000 births in the general population and 1/800 in Ashkenazi Jews. These are not universal subtype proportions.

Show evidence (1 reference)

PMID:28218669 SUPPORT

"In the general population, its incidence is approximately 1/40,000 to 1/60,000 births, rising to 1/800 in Ashkenazi Jews."

Review provides incidence estimates for Gaucher disease.

Ashkenazi Jewish

Type 1

Markedly increased prevalence due to founder effect; carrier frequency ~1/15.

Show evidence (1 reference)

PMID:10464619 SUPPORT

"Gaucher disease is the most prevalent lysosomal storage disease and has its highest incidence in the Ashkenazi Jewish population."

Review confirms highest incidence in Ashkenazi Jewish population.

🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Gaucher Disease:

Gaucher disease due to saposin C deficiency

Overlapping Features PSAP-related saposin C deficiency can produce Gaucher-like lipid storage despite normal or low activity on artificial-substrate enzyme assays.

Distinguishing Features

Consider PSAP testing when the clinical phenotype and biomarkers suggest Gaucher disease but pathogenic GBA1 variants are absent.

Show evidence (1 reference)

PMID:36544230 SUPPORT Other

"and normal or low BGLU activity in cells, a Sap C deficiency should be suspected and the PSAP gene analyzed."

The laboratory guideline recommends PSAP analysis in the described GBA1-negative diagnostic context; PSAP deficiency is a separate curated disorder.

📊

Related Datasets

5

Developing Midbrain-like Organoid of Gaucher Disease as A Platform for Drug Assessment geo:GSE303993

Gaucher disease (GD) is a lysosomal storage disorder caused by GBA1 mutations, leading to defective acid β-glucosidase (GCase) and accumulation of glucosylsphingolipids, causing inflammation and neurodegeneration. We developed midbrain-like organoids (MLOs) from induced pluripotent stem cells (iPSCs) of nGD patients with GBA1L444P/P415R and GBA1L444P/RecNcil mutations to model nGD brain pathogenesis. These nGD MLOs exhibited GCase deficiencies, reduced enzyme activities, lipids accumulation, transcriptomic alterations, and impaired dopaminergic neuron differentiation, mirroring nGD pathology.

human BULK RNA SEQ n=6

PMID:42334452

Identified by GEO DataSets index search for Gaucher Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

Use of mice defective in interferon signaling to distinguish between primary and secondary pathological pathways in a mouse model of neuronal forms of Gaucher disease geo:GSE150266

The type 1 interferon (IFN) response is part of the innate immune response and best known for its role in viral and bacterial infection. However, this pathway is also induced in sterile inflammation such as occurs in a number of neurodegenerative diseases, including neuronopathic Gaucher disease (nGD), a lysosomal storage disorder (LSD) caused by mutations in Gba1. Mice were injected with conduritol B-epoxide, an irreversible inhibitor of acid-beta glucosidase, the enzyme defective in nGD. Quadrat deficient MyTrMaSt mice, where four adaptors of pathogen recognition receptors (PRRs) are deficient, were used to determine the role of the IFN pathway in nGD pathology.

mouse BULK RNA SEQ n=14

PMID:32892753

Identified by GEO DataSets index search for Gaucher Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

Gene expression profiling of brain tissue from neuronopathic Gaucher disease mouse model of PG9VN, PG9V and wild type mice geo:GSE250051

To understand the intrinsic link between PGRN and Gba D409V mutation dosage in regulating lysosomal function and disease pathogenesis, we generated nGD model of GbaD409V/D409V and loss of PGRN (Grn-/-), termed PG9V that displayed typical neuronopathic GD (nGD). With decreasing the dose of Gba D409V, i.e., D409V/Null, in Grn KO mice (Grn-/-;GbaD409V/Null, PG9VN) led to much earlier onset and more severe neurodegenerative nGD than PG9V mice.

mouse BULK RNA SEQ n=9

PMID:39101473

Identified by GEO DataSets index search for Gaucher Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease massive:MSV000080786

Gaucher disease, a recessive inherited metabolic disorder caused by defects in the gene encoding glucosylceramidase (GlcCerase), can be divided into three subtypes according to the appearance of symptoms associated with central nervous system involvement. We now identify a protein, glycoprotein non-metastatic B (GPNMB), that acts as an authentic marker of brain pathology in neurological forms of Gaucher disease.

Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Gaucher Disease"). Retrieved 2026-08-02.

Proteomics analysis of the brain from a Gaucher disease mouse identifies pathological pathways including a possible role for transglutaminase 1 massive:MSV000092415

Gaucher disease (GD) is caused by the defective activity of acid beta-glucosidase (GCase) which results from mutations in GBA1. Neurological forms of GD (nGD) can be generated in mice by intra-peritoneal injection of conduritol B-epoxide (CBE) which irreversibly inhibits GCase. Using this approach, a number of pathological pathways have been identified in mouse brain by RNAseq analysis. However, unlike transcriptomics, proteomics gives information about protein expression which is more likely to provide insight into which cellular pathways may be impacted in disease.

mouse PROTEOMICS

Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Gaucher Disease"). Retrieved 2026-08-02.

🔬

Clinical Trials

7

NCT05324943 PHASE_I COMPLETED

GALILEO-1 evaluates single-dose intravenous FLT201 gene therapy in GD1. Registry status checked 2026-09-04.

Show evidence (1 reference)

clinicaltrials:NCT05324943 SUPPORT Other

"This study is a first-in-human, open-label, safety, tolerability, and efficacy study in adult patients with Gaucher disease Type 1."

ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.

NCT07223944 PHASE_III RECRUITING

GALILEO-3 evaluates efficacy and safety of FLT201 in adults with GD1 after ERT/SRT withdrawal. Registry status checked 2026-09-04.

Show evidence (1 reference)

clinicaltrials:NCT07223944 SUPPORT Other

"This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years."

ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.

NCT05487599 PHASE_I ACTIVE_NOT_RECRUITING

PROCEED is a Phase I/II systemic PR001/LY3884961 AAV gene-therapy study for peripheral Gaucher manifestations. Registry status checked 2026-09-04.

Show evidence (1 reference)

clinicaltrials:NCT05487599 SUPPORT Other

"Study J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD. Up to 3 dose levels of LY3884961 will be assessed in 3 dose-finding cohorts of 3 patients."

ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.

NCT04145037 PHASE_I TERMINATED

Guard1 is the terminated Phase I/II AVR-RD-02 autologous lentiviral HSC gene-therapy study. Registry status checked 2026-09-04.

Show evidence (1 reference)

clinicaltrials:NCT04145037 SUPPORT Other

"This was a multinational, open-label study to assess the safety and efficacy of AVR-RD-02 in approximately 8 to 16 subjects (male or female) who are ≥18 and ≤50 years of age and post pubertal at Screening with a confirmed diagnosis of Type 1 Gaucher disease (based on clinical phenotype,..."

ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.

NCT06272149 PHASE_I RECRUITING

Early Phase I study of intracerebroventricular AAV9-GBA1 VGN-R08b in infants with GD2. Registry status checked 2026-09-04.

Show evidence (1 reference)

clinicaltrials:NCT06272149 SUPPORT Other

"This exploratory trial is to prove the tolerability and safety of VGN-R08b to treat infants with type II Gaucher disease."

ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.

NCT02843035 PHASE_II ACTIVE_NOT_RECRUITING

Phase II LEAP investigates venglustat with imiglucerase and subsequent monotherapy extension in GD3. Registry status checked 2026-09-04.

Show evidence (1 reference)

clinicaltrials:NCT02843035 SUPPORT Other

"Evaluate short-term (Part 2) and long-term (Part 3) safety and tolerability of venglustat in combination with Cerezyme in adult GD3 participants"

The registry specifies the combination intervention and GD3 population; registration is not evidence of benefit.

NCT05222906 PHASE_III ACTIVE_NOT_RECRUITING

Phase III LEAP2MONO is a randomized active-comparator trial of venglustat versus imiglucerase in GD3. Registry status checked 2026-09-04.

Show evidence (1 reference)

clinicaltrials:NCT05222906 SUPPORT Other

"This is a parallel arm, Phase 3, double-blind, double-dummy, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of..."

ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.

🧫

Experimental Models

2

CBE-treated murine macrophage conditioned-medium model PRIMARY_CELL_CULTURE

CBE-inhibited murine macrophage/splenocyte conditioned media applied to osteoclast precursors and osteoblast cultures.

Pathograph links

Bone Remodeling Imbalance partially recapitulates fidelity: moderate observes: cellular

Limitations: Chemical GCase inhibition and conditioned-media transfer do not reproduce human genotype, marrow architecture, perfusion, or clinical osteonecrosis.

Readouts

Osteoblast alkaline phosphatase and mineralization

Direction: DECREASED

Show evidence (1 reference)

PMID:24076352 SUPPORT In Vitro

"On the other hand, addition of CM to an osteoblast cell culture resulted in a reduction in expression of alkaline phosphatase and mineralization process."

The reported measurement supports reduced osteoblast function in vitro.

Show evidence (1 reference)

PMID:24076352 SUPPORT In Vitro

"In conclusion, these results suggest implication of changes in both bone formation and bone resorption and are consistent with the idea that both sides of the homeostatic balance are affected in GD."

A chemical murine cell model supports a remodeling mechanism, with translation to patient skeletal disease qualified.

GD1 patient bone marrow stromal cells PRIMARY_CELL_CULTURE

Mesenchymal stromal cells from one adult GD1 donor with legacy N370S/L444P genotype, compared with control cells and complemented by chemical inhibition experiments.

Pathograph links

Stromal Inflammatory Secretome partially recapitulates fidelity: moderate observes: cellular

Limitations: Single patient donor and cell-culture comparison; retained osteogenic differentiation limits claims that intrinsic stromal differentiation failure explains human bone disease.

Show evidence (1 reference)

PMID:19587377 SUPPORT In Vitro

"In conclusion, Gaucher disease MSCs display an altered secretome that could contribute to skeletal disease and immune disease manifestations in a manner distinct and additive to Gaucher macrophages themselves."

The source identifies a distinct stromal inflammatory contribution, with uncertainty about clinical magnitude.

🐁

Animal Models

1

Gba1 D409V with progranulin deficiency

A sensitized neuronopathic model tests interaction between GCase dosage and progranulin loss.

Species

Mouse

Genotype

Grn-null; Gba1 D409V/D409V or D409V/null

Publication

PMID:39101473

Pathograph links

Neuroinflammation partially recapitulates fidelity: moderate observes: organism

Limitations: The additional Grn-null lesion is an experimental sensitizer; this is not evidence that GRN variants cause ordinary Gaucher disease.

Show evidence (1 reference)

PMID:39101473 SUPPORT Model Organism

"Glycosphingolipid accumulation, inflammatory responses, lysosomal-autophagy dysfunction, microgliosis, retinal gliosis, as well as α-Synuclein increases were much more pronounced in PG9VN mice."

The model links GCase dosage and sensitizing progranulin loss to inflammatory neuropathology.

{ }

Source YAML

click to show

name: Gaucher Disease
creation_date: '2026-01-07T17:31:51Z'
description: >-
  Gaucher disease is an autosomal recessive lysosomal storage disorder caused by biallelic pathogenic variants in GBA1 that result in deficient glucocerebrosidase (acid beta-glucosidase) activity. Impaired catabolism of glucocerebroside leads to its accumulation within tissue macrophages, which become lipid-laden Gaucher cells that infiltrate the spleen, liver, and bone marrow. Clinical features include hepatosplenomegaly, thrombocytopenia, anemia, and skeletal disease, with neuronopathic forms (types 2 and 3) adding progressive central nervous system involvement; GBA1 pathogenic variants are also major genetic risk factors for Parkinsonism.
category: Genetic
parents:
- Lysosomal Storage Disorder
- Sphingolipidosis
classifications:
  lysosomal_storage_category:
    classification_value: sphingolipidosis
    notes: >-
      Gaucher disease is a sphingolipidosis — lysosomal accumulation of the
      sphingolipid glucosylceramide (glucocerebroside). Complements the ICIMD
      complex-molecule-degradation axis below.
  icimd_category:
  - classification_value: sphingolipid_degradation
    notes: >-
      ICIMD (Ferreira et al. 2021, PMID:33340416): group "Sphingolipid
      degradation" under category "Disorders of complex molecule degradation"
      (the classical lysosomal disorders). Gaucher is glucocerebrosidase
      deficiency with glucosylceramide accumulation.
disease_term:
  preferred_term: Gaucher disease
  term:
    id: MONDO:0018150
    label: Gaucher disease
synonyms:
- Acid beta-glucosidase deficiency
- Glucocerebrosidase deficiency
definitions:
- name: Orphanet disease definition
  definition_type: OTHER
  description: >
    Orphanet defines Gaucher disease as a lysosomal storage disorder spanning
    three main forms plus fetal and cardiac-involvement variants.
  scope: Orphanet structured disease record for ORPHA:355
  evidence:
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Gaucher disease (GD) is a lysosomal storage disorder encompassing three main forms (types 1, 2 and 3), a fetal form and a variant with cardiac involvement (Gaucher disease - ophthalmoplegia - cardiovascular calcification or Gaucher-like disease)."
    explanation: Orphanet defines Gaucher disease as a lysosomal storage disorder with the major clinical forms represented in this entry.
external_assertions:
- name: Orphanet Gaucher disease record
  source: Orphanet
  assertion_type: Disease registry record
  external_id: ORPHA:355
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=355
  description: >
    Orphanet ORPHA:355 is the structured registry record for Gaucher disease and
    lists exact MONDO and other disease-code cross-references.
  evidence:
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0018150 | Exact"
    explanation: Orphanet maps ORPHA:355 exactly to the MONDO term used as the disease anchor in this file.
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-10:E75.2 | Narrower"
    explanation: Orphanet lists ICD-10 E75.2 as a narrower cross-reference under the Gaucher disease record.
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:230800 | Broader"
    explanation: Orphanet lists OMIM 230800 as one of the broader OMIM cross-references for Gaucher disease.
has_subtypes:
- name: Type 1
  display_name: Type 1 (Non-neuronopathic)
  subtype_term:
    preferred_term: Gaucher disease type I
    term:
      id: MONDO:0009265
      label: Gaucher disease type I
  description: >-
    Non-neuronopathic form, comprising about 90% of diagnosed cases in Europe and the USA but a smaller fraction in some other regions. Visceral, hematologic, and skeletal severity varies greatly; absence of primary childhood CNS disease does not exclude later Parkinson disease risk.
  genes:
  - preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "Type-1 Gaucher disease, which affects the majority of patients (90% in Europe and USA, but less in other regions), is characterized by effects on the viscera"
    explanation: Review confirms Type 1 is the most common form with visceral manifestations.
- name: Type 2
  display_name: Type 2 (Acute neuronopathic)
  subtype_term:
    preferred_term: Gaucher disease type II
    term:
      id: MONDO:0009266
      label: Gaucher disease type II
  description: >-
    Acute neuronopathic form with primary CNS disease beginning before age two years, limited psychomotor development, and rapid progression. Death commonly occurs by age two to four years; systemic ERT does not correct the CNS disease.
  genes:
  - preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 2 GD is characterized by primary central nervous system disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years.
    explanation: >-
      GeneReviews defines the broader onset and survival range; onset before six months and death by two years are not universal.
- name: Type 3
  display_name: Type 3 (Chronic neuronopathic)
  subtype_term:
    preferred_term: Gaucher disease type III
    term:
      id: MONDO:0009267
      label: Gaucher disease type III
  description: >
    Chronic neuronopathic form with both systemic and neurological involvement.
    Onset in childhood with slower neurological progression than Type 2.
    Hallmark feature is horizontal supranuclear gaze palsy. May also
    develop myoclonic epilepsy and cognitive decline. Survival into adulthood.
  genes:
  - preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "types 2 and 3 are also associated with neurological impairment, either severe in type 2 or variable in type 3"
    explanation: Review confirms Type 3 has variable neurological involvement distinct from severe Type 2.
- name: Perinatal lethal
  description: >-
    Perinatal presentation with skin-barrier disease and/or nonimmune hydrops fetalis.
  genes:
  - preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  review_notes: >-
    No perinatal-lethal-specific GBA1 genotype is curated here. The case
    series cited below states that further genotype-phenotype reporting is
    still needed for this form, so a genotype claim would outrun its sources.
  evidence:
  - reference: PMID:42165577
    reference_title: "Fetal/Perinatal Lethal Gaucher Disease: A Case Series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Gaucher disease is a rare lysosomal storage disease caused by mutations in the GBA gene, resulting in the accumulation of glucosylceramides in macrophages. The perinatal/lethal form, also including fetal Gaucher disease, is a distinct and severe variant"
    explanation: >-
      Places the perinatal/lethal form inside GBA-caused Gaucher disease,
      supporting the GBA1 gene binding on this subtype row. The quoted
      sentences are the series' background framing rather than its own finding.
  - reference: PMID:42165577
    reference_title: "Fetal/Perinatal Lethal Gaucher Disease: A Case Series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Further reporting of genotype-phenotype correlations is necessary in cases of fetal/perinatal Gaucher disease."
    explanation: >-
      Sources the note above that no perinatal-lethal-specific genotype is
      established, rather than asserting an absence this entry never searched.
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis.
    explanation: >-
      GeneReviews recognizes this clinical form in addition to types 1–3.
  subtype_term:
    preferred_term: Gaucher disease perinatal lethal
    term:
      id: MONDO:0011945
      label: Gaucher disease perinatal lethal
- name: Cardiovascular
  description: >-
    Cardiovascular form, often associated with p.Asp448His (legacy D409H), featuring valvular calcification, corneal opacity, and supranuclear ophthalmoplegia.
  genes:
  - preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  evidence:
  - reference: PMID:8544197
    reference_title: "Unusual expression of Gaucher's disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Genotype analysis indicated that the patient was homozygous for the D409H mutation. It is tempting to relate the phenotype of severe cardiac involvement to the D409H/D409H genotype, although further cases will be needed before this association can be confirmed."
    explanation: >-
      The sib series that tied the cardiovascular form to homozygous GBA1
      D409H, and states its own hedge, which is why this row says "often
      associated with" rather than asserting the genotype defines the form.
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia.
    explanation: >-
      GeneReviews recognizes this clinical form in addition to types 1–3.
  subtype_term:
    preferred_term: Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome
    term:
      id: MONDO:0009268
      label: Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome
mechanistic_hypotheses:
- hypothesis_group_id: canonical_gba1_glucocerebroside_lysosomal_storage_model
  hypothesis_label: Canonical GBA1 Glucocerebroside Lysosomal Storage Model
  status: CANONICAL
  description: >-
    Biallelic GBA1 pathogenic variants reduce lysosomal glucocerebrosidase activity and impair glucosylceramide and glucosylsphingosine degradation. Macrophage lipid storage, inflammatory amplification, and altered skeletal remodeling contribute to visceral, hematologic, and skeletal disease. Neuronopathic forms additionally involve neuronal and glial lipid homeostasis and injury; their CNS biology is not explained by macrophage infiltration alone. ERT and substrate reduction strongly support the systemic storage pathway, while individual toxic intermediates and CNS mechanisms require separate evidence.
  notes: >-
    The OpenScientist report is assessed twice beside the report, in assessments/openscientist-assessment-by-codex.yaml (overall PARTIALLY_SUPPORTED) and assessments/openscientist-assessment-by-claude-opus-5.yaml (overall SUPPORTED); both endorse keeping CANONICAL for the core axis, and the verdicts differ on how much of the report beyond that core is carried. Retain CANONICAL for the GBA1 enzyme/substrate axis. Glucosylsphingosine, complement signaling, bone-cell interactions, and lipid-reactive gammopathy refine that axis. Biomarker association does not prove that glucosylsphingosine is the dominant toxin, and therapy response does not identify every intervening mechanism. GBA1-associated Parkinson disease is a risk branch distinct from acute/chronic neuronopathic Gaucher disease. ER stress predominance and comparative CNS treatment efficacy remain unresolved.
  evidence:
  - reference: PMID:10464619
    reference_title: "Gaucher disease: gene frequencies and genotype/phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the presence of a single N370S allele is diagnostic of the type 1 or nonneuronopathic"
    explanation: >
      Canonical mechanism review used as the seed reference for the
      hypothesis-search deep-research run.
  - reference: PMID:36739645
    reference_title: Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Organ volumes and hematologic parameters improved in parallel with reductions in plasma glucosylsphingosine during eliglustat treatment in both trials.
    explanation: >-
      Treatment-linked substrate and clinical responses support the canonical pathway without proving mediator-specific causation.
    directness: INDIRECT
- hypothesis_group_id: complement_amplification
  hypothesis_label: Complement amplification of lipid storage
  status: EMERGING
  description: >-
    A C5a/C5aR1-dependent inflammatory and substrate-synthesis feedback circuit extends the canonical storage mechanism. Intervention support comes from experimental systems, and therapeutic benefit in Gaucher patients remains unestablished.
  evidence:
  - reference: PMID:28225753
    reference_title: Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Marked local and systemic complement activation occurred in GCase-deficient mice or after pharmacological inhibition of GCase and was associated with GC storage, tissue inflammation and proinflammatory cytokine production.
    explanation: >-
      Both genetic and pharmacological mouse systems support complement activation; this does not demonstrate clinical efficacy of complement inhibition.
- hypothesis_group_id: stored_lipid_immune_activation
  hypothesis_label: Innate immune activation by stored glucosylceramide
  status: EMERGING
  description: >-
    Stored or released glucosylceramide can activate Mincle-dependent myeloid inflammation. Experimental receptor and ligand results support a mechanism beyond passive storage, without establishing human clinical effect sizes.
  evidence:
  - reference: PMID:28373578
    reference_title: Intracellular metabolite β-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Synthetic β-GlcCer activated myeloid cells and induced production of inflammatory cytokines; this production was abrogated in Mincle-deficient cells.
    explanation: >-
      Ligand and receptor-loss assays support Mincle-dependent cytokine induction; human Gaucher contribution is not established.
pathophysiology:
- name: GBA1 Mutation
  description: >
    Biallelic GBA1 pathogenic variants reduce lysosomal glucocerebrosidase
    activity through catalytic loss, protein misfolding, or impaired delivery
    to the lysosome. Genotype severity helps shape the clinical path: at least
    one N370S allele is associated with non-neuronopathic disease, while L444P
    homozygosity is strongly associated with neuronopathic disease.
  genes:
  - preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  downstream:
  - target: Glucocerebrosidase Deficiency
    description: GBA1 mutations reduce or abolish glucocerebrosidase enzyme activity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mutations in the GBA1 gene lead to a marked decrease in GCase activity."
      explanation: This review directly links pathogenic GBA1 mutations to reduced glucocerebrosidase activity.
  evidence:
  - reference: PMID:10464619
    reference_title: "Gaucher disease: gene frequencies and genotype/phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the presence of a single N370S allele is diagnostic of the type 1 or nonneuronopathic variant, whereas the L444P/L444P genotype is highly associated with neuronopathic variants in the Caucasian population."
    explanation: This genotype-phenotype review supports the mutation severity branch used in the pathograph.
- name: Glucocerebrosidase Deficiency
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Hydrolase or Cofactor Deficiency"
  description: >
    Deficient beta-glucocerebrosidase (glucosylceramidase) enzyme activity
    resulting from GBA1 mutations.
  genes:
  - preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  molecular_functions:
  - preferred_term: glucocerebrosidase activity
    term:
      id: GO:0004348
      label: glucosylceramidase activity
    modifier: DECREASED
  downstream:
  - target: Impaired Sphingolipid Catabolism
    description: Loss of glucocerebrosidase activity impairs lysosomal degradation of glucosylceramide.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This leads to a markedly decreased activity of the lysosomal enzyme, glucocerebrosidase (GCase, also called glucosylceramidase or acid β-glucosidase, EC: 4.2.1.25), which hydrolyzes glucosylceramide (GlcCer) into ceramide and glucose"
      explanation: The review describes the normal GCase reaction and therefore supports impaired glucosylceramide catabolism when the enzyme is deficient.
  - target: Neuronal Glycosphingolipid Accumulation
    description: Very low residual GCase activity in severe genotypes permits neuronal glycosphingolipid storage.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - low residual GCase activity in neuronopathic genotypes
    - neuronal glucosylceramide and glucosylsphingosine accumulation
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "GlcCer turnover in neurons is low and its accumulation is only significant when residual GCase activity is drastically decreased, i.e., only with some types of GBA1 mutations"
      explanation: This supports the severe-genotype branch from GCase deficiency to neuronal lipid accumulation.
  - target: GBA1-Associated Alpha-Synuclein Proteostasis
    description: >-
      Reduced GCase activity impairs lysosomal protein degradation and increases alpha-synuclein in experimental neuronal systems; this supports a possible Parkinson-risk mechanism rather than universal neuronopathic Gaucher pathology.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced lysosomal GCase activity
    - impaired autophagic turnover of alpha-synuclein
    evidence:
    - reference: PMID:21700325
      reference_title: Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: functional loss of GD-linked glucocerebrosidase (GCase) in primary cultures or human iPS neurons compromises lysosomal protein degradation, causes accumulation of α-synuclein (α-syn), and results in neurotoxicity through aggregation-dependent mechanisms.
      explanation: >-
        Primary neuronal cultures and human iPS neurons support this mechanistic branch; clinical penetrance remains incomplete.
  - target: Stromal Inflammatory Secretome
    description: >-
      GCase-deficient stromal cells show lipid accumulation and altered mediator secretion in vitro.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19587377
      reference_title: Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In conclusion, Gaucher disease MSCs display an altered secretome that could contribute to skeletal disease and immune disease manifestations in a manner distinct and additive to Gaucher macrophages themselves.
      explanation: >-
        The source identifies a distinct stromal inflammatory contribution, with uncertainty about clinical magnitude.
    intermediate_mechanisms:
    - stromal glucosylceramide accumulation
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages."
    explanation: Review confirms glucocerebrosidase deficiency causes glucosylceramide accumulation in macrophages.
- name: Impaired Sphingolipid Catabolism
  description: >
    Deficient glucocerebrosidase cannot degrade glucocerebroside (glucosylceramide) in lysosomes,
    leading to substrate accumulation.
  biological_processes:
  - preferred_term: Sphingolipid Catabolism
    term:
      id: GO:0030149
      label: sphingolipid catabolic process
    modifier: DECREASED
  downstream:
  - target: Glucocerebroside Accumulation in Macrophages
    description: Undegraded glucosylceramide accumulates primarily in macrophages.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages."
      explanation: The review directly connects GCase deficiency with macrophage glucosylceramide accumulation.
  - target: Glucosylsphingosine Accumulation
    description: GCase deficiency favors alternative conversion of glucosylceramide to glucosylsphingosine.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - ceramidase-mediated deacylation of glucosylceramide
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "GlcCer is also the substrate of an alternative pathway in which a ceramidase transforms it into glucosylsphingosine"
      explanation: This supports glucosylsphingosine as a downstream metabolite of accumulated glucosylceramide.
    - reference: PMID:35764179
      reference_title: "Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Reduced GCase activity leads to the accumulation of glucosylceramide (GlcCer), which is deacylated by lysosomal acid ceramidase to a toxic metabolite"
      explanation: >-
        Names lysosomal acid ceramidase as the enzyme performing the deacylation
        step recorded in this edge's intermediate mechanism, and characterizes
        the product as a toxic metabolite rather than an inert marker.
- name: Glucocerebroside Accumulation in Macrophages
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  description: >
    Glucocerebroside accumulates primarily in macrophages due to their role in
    phagocytosis and membrane turnover.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  downstream:
  - target: Gaucher Cell Formation
    description: Lipid-laden macrophages become Gaucher cells.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mutations in the GBA1 gene lead to a marked decrease in GCase activity. The consequences of this deficiency are generally attributed to the accumulation of the GCase substrate, GlcCer, in macrophages, inducing their transformation into Gaucher cells."
      explanation: This directly supports the transformation from lipid-loaded macrophages to Gaucher cells.
  - target: Complement C5aR1 Activation
    description: >-
      Stored lipid and lipid-reactive antibodies can activate complement in experimental Gaucher disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28225753
      reference_title: Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Marked local and systemic complement activation occurred in GCase-deficient mice or after pharmacological inhibition of GCase and was associated with GC storage, tissue inflammation and proinflammatory cytokine production.
      explanation: >-
        Both genetic and pharmacological mouse systems support complement activation; this does not demonstrate clinical efficacy of complement inhibition.
    intermediate_mechanisms:
    - lipid-reactive IgG
    - complement cleavage and C5a generation
    hypothesis_groups:
    - complement_amplification
  - target: Mincle-Dependent Lipid Sensing
    description: >-
      Exposed glucosylceramide can act as an endogenous Mincle ligand in experimental myeloid systems.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28373578
      reference_title: Intracellular metabolite β-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Synthetic β-GlcCer activated myeloid cells and induced production of inflammatory cytokines; this production was abrogated in Mincle-deficient cells.
      explanation: >-
        Ligand and receptor-loss assays support Mincle-dependent cytokine induction; human Gaucher contribution is not established.
    intermediate_mechanisms:
    - release or exposure of cellular glucosylceramide
    hypothesis_groups:
    - stored_lipid_immune_activation
- name: Gaucher Cell Formation
  description: >
    Lipid-laden macrophages (Gaucher cells) accumulate in spleen, liver, bone marrow, and other organs.
    These cells have characteristic crinkled tissue paper appearance and cause organ dysfunction
    through infiltration and inflammatory cytokine release.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: Macrophage Activation
    term:
      id: GO:0042116
      label: macrophage activation
    modifier: INCREASED
  downstream:
  - target: Visceral Reticuloendothelial Infiltration
    description: Gaucher cells infiltrate spleen and liver, causing reticuloendothelial organ enlargement.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
      explanation: This directly supports Gaucher cell infiltration of spleen and liver as the upstream mechanism for organomegaly.
  - target: Bone Marrow Infiltration
    description: Gaucher cell infiltration of marrow disrupts hematopoietic space and contributes to cytopenias.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
      explanation: This directly supports marrow infiltration as a cause of cytopenias.
  - target: Macrophage Inflammatory Mediator Release
    description: Gaucher and activated monocyte/macrophage populations release cytokines, chemokines, chitotriosidase, and CCL18.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Gaucher-cell polarization
    - monocyte/macrophage activation
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Thus numerous cytokines, chemokines and other molecules—including IL-1β, IL-6, IL-8, TNFα (Tumor Necrosis Factor), M-CSF (Macrophage-Colony Stimulating Factor), MIP-1β, IL-18, IL-10, TGFβ, CCL-18, chitotriosidase, CD14s, and CD163s—are present in increased amounts in Gaucher patients’ plasma and could be implicated in hematological and bone complications"
      explanation: This supports inflammatory mediator release downstream of macrophage involvement in Gaucher disease.
  - target: Bone Infarction
    description: >-
      Marrow Gaucher-cell accumulation may contribute to focal ischemic injury through vascular
      compression. This is a proposed route; inflammatory and mechanical factors may also contribute.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28218669
      reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: GlcCer accumulation in Gaucher cells is considered the first step towards bone involvement, leading to the vascular compression which is the source of necrotic complications
      explanation: >-
        This narrative-review synthesis proposes a vascular-compression route from stored-lipid
        macrophages to necrotic bone complications; it does not report a direct experiment or
        establish this as the sole or universally demonstrated mechanism.
    - reference: PMID:28218669
      reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The pathophysiological mechanism can involve other potential factors, such as alterations in the bone marrow or immune cells, inflammation, macrophage-derived factors, cytokines, and hormones
      explanation: >-
        This narrative-review synthesis, rather than a primary experimental or cohort result,
        explicitly leaves room for additional skeletal injury mechanisms.
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
    explanation: Review confirms Gaucher cell infiltration causes the major clinical manifestations.
- name: Visceral Reticuloendothelial Infiltration
  description: >
    Gaucher cells accumulate in reticuloendothelial organs, especially spleen
    and liver, producing splenomegaly and hepatomegaly.
  locations:
  - preferred_term: spleen
    term:
      id: UBERON:0002106
      label: spleen
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Hepatomegaly
    description: Liver infiltration by Gaucher cells enlarges the liver.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
      explanation: This directly links liver Gaucher cell infiltration to hepatomegaly.
  - target: Splenomegaly
    description: Spleen infiltration by Gaucher cells enlarges the spleen.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
      explanation: This directly links spleen Gaucher cell infiltration to splenomegaly.
  - target: Failure to Thrive
    description: >-
      Systemic disease burden may limit growth and weight gain in Type 1 disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28218669
      reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Growth retardation (30% of patients) may be the first sign, sometimes associated with cachexia.
      explanation: >-
        The review describes growth retardation in Type 1 disease; the specific growth-limiting intermediates remain incompletely defined.
      directness: INDIRECT
  - target: Splenic Sequestration
    description: >-
      Enlarged, infiltrated spleen contributes to sequestration of blood cells.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28218669
      reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells.
      explanation: >-
        Clinical review links reticuloendothelial organ involvement to cytopenias.
      directness: INDIRECT
- name: Bone Marrow Infiltration
  description: >-
    Gaucher macrophages occupy bone marrow and disturb the hematopoietic microenvironment. Marrow suppression and splenic sequestration both contribute to cytopenias; marrow involvement alone does not explain all hematologic disease.
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  biological_processes:
  - preferred_term: hemopoiesis
    modifier: DECREASED
    term:
      id: GO:0030097
      label: hemopoiesis
  downstream:
  - target: Thrombocytopenia
    description: Marrow infiltration and splenic involvement reduce circulating platelet counts.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28218669
      reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells.
      explanation: >-
        Review-level evidence supports the marrow contribution; splenic sequestration is an additional pathway.
      directness: INDIRECT
    intermediate_mechanisms:
    - reduced effective hematopoiesis
  - target: Anemia
    description: Marrow infiltration contributes to reduced red-cell output and anemia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28218669
      reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells.
      explanation: >-
        Review-level evidence supports the marrow contribution; splenic sequestration is an additional pathway.
      directness: INDIRECT
    intermediate_mechanisms:
    - reduced effective hematopoiesis
  - target: Fatigue
    description: Cytopenias and systemic Gaucher disease burden can manifest as fatigue.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - anemia
    - systemic disease burden
    evidence:
    - reference: ORPHA:355
      reference_title: "Gaucher disease"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0012378 | Fatigue | Very frequent (99-80%)"
      explanation: Orphanet supports fatigue as a very frequent Gaucher disease phenotype.
- name: Macrophage Inflammatory Mediator Release
  description: >
    Gaucher disease includes activated monocyte/macrophage states and elevated
    inflammatory mediators, with chitotriosidase and CCL18 reflecting Gaucher
    cell burden and cytokines contributing to hematologic and skeletal disease.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: macrophage activation
    term:
      id: GO:0042116
      label: macrophage activation
    modifier: INCREASED
  downstream:
  - target: Bone Remodeling Imbalance
    description: Inflammatory mediators stimulate bone resorption and contribute to skeletal disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - osteoclast stimulation
    - osteoblast inhibition
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Osteoporosis may be linked to IL-10, which inhibits osteoblast activity, but also to IL-1β, IL-6 and M-CSF, MIP-1α and MIP-1β, which stimulate bone resorption by increasing osteoclast activity"
      explanation: This supports inflammatory mediator effects as part of the skeletal disease branch.
- name: Glucosylsphingosine Accumulation
  description: >
    GCase deficiency favors formation and accumulation of glucosylsphingosine
    (Lyso-Gb1), a soluble bioactive sphingolipid that contributes to neuronopathic
    toxicity and may also affect bone.
  biological_processes:
  - preferred_term: Sphingolipid Catabolism
    term:
      id: GO:0030149
      label: sphingolipid catabolic process
    modifier: DECREASED
  downstream:
  - target: Neuronal Dysfunction and Loss
    description: >-
      Glucosylsphingosine is a candidate contributor to neuronal toxicity; the intervening injury processes and its relative importance versus other lipids remain incompletely established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the accumulation of glucosylsphingosine may cause neuronal dysfunction and death, leading mainly to GD-related neurological symptoms"
      explanation: This supports glucosylsphingosine accumulation as a proximal driver of neuronopathic disease.
  - target: Bone Remodeling Imbalance
    description: Sphingolipid imbalance, including sphingosine generated from glucosylsphingosine metabolism, contributes to skeletal toxicity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - sphingosine generation
    - bone-cell toxicity
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Sphingosine could be particularly toxic to bone; in this model, deletion of GBA2 could reverse the Gaucher disease phenotype, particularly the bone abnormalities."
      explanation: This mouse-model finding partially supports the sphingolipid branch contributing to bone disease.
  - target: Lysolipid-Reactive B-Cell Stimulation
    description: >-
      Accumulated lysolipid can provide chronic antigenic stimulation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26863356
      reference_title: Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Substrate reduction ameliorates Gaucher's disease-associated gammopathy in mice.
      explanation: >-
        Experimental reduction of substrate supports a lipid-dependent contribution to gammopathy; it does not establish prevention of human myeloma.
- name: Bone Remodeling Imbalance
  description: >-
    Bone formation and resorption are imbalanced in Gaucher disease. Macrophage-derived mediators can enhance osteoclast differentiation and reduce osteoblast mineralization in experimental systems; structural infarction is modeled separately.
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  biological_processes:
  - preferred_term: bone remodeling
    modifier: DYSREGULATED
    term:
      id: GO:0046849
      label: bone remodeling
  downstream:
  - target: Bone Pain
    description: Skeletal infiltration, bone crises, and infarction cause recurrent bone pain.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19047232
      reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The parameters measured were hemoglobin levels, platelet counts, spleen and liver volumes, z scores for height and bone mineral density, and reports of bone pain and bone crises."
      explanation: This cohort identifies bone pain and bone crises as measured skeletal manifestations in Gaucher disease.
  - target: Osteopenia
    description: Dysregulated Gaucher skeletal remodeling lowers bone mass and produces osteopenia.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:355
      reference_title: "Gaucher disease"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000938 | Osteopenia | Frequent (79-30%)"
      explanation: Orphanet supports osteopenia as a frequent Gaucher disease phenotype.
  - target: Pathologic Fractures
    description: Low bone mass and disordered remodeling increase pathological fracture risk.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Loss of bone mass occurs earlier and is more severe in patients with GD and may cause pathological fractures (of long bones, vertebrae, etc.)."
      explanation: This directly links bone mass loss to pathological fractures.
  - target: Erlenmeyer Flask Deformity
    description: Abnormal skeletal remodeling produces the characteristic distal femur deformity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22010032
      reference_title: "Quantifying the Erlenmeyer flask deformity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Erlenmeyer flask deformity is a common radiological finding in patients with Gaucher's disease"
      explanation: This supports Erlenmeyer flask deformity as a downstream skeletal phenotype.
  evidence:
  - reference: PMID:24076352
    reference_title: Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: In conclusion, these results suggest implication of changes in both bone formation and bone resorption and are consistent with the idea that both sides of the homeostatic balance are affected in GD.
    explanation: >-
      A chemical murine cell model supports a remodeling mechanism, with translation to patient skeletal disease qualified.
- name: Neuronal Glycosphingolipid Accumulation
  description: >-
    In neuronopathic Gaucher disease, low GCase activity permits neuronal/glial glucosylceramide and glucosylsphingosine accumulation. Their relative contributions to neuronal injury are unresolved; CNS storage is not equivalent to visceral Gaucher-cell infiltration.
  subtypes:
  - Type 2
  - Type 3
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Neuroinflammation
    description: Neuronal lipid storage and injury are accompanied by microgliosis and astrogliosis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30315684
      reference_title: "Neurological effects of glucocerebrosidase gene mutations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A common feature appears to be microgliosis and subsequent astrogliosis and neuronal loss, particularly in hippocampal regions"
      explanation: This supports glial activation downstream of neuronopathic substrate accumulation.
  - target: Neuronal Dysfunction and Loss
    description: Neuronal lipid toxicity causes neuronal dysfunction and death, producing oculomotor, bulbar, pyramidal, seizure, and developmental phenotypes.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the accumulation of glucosylsphingosine may cause neuronal dysfunction and death, leading mainly to GD-related neurological symptoms"
      explanation: This supports neuronal lipid toxicity as the upstream mechanism for neuronopathic clinical features.
  evidence:
  - reference: PMID:9497857
    reference_title: "Gaucher's disease: clinical features and natural history."
    supports: SUPPORT
    snippet: "Severe deficiency of glucocerebrosidase caused by disabling mutations is additionally associated with neurological manifestations that in part reflect a failure to degrade endogenous neuronal glycosphingolipids"
    explanation: Review explains that neuronopathic disease reflects failure to degrade neuronal glycosphingolipids.
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "the accumulation of glucosylsphingosine may cause neuronal dysfunction and death, leading mainly to GD-related neurological symptoms"
    explanation: Review confirms glucosylsphingosine accumulation causes neuronal dysfunction and death.
- name: Neuroinflammation
  description: >
    Microglial activation and neuroinflammation contribute to neurodegeneration
    in neuronopathic Gaucher disease.
  subtypes:
  - Type 2
  - Type 3
  cell_types:
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: Neuroinflammatory Response
    term:
      id: GO:0150076
      label: neuroinflammatory response
    modifier: INCREASED
  downstream:
  - target: Neuronal Dysfunction and Loss
    description: >-
      Activated microglia phagocytose impaired neurons in the Gba1 D409V/progranulin-null mouse model; the contribution to ordinary human neuronopathic disease remains qualified by the sensitized model.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39101473
      reference_title: Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Neurodegeneration in PG9VN was characterized by activated microglial phagocytosis of impaired neurons and programmed cell death due to necrosis and, possibly, pyroptosis.
      explanation: >-
        Experimental pathology supports a glial contribution to neuronal loss in a sensitized Gba1/Grn mouse model, without establishing the human effect size.
    intermediate_mechanisms:
    - microglial phagocytosis of impaired neurons
  evidence:
  - reference: PMID:30315684
    reference_title: "Neurological effects of glucocerebrosidase gene mutations."
    supports: SUPPORT
    snippet: "A common feature appears to be microgliosis and subsequent astrogliosis and neuronal loss, particularly in hippocampal regions"
    explanation: Review of postmortem and mouse model studies confirms microgliosis and astrogliosis as common neuropathological features in neuronopathic Gaucher disease.
- name: Neuronal Dysfunction and Loss
  description: >
    Neuronopathic Gaucher disease progresses through neuronal dysfunction and
    loss in vulnerable CNS regions, producing supranuclear gaze palsy, bulbar
    dysfunction, pyramidal or extrapyramidal signs, seizures, myoclonus, and
    developmental impairment.
  subtypes:
  - Type 2
  - Type 3
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Oculomotor Apraxia
    description: >-
      Dysfunction of neuronal circuits controlling saccades contributes to oculomotor apraxia in chronic neuronopathic disease; the clinical cohort does not identify the intervening circuit lesion.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37893235
      reference_title: 'Clinical Outcomes of Patients with Chronic Neuropathic Form of Gaucher Disease in the Spanish Real-World Setting: A Retrospective Study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The most frequent neurological abnormalities at onset were psychomotor retardation (14/19) and extrinsic muscle disorders (11/19), including oculomotor apraxia, supranuclear palsy, and strabismus.
      explanation: >-
        The GD3 cohort explicitly reports oculomotor apraxia; the combined 11/19 proportion is not an apraxia-specific frequency.
  - target: Horizontal Supranuclear Gaze Palsy
    description: Chronic neuronopathic disease commonly affects horizontal supranuclear gaze.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Some patients present moderate systemic involvement with horizontal ophthalmoplegia as the only neurological symptom"
      explanation: This supports horizontal gaze palsy as a downstream Type 3 neurologic phenotype.
  - target: Seizures
    description: Progressive neuronal dysfunction produces seizures and myoclonic epilepsy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Seizures occurring later manifest as myoclonic epilepsy that is resistant to antiepileptic drugs."
      explanation: This supports seizures as a downstream neuronopathic phenotype.
  - target: Myoclonus
    description: Chronic neuronopathic disease may progress to myoclonus epilepsy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "others present more severe forms with varying neurological signs including progressive myoclonus epilepsy (16% of patients)"
      explanation: This supports myoclonus as a downstream Type 3 phenotype.
  - target: Dysphagia
    description: Bulbar dysfunction in acute neuronopathic disease causes swallowing impairment.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "bulbar signs (particularly severe swallowing disorders)"
      explanation: This directly supports dysphagia as a downstream bulbar phenotype.
  - target: Spasticity
    description: Pyramidal tract involvement produces progressive spasticity and rigidity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "hypertonia with pyramidal and possibly extrapyramidal rigidity"
      explanation: This supports spasticity and rigidity as downstream pyramidal/extrapyramidal features.
  - target: Global Developmental Delay
    description: Early neuronopathic injury alters psychomotor development.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Psychomotor development is then altered, although some children may still continue to acquire skills."
      explanation: This supports developmental delay as a downstream neuronopathic phenotype.
  - target: Strabismus
    description: Oculomotor pathway involvement may present as bilateral fixed strabismus.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28218669
      reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "oculomotor paralysis (or bilateral fixed strabismus) is very suggestive of the disease"
      explanation: This supports strabismus as a downstream oculomotor phenotype.
- name: GBA1-Associated Alpha-Synuclein Proteostasis
  description: >
    Reduced GCase activity and mutant GCase handling perturb autophagy and
    alpha-synuclein turnover, creating a GBA1-linked Parkinson disease risk
    branch that overlaps with but is distinct from classic neuronopathic Gaucher
    disease.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  biological_processes:
  - preferred_term: Sphingolipid Catabolism
    term:
      id: GO:0030149
      label: sphingolipid catabolic process
    modifier: DECREASED
  downstream:
  - target: Parkinsonism
    description: Impaired alpha-synuclein proteostasis increases Parkinson disease risk and can manifest clinically as parkinsonism.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - alpha-synuclein accumulation
    - Lewy pathology
    - substantia nigra degeneration
    evidence:
    - reference: PMID:30315684
      reference_title: "Neurological effects of glucocerebrosidase gene mutations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mutations of the GBA allele are the most significant genetic risk factor for idiopathic PD, found in 5%-20% of idiopathic PD cases depending on ethnicity."
      explanation: This supports GBA1-linked Parkinson disease risk as a downstream phenotype branch.
  evidence:
  - reference: PMID:21700325
    reference_title: Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: functional loss of GD-linked glucocerebrosidase (GCase) in primary cultures or human iPS neurons compromises lysosomal protein degradation, causes accumulation of α-synuclein (α-syn), and results in neurotoxicity through aggregation-dependent mechanisms.
    explanation: >-
      Primary neuronal cultures and human iPS neurons support this mechanistic branch; clinical penetrance remains incomplete.
- name: Splenic Sequestration
  description: >-
    Hypersplenic pooling and destruction of blood cells contribute to thrombocytopenia and anemia alongside marrow disease.
  evidence:
  - reference: PMID:28218669
    reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells.
    explanation: >-
      Clinical review links reticuloendothelial organ involvement to cytopenias.
    directness: INDIRECT
  downstream:
  - target: Anemia
    description: >-
      Hypersplenism contributes to anemia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28218669
      reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells.
      explanation: >-
        Clinical review links reticuloendothelial organ involvement to cytopenias.
      directness: INDIRECT
  - target: Thrombocytopenia
    description: >-
      Splenic sequestration contributes to low platelet counts.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28218669
      reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells.
      explanation: >-
        Clinical review links reticuloendothelial organ involvement to cytopenias.
      directness: INDIRECT
- name: Complement C5aR1 Activation
  mechanism_confidence: PROVISIONAL
  description: >-
    Complement C5a signaling through C5aR1 amplifies inflammation in experimental Gaucher disease. Human complement and antibody findings support relevance, but intervention evidence remains preclinical.
  evidence:
  - reference: PMID:28225753
    reference_title: Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Marked local and systemic complement activation occurred in GCase-deficient mice or after pharmacological inhibition of GCase and was associated with GC storage, tissue inflammation and proinflammatory cytokine production.
    explanation: >-
      Both genetic and pharmacological mouse systems support complement activation; this does not demonstrate clinical efficacy of complement inhibition.
  biological_scale: CELLULAR
  downstream:
  - target: Increased Glucosylceramide Synthesis
    description: >-
      C5aR1 signaling increases glucosylceramide synthase production.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28225753
      reference_title: Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Subsequent C5aR1 activation controlled UDP-glucose ceramide glucosyltransferase production, thereby tipping the balance between GC formation and degradation.
      explanation: >-
        Experimental evidence supports a C5aR1-dependent substrate-synthesis amplification mechanism.
    hypothesis_groups:
    - complement_amplification
  - target: Macrophage Inflammatory Mediator Release
    description: >-
      Complement signaling enhances inflammatory-cell recruitment and cytokine production.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28225753
      reference_title: Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Marked local and systemic complement activation occurred in GCase-deficient mice or after pharmacological inhibition of GCase and was associated with GC storage, tissue inflammation and proinflammatory cytokine production.
      explanation: >-
        Both genetic and pharmacological mouse systems support complement activation; this does not demonstrate clinical efficacy of complement inhibition.
    hypothesis_groups:
    - complement_amplification
- name: Increased Glucosylceramide Synthesis
  mechanism_confidence: PROVISIONAL
  description: >-
    C5aR1-dependent glucosylceramide synthase upregulation increases substrate supply and amplifies storage in experimental Gaucher disease.
  evidence:
  - reference: PMID:28225753
    reference_title: Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Subsequent C5aR1 activation controlled UDP-glucose ceramide glucosyltransferase production, thereby tipping the balance between GC formation and degradation.
    explanation: >-
      Experimental evidence supports a C5aR1-dependent substrate-synthesis amplification mechanism.
  biological_scale: MOLECULAR
  downstream:
  - target: Glucocerebroside Accumulation in Macrophages
    description: >-
      Increased substrate synthesis adds to accumulation when degradation is deficient.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28225753
      reference_title: Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Subsequent C5aR1 activation controlled UDP-glucose ceramide glucosyltransferase production, thereby tipping the balance between GC formation and degradation.
      explanation: >-
        Experimental evidence supports a C5aR1-dependent substrate-synthesis amplification mechanism.
    intermediate_mechanisms:
    - synthesis exceeds residual lysosomal clearance
    hypothesis_groups:
    - complement_amplification
- name: Lysolipid-Reactive B-Cell Stimulation
  mechanism_confidence: PROVISIONAL
  description: >-
    Lysolipid-reactive clonal immunoglobulin and substrate-responsive murine gammopathy support antigen-driven B-cell/plasma-cell stimulation. Additional changes required for malignant transformation remain unresolved.
  evidence:
  - reference: PMID:26863356
    reference_title: Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Substrate reduction ameliorates Gaucher's disease-associated gammopathy in mice.
    explanation: >-
      Experimental reduction of substrate supports a lipid-dependent contribution to gammopathy; it does not establish prevention of human myeloma.
  downstream:
  - target: Monoclonal Gammopathy
    description: >-
      Chronic antigenic stimulation can contribute to clonal gammopathy.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26863356
      reference_title: Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Substrate reduction ameliorates Gaucher's disease-associated gammopathy in mice.
      explanation: >-
        Experimental reduction of substrate supports a lipid-dependent contribution to gammopathy; it does not establish prevention of human myeloma.
- name: Bone Infarction
  description: >-
    Focal skeletal ischemia produces bone infarcts and epiphyseal avascular necrosis. The relative
    roles of marrow infiltration, vascular compromise, and inflammatory or mechanical factors
    remain incompletely established.
  evidence:
  - reference: PMID:28218669
    reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The painful bone crises are probably associated with ischemic vaso-occlusive phenomena. It seems that they may be reversible and do not show up as lesions in medical imaging. However, they usually cause abnormalities referred to as bone infarcts on long bones (metaphyses or diaphyses) and flat bones, and lesions referred to as avascular necrosis (AVN) on the epiphyses.
    explanation: >-
      This narrative-review synthesis describes ischemic skeletal events and their anatomic
      manifestations; it is not a primary cohort result and qualifies the link between painful
      crises and vaso-occlusion.
  downstream:
  - target: Osteonecrosis
    description: >-
      Epiphyseal ischemic bone injury manifests as avascular osteonecrosis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28218669
      reference_title: A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: In addition to the vascular theory explaining the ischemic events (bone infarcts and AVN), a mechanical theory has also been put forward to explain the spontaneous or trabecular microfractures that are observed (mechanical or spontaneous AVN), particularly on the femoral head, the femoral condyle and the tibial plateau.
      explanation: >-
        This narrative-review synthesis links ischemic events to avascular necrosis and describes
        an alternative mechanical theory. It does not report a direct mechanistic experiment or
        imply that every episode of bone pain progresses to necrosis.
  - target: Bone Pain
    description: >-
      Bone infarction can produce severe bone crises.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:2013590
      reference_title: Bone scans in the diagnosis of bone crisis in patients who have Gaucher disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Of thirty-four occurrences of bone pain in seventeen children and young adults who had type-I Gaucher disease, twenty-five were finally diagnosed as bone crises.
      explanation: >-
        Primary series anchors painful bone crises; associated reduced radionuclide uptake supports an ischemic component without proving one vascular mechanism.
    - reference: PMID:2013590
      reference_title: Bone scans in the diagnosis of bone crisis in patients who have Gaucher disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: At the onset of a crisis, the bone scan typically showed decreased uptake of radionuclide at the involved site.
      explanation: >-
        Regional reduction in radionuclide uptake accompanies acute painful bone crises, consistent with an ischemic/infarct component.
    - reference: PMID:20301446
      reference_title: Gaucher Disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: analgesics for bone pain; joint replacement surgery for relief from chronic pain and restoration of function
      explanation: >-
        GeneReviews directly documents clinically significant bone pain and its management.
- name: Mincle-Dependent Lipid Sensing
  mechanism_confidence: PROVISIONAL
  description: >-
    Mincle recognizes glucosylceramide and stimulates inflammatory myeloid-cell responses in ligand assays and mouse genetic systems. This is a preclinical extension; the magnitude of its contribution to human Gaucher disease remains unknown.
  evidence:
  - reference: PMID:28373578
    reference_title: Intracellular metabolite β-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Synthetic β-GlcCer activated myeloid cells and induced production of inflammatory cytokines; this production was abrogated in Mincle-deficient cells.
    explanation: >-
      Ligand and receptor-loss assays support Mincle-dependent cytokine induction; human Gaucher contribution is not established.
  biological_scale: CELLULAR
  downstream:
  - target: Macrophage Inflammatory Mediator Release
    description: >-
      Mincle-dependent myeloid signaling induces inflammatory cytokine production in vitro.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28373578
      reference_title: Intracellular metabolite β-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Synthetic β-GlcCer activated myeloid cells and induced production of inflammatory cytokines; this production was abrogated in Mincle-deficient cells.
      explanation: >-
        Ligand and receptor-loss assays support Mincle-dependent cytokine induction; human Gaucher contribution is not established.
    hypothesis_groups:
    - stored_lipid_immune_activation
- name: Stromal Inflammatory Secretome
  mechanism_confidence: PROVISIONAL
  description: >-
    Bone marrow stromal cells from one patient showed an altered inflammatory secretome despite preserved osteogenic differentiation. Its contribution to human skeletal disease remains a model-supported possibility.
  evidence:
  - reference: PMID:19587377
    reference_title: Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: In conclusion, Gaucher disease MSCs display an altered secretome that could contribute to skeletal disease and immune disease manifestations in a manner distinct and additive to Gaucher macrophages themselves.
    explanation: >-
      The source identifies a distinct stromal inflammatory contribution, with uncertainty about clinical magnitude.
  biological_scale: CELLULAR
  downstream:
  - target: Bone Remodeling Imbalance
    description: >-
      Stromal inflammatory mediators may influence local bone-cell homeostasis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19587377
      reference_title: Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In conclusion, Gaucher disease MSCs display an altered secretome that could contribute to skeletal disease and immune disease manifestations in a manner distinct and additive to Gaucher macrophages themselves.
      explanation: >-
        The source identifies a distinct stromal inflammatory contribution, with uncertainty about clinical magnitude.
phenotypes:
- name: Hepatomegaly
  category: Gastrointestinal
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Often massive, may be first sign. Present across all subtypes.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
    explanation: Review confirms hepatomegaly as a major manifestation of Gaucher disease.
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002240 | Hepatomegaly | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation independently classifies hepatomegaly as very frequent in Gaucher disease.
- name: Splenomegaly
  category: Hematologic
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: >-
    Often massive. Splenectomy is reserved for selected severe complications because it can worsen other Gaucher manifestations.
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells."
    explanation: Review confirms splenomegaly as a major manifestation caused by Gaucher cell infiltration.
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001744 | Splenomegaly | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation independently classifies splenomegaly as very frequent in Gaucher disease.
- name: Thrombocytopenia
  category: Hematologic
  frequency: FREQUENT
  notes: Due to splenic sequestration and bone marrow infiltration
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: PMID:19047232
    reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
    supports: SUPPORT
    snippet: "More than 50% of patients had platelet counts of <100000 platelets per mm3 at baseline, but >95% had platelet counts above this level after 8 years of treatment."
    explanation: Study documents thrombocytopenia as a common baseline finding in Gaucher disease patients.
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001873 | Thrombocytopenia | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation supports classifying thrombocytopenia as frequent in Gaucher disease.
- name: Anemia
  category: Hematologic
  frequency: VERY_FREQUENT
  notes: >-
    Contributions include marrow involvement and splenic sequestration; the cited pediatric cohort and Orphanet frequency classes use different ascertainment frames.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:19047232
    reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
    supports: SUPPORT
    snippet: "Anemia, although not severe, was present in >50% of patients at baseline and resolved for all patients after 8 years of treatment."
    explanation: Study confirms anemia as a common finding in over half of Gaucher disease patients.
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001903 | Anemia | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation independently classifies anemia as very frequent in Gaucher disease.
- name: Fatigue
  category: Constitutional
  frequency: VERY_FREQUENT
  notes: Orphanet classifies fatigue among the very frequent Gaucher disease phenotypes.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012378 | Fatigue | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation supports fatigue as a very frequent phenotype in Gaucher disease.
- name: Bone Pain
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Bone crises can be severe
  phenotype_term:
    preferred_term: Bone Pain
    term:
      id: HP:0002653
      label: Bone pain
  evidence:
  - reference: PMID:19047232
    reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
    supports: SUPPORT
    snippet: "Seventeen percent of patients reported a bone crisis before treatment and in the first 2 years of treatment, but no bone crises were reported after 2 years of enzyme replacement therapy."
    explanation: Study documents bone crises/pain as a significant manifestation that resolves with treatment.
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002653 | Bone pain | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation supports classifying bone pain as frequent in Gaucher disease.
- name: Osteopenia
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Orphanet classifies osteopenia as a frequent skeletal phenotype.
  phenotype_term:
    preferred_term: Osteopenia
    term:
      id: HP:0000938
      label: Osteopenia
  evidence:
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000938 | Osteopenia | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation supports osteopenia as a frequent Gaucher disease phenotype.
- name: Pathologic Fractures
  category: Musculoskeletal
  notes: Due to bone disease and osteopenia
  phenotype_term:
    preferred_term: Pathologic Fractures
    term:
      id: HP:0002756
      label: Pathologic fracture
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "Loss of bone mass occurs earlier and is more severe in patients with GD and may cause pathological fractures (of long bones, vertebrae, etc.)."
    explanation: Review confirms pathological fractures result from accelerated bone mass loss in Gaucher disease.
- name: Erlenmeyer Flask Deformity
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Characteristic bone remodeling defect in distal femur
  phenotype_term:
    preferred_term: Erlenmeyer Flask Deformity
    term:
      id: HP:0004975
      label: Erlenmeyer flask deformity of the femurs
  evidence:
  - reference: PMID:22010032
    reference_title: "Quantifying the Erlenmeyer flask deformity."
    supports: SUPPORT
    snippet: "Erlenmeyer flask deformity is a common radiological finding in patients with Gaucher's disease"
    explanation: Study confirms Erlenmeyer flask deformity is a characteristic radiological finding in Gaucher disease.
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004975 | Erlenmeyer flask deformity of the femurs | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation supports Erlenmeyer flask deformity as frequent in Gaucher disease.
# Neuronopathic phenotypes (Types 2 and 3)
- name: Oculomotor Apraxia
  category: Neurologic
  subtype: Type 3
  notes: Oculomotor apraxia is reported in GD3 and should not be equated with fixed strabismus or extraocular muscle paralysis.
  phenotype_term:
    preferred_term: Oculomotor apraxia
    term:
      id: HP:0000657
      label: Oculomotor apraxia
  evidence:
  - reference: PMID:37893235
    reference_title: 'Clinical Outcomes of Patients with Chronic Neuropathic Form of Gaucher Disease in the Spanish Real-World Setting: A Retrospective Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most frequent neurological abnormalities at onset were psychomotor retardation (14/19) and extrinsic muscle disorders (11/19), including oculomotor apraxia, supranuclear palsy, and strabismus.
    explanation: >-
      The GD3 cohort explicitly reports oculomotor apraxia; the combined 11/19 proportion is not an apraxia-specific frequency.
- name: Horizontal Supranuclear Gaze Palsy
  category: Neurologic
  subtype: Type 3
  notes: Hallmark neurological feature of Type 3 Gaucher disease
  phenotype_term:
    preferred_term: Horizontal supranuclear gaze palsy
    term:
      id: HP:0007817
      label: Horizontal supranuclear gaze palsy
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "Some patients present moderate systemic involvement with horizontal ophthalmoplegia as the only neurological symptom"
    explanation: Review identifies horizontal ophthalmoplegia as the cardinal and sometimes sole neurological sign in Type 3.
- name: Seizures
  category: Neurologic
  notes: >-
    Seizures occur in neuronopathic forms, including progressive myoclonic epilepsy in Type 3; the cited sentence does not support a Type 2 frequency estimate.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "Seizures occurring later manifest as myoclonic epilepsy that is resistant to antiepileptic drugs."
    explanation: Review confirms seizures as a feature of Type 2, progressing to drug-resistant myoclonic epilepsy.
- name: Myoclonus
  category: Neurologic
  frequency: OCCASIONAL
  subtype: Type 3
  notes: Progressive myoclonic epilepsy is a feature of Type 3
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "others present more severe forms with varying neurological signs including progressive myoclonus epilepsy (16% of patients)"
    explanation: Review documents progressive myoclonus epilepsy in 16% of Type 3 patients.
- name: Dysphagia
  category: Neurologic
  subtype: Type 2
  notes: Bulbar dysfunction with swallowing difficulty in Type 2
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "bulbar signs (particularly severe swallowing disorders)"
    explanation: Review identifies severe swallowing disorders (dysphagia) as part of the Type 2 diagnostic triad.
- name: Spasticity
  category: Neurologic
  subtype: Type 2
  notes: Progressive spasticity and opisthotonus in Type 2
  phenotype_term:
    preferred_term: Progressive spasticity
    term:
      id: HP:0002191
      label: Progressive spasticity
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "hypertonia with pyramidal and possibly extrapyramidal rigidity"
    explanation: Review confirms pyramidal tract involvement with hypertonia and rigidity in Type 2.
- name: Global Developmental Delay
  category: Neurologic
  subtype: Type 2
  notes: Failure to achieve milestones in Type 2; developmental regression in Type 3
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "Psychomotor development is then altered, although some children may still continue to acquire skills."
    explanation: Review confirms altered psychomotor development as a feature of Type 2.
- name: Strabismus
  category: Neurologic
  subtype: Type 2
  notes: Convergent strabismus may be present in neuronopathic forms
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "oculomotor paralysis (or bilateral fixed strabismus) is very suggestive of the disease"
    explanation: Review identifies bilateral fixed strabismus as an alternative presentation of oculomotor involvement in Type 2.
- name: Failure to Thrive
  category: Growth
  frequency: FREQUENT
  subtype: Type 1
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "Growth retardation (30% of patients) may be the first sign, sometimes associated with cachexia."
    explanation: >-
      The review places this 30% growth-retardation figure in Type 1 disease; it is not a frequency estimate for Type 2.
- name: Parkinsonism
  category: Neurologic
  subtype: Type 1
  notes: >
    GBA1 mutations increase Parkinson disease risk in Type 1 Gaucher disease
    patients and carriers, although penetrance is incomplete.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  evidence:
  - reference: PMID:30315684
    reference_title: "Neurological effects of glucocerebrosidase gene mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations of the GBA allele are the most significant genetic risk factor for idiopathic PD, found in 5%-20% of idiopathic PD cases depending on ethnicity."
    explanation: This review supports GBA1 mutation-associated Parkinson disease risk.
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with type-1 GD-but also carriers of GBA1 mutation-have been found to be predisposed to developing Parkinson's disease"
    explanation: This Gaucher disease review specifically links Type 1 Gaucher disease and GBA1 carrier status to Parkinson disease predisposition.
- name: Monoclonal Gammopathy
  description: >-
    MGUS and other gammopathies are enriched in GD1, including at younger ages.
  phenotype_term:
    preferred_term: Monoclonal gammopathy
    term:
      id: HP:0031047
      label: Paraproteinemia
  evidence:
  - reference: PMID:36054609
    reference_title: Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Age-specific incidence rates of MGUS were unexpectedly high among younger patients.
    explanation: >-
      Large international registry supports the clinical gammopathy association.
  subtype: Type 1
  notes: The bound HPO paraproteinemia term covers circulating monoclonal immunoglobulin; MGUS is specified in the clinical description.
  sequelae:
  - target: Multiple Myeloma
    description: >-
      MGUS can progress to multiple myeloma; the reported ten-year progression estimate was similar to that of the general population.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36054609
      reference_title: Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The 10-year cumulative incidence of MM after diagnosis of MGUS was 7.9%, comparable to the general population.
      explanation: >-
        Supports progression from a precursor gammopathy without claiming an accelerated GD-specific transformation rate.
- name: Multiple Myeloma
  description: >-
    GD1 increases myeloma risk; the reported ninefold estimate is relative to the US population and is not penetrance.
  phenotype_term:
    preferred_term: Multiple myeloma
    term:
      id: HP:0006775
      label: Multiple myeloma
  evidence:
  - reference: PMID:36054609
    reference_title: Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'compared to the general population: non-Hodgkin lymphoma was approximately three times higher; MM was approximately nine times higher.'
    explanation: >-
      The registry compares myeloma risk with the general US population.
  subtype: Type 1
- name: Osteonecrosis
  description: >-
    Bone infarction and osteonecrosis may progress to joint collapse and remain possible despite therapy.
  phenotype_term:
    preferred_term: Avascular necrosis
    term:
      id: HP:0010885
      label: Avascular necrosis
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 GD is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia, thrombocytopenia, lung disease, and the absence of primary central nervous system disease.
    explanation: >-
      GeneReviews supplies the Type 1 clinical baseline.
  subtype: Type 1
- name: Lung Disease
  description: >-
    Pulmonary manifestations include infiltrative and vascular disease; their frequency and pathogenesis vary among subtypes.
  phenotype_term:
    preferred_term: Lung disease
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 GD is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia, thrombocytopenia, lung disease, and the absence of primary central nervous system disease.
    explanation: >-
      GeneReviews supplies the Type 1 clinical baseline.
  notes: HPO was searched during review; no single term adequately represents the combined infiltrative and pulmonary vascular involvement. Abnormal lung morphology alone would omit the vascular component.
- name: Ichthyosis
  description: >-
    Manifestation of the perinatal-lethal form.
  phenotype_term:
    preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis.
    explanation: >-
      GeneReviews describes severe perinatal skin and hydrops presentations.
  subtype: Perinatal lethal
- name: Nonimmune Hydrops Fetalis
  description: >-
    Manifestation of the perinatal-lethal form.
  phenotype_term:
    preferred_term: Nonimmune hydrops fetalis
    term:
      id: HP:0001790
      label: Nonimmune hydrops fetalis
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis.
    explanation: >-
      GeneReviews describes severe perinatal skin and hydrops presentations.
  subtype: Perinatal lethal
- name: Valvular Calcification
  description: >-
    Aortic and mitral valve calcification characterizes the cardiovascular form.
  phenotype_term:
    preferred_term: Cardiac valve calcification
    term:
      id: HP:0005146
      label: Cardiac valve calcification
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia.
    explanation: >-
      GeneReviews describes the cardiovascular clinical form.
  subtype: Cardiovascular
- name: Corneal Opacity
  description: >-
    Manifestation of the cardiovascular form.
  phenotype_term:
    preferred_term: Corneal opacity
    term:
      id: HP:0007957
      label: Corneal opacity
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia.
    explanation: >-
      GeneReviews describes the cardiovascular clinical form.
  subtype: Cardiovascular
- name: Kyphosis
  description: >-
    Thoracic kyphosis occurs in types 1 and 3. Its response to ERT/SRT remains incompletely characterized.
  phenotype_term:
    preferred_term: Thoracic kyphosis
    term:
      id: HP:0002942
      label: Thoracic kyphosis
  evidence:
  - reference: PMID:40112481
    reference_title: 'Challenges in Gaucher disease: Perspectives from an expert panel.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Thoracic kyphosis is a common complication of GD types 1 and 3, and there is very limited information regarding the effects of ERT or substrate synthesis inhibition therapy (SSIT) on this condition.
    explanation: >-
      Expert synthesis identifies kyphosis and the treatment-response evidence gap.
biochemical:
- name: Beta-glucocerebrosidase Activity
  presence: Decreased
  context: Enzyme activity in leukocytes typically less than 15% of normal
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes."
    explanation: Review confirms diagnosis via enzyme activity measurement in leukocytes.
- name: Chitotriosidase
  presence: Elevated
  context: >-
    Macrophage-burden marker; also elevated in other conditions and absent or low in patients with CHIT1 null variants.
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "This is the case for chitotriosidase and CCL18, which thus constitute quite specific disease biomarkers"
    explanation: Review confirms chitotriosidase as a specific biomarker expressed by Gaucher cells.
  - reference: PMID:25755533
    reference_title: "Gaucher disease."
    supports: SUPPORT
    snippet: "Monitoring of patients on ERT involves evaluation of growth, blood counts, liver and spleen size and biomarkers such as chitotriosidase which reflect the disease burden."
    explanation: Review confirms chitotriosidase is used for monitoring disease burden during ERT.
  - reference: PMID:36739645
    reference_title: Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Serum chitotriosidase activity, a widely used GD biomarker, is also elevated in many other conditions but is not measurable in 5-10% of individuals due to a common CHIT1 null variant.
    explanation: >-
      This biomarker is neither universal nor specific.
  readouts:
  - target: Macrophage Inflammatory Mediator Release
    relationship: READOUT_OF
    description: Secreted enzyme activity reflects Gaucher macrophage burden, with CHIT1 genotype limitations.
- name: Glucosylsphingosine (Lyso-Gb1)
  presence: Elevated
  context: >-
    Diagnostic and pharmacodynamic biomarker. Correlations with burden or response do not establish an independently validated surrogate endpoint or that the metabolite is the dominant tissue toxin.
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "Glucosylsphingosine is a novel biomarker whose sensitivity and specificity are superior to those of chitotriosidase and CCL18"
    explanation: Review confirms glucosylsphingosine as superior biomarker to chitotriosidase for GD monitoring.
  - reference: PMID:39499245
    reference_title: "Biomarker testing for lysosomal diseases: A technical standard of the American College of Medical Genetics and Genomics (ACMG)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "glucosylsphingosine (lyso-Gb1), galactosylsphingosine (psychosine), and glucose tetrasaccharide (Glca1-6Glca1-4Glca1-4Glc, Glc4) are biomarkers associated with Fabry, Gaucher, Krabbe, and Pompe disease, respectively"
    explanation: ACMG technical standard establishes glucosylsphingosine (lyso-Gb1) as the disease-specific biomarker for Gaucher disease.
  - reference: PMID:36544230
    reference_title: "Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "chitotriosidase activity, PARC/CCL18 or GlcSph concentrations can be used as a first line test"
    explanation: IWGGD laboratory-diagnosis guideline recommends GlcSph (lyso-Gb1) among first-line biomarker tests when Gaucher disease is suspected.
  readouts:
  - target: Glucosylsphingosine Accumulation
    relationship: READOUT_OF
    description: Circulating lyso-Gb1 measures substrate-related burden; tissue and clinical effects require separate assessment.
    evidence:
    - reference: PMID:36739645
      reference_title: Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: These clinical trial data add to the growing body of evidence supporting plasma glucosylsphingosine as both a diagnostic and pharmacodynamic/response biomarker for GD1.
      explanation: >-
        Supports biomarker use, without assuming causal mediation.
- name: Ferritin
  presence: Elevated
  context: Common elevation can reflect inflammatory iron redistribution; ferritin alone does not establish systemic iron overload.
  evidence:
  - reference: PMID:25153906
    reference_title: Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Gaucher disease induces some metabolic abnormalities so increased serum ferritin appears in more than 60% at diagnosis.
    explanation: >-
      Clinical study introduction documents frequent ferritin elevation.
genetic:
- name: GBA1
  gene_term:
    preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: Type 1
  notes: >
    Autosomal recessive. p.Asn409Ser (legacy N370S) is the most common mutation in Ashkenazi Jewish population. The presence of at least one p.Asn409Ser (legacy N370S) allele is protective against neuronopathic disease (diagnostic of Type 1).
  variants:
  - name: N370S homozygous
    description: Most common genotype in Ashkenazi Jewish patients. Always non-neuronopathic (Type 1).
  - name: N370S/other
    description: Compound heterozygotes with N370S are Type 1.
  evidence:
  - reference: PMID:10464619
    reference_title: "Gaucher disease: gene frequencies and genotype/phenotype correlations."
    supports: SUPPORT
    snippet: "the presence of a single N370S allele is diagnostic of the type 1 or nonneuronopathic variant"
    explanation: Grabowski review confirms N370S allele is protective against neuronopathic disease.
  - reference: CGGV:assertion_fbc5a876-f97e-4f9c-be99-664e2f6c8470-2020-06-24T160000.000Z
    reference_title: "GBA1 / Gaucher disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GBA1 | HGNC:4177 | Gaucher disease | MONDO:0018150 | AR | Definitive"
    explanation: ClinGen classifies the GBA1-Gaucher disease gene-disease relationship as definitive with autosomal recessive inheritance.
- name: GBA1
  gene_term:
    preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: Type 2
  notes: >-
    Severe biallelic GBA1 variants, including null and recombinant alleles, can produce acute neuronopathic disease. p.Leu483Pro (legacy L444P) associates with neuronopathic disease but does not by itself distinguish Type 2 from Type 3.
  variants:
  - name: L444P homozygous
    description: Highly associated with neuronopathic variants in Caucasian population.
  evidence:
  - reference: PMID:10464619
    reference_title: "Gaucher disease: gene frequencies and genotype/phenotype correlations."
    supports: SUPPORT
    snippet: "the L444P/L444P genotype is highly associated with neuronopathic variants in the Caucasian population"
    explanation: Grabowski review confirms L444P homozygosity predicts neuronopathic disease.
- name: GBA1
  gene_term:
    preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: Type 3
  notes: >
    Type 3 patients typically carry p.Leu483Pro (legacy L444P) or other severe mutations. The p.Asp448His (legacy D409H) mutation is specifically associated with the cardiac variant (Type 3c) with cardiovascular calcification.
  variants:
  - name: L444P homozygous (Type 3)
    description: May present as Type 3 with slower neurological progression.
  - name: D409H homozygous
    description: Associated with cardiac variant with cardiovascular calcification.
  evidence:
  - reference: PMID:10464619
    reference_title: "Gaucher disease: gene frequencies and genotype/phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the L444P/L444P genotype is highly associated with neuronopathic variants in the Caucasian population"
    explanation: >-
      Sources the L444P association with neuronopathic disease stated in this
      record. The review does not separate Type 2 from Type 3 on this
      genotype, which is why the record says "typically carry" rather than
      treating L444P as diagnostic of Type 3.
  - reference: PMID:8544197
    reference_title: "Unusual expression of Gaucher's disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "It is tempting to relate the phenotype of severe cardiac involvement to the D409H/D409H genotype, although further cases will be needed before this association can be confirmed."
    explanation: >-
      Sources the D409H-cardiac association stated in this record, including
      the authors' own caution about it.
- name: GBA1
  gene_term:
    preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: Cardiovascular
  notes: >-
    The cardiovascular form (GD3c) is the same GBA1 disease as the other
    forms. Homozygosity for p.Asp448His (legacy D409H) is the genotype
    reported in the three-sib series cited below, whose authors describe the
    genotype-phenotype link as unconfirmed pending further cases.
  variants:
  - name: D409H homozygous (cardiovascular form)
    description: >-
      Reported in three sisters with calcification of the ascending aorta and
      of the aortic and mitral valves, ophthalmoplegia and saccadic eye
      movements in two of them, and glucocerebrosidase activity reduced to
      4% (fibroblast) and 11% (liver) of mean normal values in the one sib
      sampled.
    gene:
      preferred_term: GBA1
      term:
        id: hgnc:4177
        label: GBA
  evidence:
  - reference: PMID:8544197
    reference_title: "Unusual expression of Gaucher's disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Tissue was obtained from one of the sibs and fibroblast and liver beta-glucocerebrosidase activity was reduced to 4% and 11% of mean normal values. Genotype analysis indicated that the patient was homozygous for the D409H mutation."
    explanation: >-
      Establishes GBA1 as the gene for the cardiovascular form, with the
      enzyme deficit and the D409H genotype measured in the same patient.
- name: GBA1
  gene_term:
    preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  association: Risk Factor
  relationship_type: RISK_FACTOR
  variant_origin: GERMLINE
  review_notes: >-
    The risk this record carries is risk of Parkinson disease in GBA1
    heterozygotes and in people with Gaucher disease, not risk of Gaucher
    disease itself. It is kept here because the mechanism is curated in this
    entry (pathophysiology#GBA1-Associated Alpha-Synuclein Proteostasis), but
    the KGX exporter emits every genetic[] record as a gene-to-this-disease
    edge and does not read relationship_type (dismech#12320), so this record
    currently exports as an undifferentiated GBA1-to-Gaucher-disease edge.
  notes: >
    GBA1 mutations (both homozygous and heterozygous) are the most significant genetic risk factor for Parkinson disease. OR 5.43 across centers. Found in 5-20% of idiopathic PD cases depending on ethnicity.
  evidence:
  - reference: PMID:19846850
    reference_title: "Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease."
    supports: SUPPORT
    snippet: "The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers."
    explanation: Landmark multicenter NEJM study confirms strong GBA-Parkinson association with OR 5.43.
  - reference: PMID:30315684
    reference_title: "Neurological effects of glucocerebrosidase gene mutations."
    supports: SUPPORT
    snippet: "Mutations of the GBA allele are the most significant genetic risk factor for idiopathic PD, found in 5%-20% of idiopathic PD cases depending on ethnicity."
    explanation: Review confirms GBA mutations are the most significant genetic risk factor for PD.
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "Patients with type-1 GD-but also carriers of GBA1 mutation-have been found to be predisposed to developing Parkinson's disease"
    explanation: Review confirms both GD patients and GBA1 carriers have increased PD risk.
prevalence:
- population: Worldwide
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.0
  rate_high: 9.0
  percentage: "1-9 / 100 000"
  notes: Orphanet reports worldwide prevalence at birth in the 1-9 per 100,000 class.
  evidence:
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Worldwide | Prevalence at birth | PMID:23046562"
    explanation: Orphanet provides a worldwide prevalence-at-birth class for Gaucher disease.
- population: Europe
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.0
  rate_high: 9.0
  percentage: "1-9 / 100 000"
  notes: Orphanet reports both European annual incidence and point prevalence in the 1-9 per 100,000 class.
  evidence:
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Europe | Point prevalence | EXPERT"
    explanation: Orphanet provides a European point-prevalence class for Gaucher disease.
- subtype: Type 1
  population: Global
  notes: >-
    Incidence estimates depend on population; the cited review reports approximately 1/40,000–1/60,000 births in the general population and 1/800 in Ashkenazi Jews. These are not universal subtype proportions.
  evidence:
  - reference: PMID:28218669
    reference_title: "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments."
    supports: SUPPORT
    snippet: "In the general population, its incidence is approximately 1/40,000 to 1/60,000 births, rising to 1/800 in Ashkenazi Jews."
    explanation: Review provides incidence estimates for Gaucher disease.
- subtype: Type 1
  population: Ashkenazi Jewish
  notes: Markedly increased prevalence due to founder effect; carrier frequency ~1/15.
  evidence:
  - reference: PMID:10464619
    reference_title: "Gaucher disease: gene frequencies and genotype/phenotype correlations."
    supports: SUPPORT
    snippet: "Gaucher disease is the most prevalent lysosomal storage disease and has its highest incidence in the Ashkenazi Jewish population."
    explanation: Review confirms highest incidence in Ashkenazi Jewish population.
progression:
- phase: Disease onset
  age_range: All ages
  notes: Orphanet records disease-level onset across all ages, complementing the subtype-specific onset patterns below.
  evidence:
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: All ages"
    explanation: Orphanet's natural-history field supports broad all-age onset for Gaucher disease overall.
- phase: Onset
  subtype: Type 1
  age_range: Childhood-Adulthood
  notes: Highly variable onset; some patients remain asymptomatic.
- phase: Onset
  subtype: Type 2
  age_range: before 2 years
  notes: >-
    GeneReviews describes early CNS onset and death commonly by two to four years; considerable clinical variability remains.
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 2 GD is characterized by primary central nervous system disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years.
    explanation: >-
      GeneReviews defines the broader onset and survival range; onset before six months and death by two years are not universal.
- phase: Death
  subtype: Type 2
  age_range: 2-4 years
  notes: >-
    GeneReviews describes early CNS onset and death commonly by two to four years; considerable clinical variability remains.
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 2 GD is characterized by primary central nervous system disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years.
    explanation: >-
      GeneReviews defines the broader onset and survival range; onset before six months and death by two years are not universal.
- phase: Onset
  subtype: Type 3
  age_range: Childhood
  notes: Neurological symptoms appear in childhood with slower progression than Type 2.
- phase: Chronic
  subtype: Type 3
  notes: Survival into adulthood with progressive neurological decline and systemic disease.
treatments:
- name: Enzyme Replacement Therapy
  description: >-
    Imiglucerase, velaglucerase alfa, or taliglucerase alfa restore enzyme activity in systemic tissues. ERT improves hematovisceral manifestations in GD1 and GD3, with variable skeletal response, but does not adequately cross the blood-brain barrier or correct neuronopathic disease.
  treatment_term:
    preferred_term: enzyme replacement therapy
    term:
      id: NCIT:C16221
      label: Protein Replacement Therapy
    therapeutic_agent:
    - preferred_term: imiglucerase
    - preferred_term: velaglucerase alfa
    - preferred_term: taliglucerase alfa
  target_mechanisms:
  - target: Glucocerebrosidase Deficiency
    treatment_effect: RESTORES
    description: Recombinant enzyme replacement restores systemic glucocerebrosidase activity upstream of macrophage storage.
    evidence:
    - reference: PMID:19047232
      reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal."
      explanation: Clinical response to enzyme replacement supports correction of the upstream systemic enzyme-deficiency pathway.
  evidence:
  - reference: PMID:19047232
    reference_title: "Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1."
    supports: SUPPORT
    snippet: "Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal."
    explanation: Long-term study demonstrates effectiveness of enzyme replacement therapy in children with Gaucher disease.
  - reference: PMID:25755533
    reference_title: "Gaucher disease."
    supports: SUPPORT
    snippet: "ERT is of no benefit in type 2 disease."
    explanation: Review confirms ERT does not help neurological disease in Type 2 due to BBB.
  - reference: PMID:41821052
    reference_title: 'The global impact of imiglucerase therapy in children with Gaucher disease types 1 and 3: a real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Despite complex disease burden in GD3, imiglucerase therapy led to marked hematovisceral disease reversal and meaningful growth improvements, closely paralleling responses in GD1.
    explanation: >-
      Large pediatric registry distinguishes systemic efficacy in GD3 from absent proof of CNS rescue.
  therapeutic_modality: PROTEIN_REPLACEMENT
- name: Substrate Reduction Therapy
  description: >-
    Eliglustat and miglustat reduce glucosylceramide synthesis in selected patients with GD1. Eliglustat selection depends on CYP2D6 metabolism, interactions, and clinical suitability. Miglustat can cross the BBB but has not established neurological efficacy in neuronopathic Gaucher disease.
  treatment_term:
    preferred_term: substrate reduction therapy
    term:
      id: NCIT:C85876
      label: Substrate Deprivation Therapy
    therapeutic_agent:
    - preferred_term: eliglustat
    - preferred_term: miglustat
  target_mechanisms:
  - target: Glucocerebroside Accumulation in Macrophages
    treatment_effect: INHIBITS
    description: Glucosylceramide synthase inhibition reduces substrate supply upstream of macrophage storage.
    evidence:
    - reference: PMID:25688781
      reference_title: "Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "treatment with eliglustat compared with placebo for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count."
      explanation: Clinical response to eliglustat supports substrate reduction acting upstream of visceral and hematologic manifestations.
  evidence:
  - reference: PMID:25688781
    reference_title: "Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial."
    supports: SUPPORT
    snippet: "treatment with eliglustat compared with placebo for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count."
    explanation: Phase 3 ENGAGE trial demonstrates eliglustat substrate reduction therapy effectively improves clinical manifestations in Gaucher disease.
  - reference: PMID:19067373
    reference_title: Randomized, controlled trial of miglustat in Gaucher's disease type 3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: No significant between-group differences in vertical saccadic eye movement velocity or in the other neurological or neuropsychological evaluations were observed.
    explanation: >-
      Randomized GD3 comparison found no established neurological benefit from adjunctive miglustat.
  therapeutic_modality: SMALL_MOLECULE
- name: Supportive Care
  description: Pain management, orthopedic interventions, transfusions as needed.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: orthopedic management of bone disease; analgesics for bone pain; joint replacement surgery for relief from chronic pain and restoration of function;
    explanation: >-
      GeneReviews supports symptomatic orthopedic and pain care.
- name: Orthopedic Management of Skeletal Disease
  description: >
    Management of Gaucher-related bone disease, including avascular necrosis
    (osteonecrosis) of the femoral and humeral heads. Early diagnosis enables
    joint-preserving surgical intervention, while advanced osteonecrosis with
    articular collapse may require total joint arthroplasty.
  treatment_term:
    preferred_term: orthopedic surgical procedure
    term:
      id: NCIT:C16186
      label: Orthopedic Surgical Procedure
  evidence:
  - reference: PMID:36436966
    reference_title: "ACR Appropriateness Criteria® Osteonecrosis: 2022 Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Risk factors for osteonecrosis are numerous and include trauma, corticosteroid therapy, alcohol use, HIV, lymphoma/leukemia, blood dyscrasias, chemotherapy, radiation therapy, Gaucher disease, and Caisson disease"
    explanation: ACR guideline identifies Gaucher disease as an established risk factor for osteonecrosis warranting imaging-guided orthopedic management.
  - reference: PMID:36436966
    reference_title: "ACR Appropriateness Criteria® Osteonecrosis: 2022 Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "to allow for possible early surgical prevention to prevent articular collapse and need for joint replacements"
    explanation: ACR guideline supports early surgical intervention in osteonecrosis to prevent articular collapse and the need for joint replacement.
  - reference: PMID:30414226
    reference_title: "Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For type 1 disease, seven major signs (splenomegaly, thrombocytopenia, bone-related manifestations, anaemia, hyperferritinaemia, hepatomegaly and gammopathy)"
    explanation: GED-C consensus identifies bone-related manifestations as a major presenting sign of type 1 Gaucher disease, underpinning the need for skeletal disease management.
- name: Genetic Counseling
  description: Family screening, prenatal diagnosis available.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Once the GBA1 pathogenic variants have been identified in an affected family member, molecular genetic carrier testing for at-risk family members, preimplantation genetic testing, and prenatal testing for GD are possible.
    explanation: >-
      GeneReviews supports familial and reproductive testing.
- name: Lentiviral Gene Therapy
  description: >
    Autologous transplant of CD34+ hematopoietic stem cells transduced with
    lentiviral vector carrying functional GBA1 gene. Restores glucocerebrosidase
    production from transduced cells. First-in-human case demonstrates sustained
    therapeutic response with maintained enzyme levels, reduced biomarkers
    (lyso-GB1), and organ volume improvement at 5-year follow-up without need
    for additional enzyme replacement or substrate reduction therapy.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  therapeutic_modality: GENE_THERAPY
  notes: >-
    Investigational. Evidence to date is a single first-in-human case report
    (n=1), in contrast to the established enzyme replacement and substrate
    reduction therapies; not an approved therapy.
  target_mechanisms:
  - target: Glucocerebrosidase Deficiency
    treatment_effect: RESTORES
    description: Transduced CD34+ cells produce functional glucocerebrosidase, restoring systemic enzyme activity.
    evidence:
    - reference: PMID:42324119
      reference_title: "Gaucher Disease Treated With Lentiviral-Mediated Gene Therapy: First Case."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "At 5 years of follow-up, dried blood spot GCase enzyme levels have remained in the normal range"
      explanation: Case demonstrates sustained restoration of enzyme activity to normal levels following gene therapy.
  evidence:
  - reference: PMID:42324119
    reference_title: "Gaucher Disease Treated With Lentiviral-Mediated Gene Therapy: First Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This case shows a sustained response to a single dose of lentiviral gene therapy for Gaucher disease."
    explanation: Case report demonstrates durable long-term efficacy of lentiviral gene therapy approach in Gaucher disease.
- name: Surveillance and Treatment Precautions
  description: >-
    Assess progression at least every six months across hematologic, skeletal, pulmonary, cardiac, psychiatric, and neurologic domains; image liver and spleen periodically. Avoid NSAIDs with moderate-to-severe thrombocytopenia and, if possible, eliglustat during pregnancy.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical assessment of disease progression at least every six months to include hematologic, orthopedic, pulmonary, cardiac, psychiatric, and neurologic assessment;
    explanation: >-
      GeneReviews provides the surveillance baseline.
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Nonsteroidal anti-inflammatory drugs in individuals with moderate-to-severe thrombocytopenia.
    explanation: >-
      Identifies the medication precaution.
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The lack of studies on the safety of eliglustat use during pregnancy and lactation has led to the recommendation that this medication be avoided during pregnancy, if possible.
    explanation: >-
      Records the reproductive treatment precaution.
- name: Ambroxol Chaperone Therapy
  description: >-
    Investigational pharmacologic enhancement of residual mutant GCase stability and activity. A 28-patient uncontrolled series found variable systemic improvement and two nonresponders; it does not establish comparative efficacy or a neurological cure. A separate 13-patient GD3 study on stable ERT reported improvement in selected neurologic symptoms; absence of a concurrent control limits inference.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ambroxol
  evidence:
  - reference: PMID:37342037
    reference_title: Use of Ambroxol as Therapy for Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Two patients with severe symptoms at baseline experienced deterioration of hematologic parameters and biomarkers and were deemed nonresponders; clinical response was observed in the other 26 patients.
    explanation: >-
      Uncontrolled case-series response is preliminary and heterogeneous.
  - reference: PMID:41901003
    reference_title: Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We evaluated 13 patients with type 3 GD (L444P/L444P homozygotes) who received ambroxol at 10 mg/kg/day for one year as part of a clinical trial.
    explanation: >-
      Additional small uncontrolled GD3 cohort on stable ERT; preliminary benefit signals require comparative confirmation.
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Glucocerebrosidase Deficiency
    treatment_effect: RESTORES
    description: Chaperoning can enhance stability and residual activity for responsive variants.
    evidence:
    - reference: PMID:37342037
      reference_title: Use of Ambroxol as Therapy for Gaucher Disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Ambroxol was identified as an enhancer of stability and residual activity of several misfolded glucocerebrosidase variants in 2009.
      explanation: >-
        The reported chaperone mechanism is variant-dependent.
- name: Hematopoietic Stem Cell Transplantation
  description: >-
    Selected severe cases, particularly chronic neuronopathic disease, may be considered for transplantation at specialist centers. This option has substantial treatment risk and should not imply established reversal of CNS injury.
  treatment_term:
    preferred_term: Hematopoietic Cell Transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hematopoietic stem cell transplantation may be an option in individuals with severe GD, primarily those with chronic neurologic involvement (type 3 GD).
    explanation: >-
      GeneReviews recognizes selected-use transplantation.
  therapeutic_modality: CELL_THERAPY
- name: Venglustat
  description: >-
    Investigational brain-penetrant glucosylceramide synthase inhibitor. Phase 2 LEAP demonstrated CSF substrate lowering with heterogeneous clinical signals; neurological efficacy must be distinguished from biochemical target engagement. The ongoing Phase 3 LEAP2MONO program compares venglustat with imiglucerase.
  treatment_term:
    preferred_term: Substrate Deprivation Therapy
    term:
      id: NCIT:C85876
      label: Substrate Deprivation Therapy
    therapeutic_agent:
    - preferred_term: venglustat
  evidence:
  - reference: PMID:36256599
    reference_title: 'Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: After 1 year of treatment, median (inter-quartile range) glucosylceramide decreased 78% (72, 84) in plasma and 81% (77, 83) in CSF; median (inter-quartile range) glucosylsphingosine decreased 56% (41, 60) in plasma and 70% (46, 76) in CSF.
    explanation: >-
      LEAP demonstrates CNS substrate target engagement in 11 adults, not a controlled demonstration of neurological rescue.
  - reference: PMID:36256599
    reference_title: 'Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: neurocognition, assessed by Vineland II, deteriorated in all domains over time, which illustrates disease progression despite the intervention.
    explanation: >-
      The published phase 2 study includes progression despite marked CSF substrate lowering.
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Neuronal Glycosphingolipid Accumulation
    treatment_effect: INHIBITS
    description: Reduces glycosphingolipid substrate synthesis and CSF lipid concentrations; clinical neuroprotection is a separate claim.
    evidence:
    - reference: PMID:36256599
      reference_title: 'Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: After 1 year of treatment, median (inter-quartile range) glucosylceramide decreased 78% (72, 84) in plasma and 81% (77, 83) in CSF; median (inter-quartile range) glucosylsphingosine decreased 56% (41, 60) in plasma and 70% (46, 76) in CSF.
      explanation: >-
        LEAP demonstrates CNS substrate target engagement in 11 adults, not a controlled demonstration of neurological rescue.
- name: AAV Gene Augmentation
  description: >-
    Investigational vector-mediated GBA1 augmentation includes systemic FLT201/PR001 programs and CNS-directed VGN-R08b. Routes, target tissues, eligibility, and evidence differ; these approaches should not be represented as established equivalents to systemic ERT.
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  evidence:
  - reference: clinicaltrials:NCT07223944
    reference_title: A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients With Gaucher Disease Type 1
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The study aims to confirm the efficacy and safety of FLT201 in this population after discontinuation of ERT/SRT.
    explanation: >-
      The registered trial establishes investigation of systemic AAV gene augmentation; efficacy is not inferred from registration.
  therapeutic_modality: GENE_THERAPY
  target_mechanisms:
  - target: Glucocerebrosidase Deficiency
    treatment_effect: RESTORES
    description: Investigational gene addition aims to augment functional GCase rather than repair the inherited alleles.
    evidence:
    - reference: clinicaltrials:NCT07223944
      reference_title: A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients With Gaucher Disease Type 1
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The study aims to confirm the efficacy and safety of FLT201 in this population after discontinuation of ERT/SRT.
      explanation: >-
        The registered trial establishes investigation of systemic AAV gene augmentation; efficacy is not inferred from registration.
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:355
    reference_title: "Gaucher disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet lists autosomal recessive inheritance for Gaucher disease.
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: If both parents are known to be heterozygous for a GBA1 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being a heterozygote, and a 25% chance of inheriting neither of the familial GBA1 pathogenic variants.
    explanation: >-
      Specifies the parental-genotype condition for Mendelian recurrence probabilities.
  description: >-
    When both parents are heterozygous for pathogenic GBA1 variants, each pregnancy has a 25% affected, 50% heterozygous, and 25% noncarrier probability; these figures do not apply unchanged when a parent is biallelic.
datasets:
- accession: geo:GSE303993
  title: Developing Midbrain-like Organoid of Gaucher Disease as A Platform for Drug Assessment
  description: Gaucher disease (GD) is a lysosomal storage disorder caused by GBA1 mutations, leading to defective acid β-glucosidase (GCase) and accumulation of glucosylsphingolipids, causing inflammation and neurodegeneration. We developed midbrain-like organoids (MLOs) from induced pluripotent stem cells (iPSCs) of nGD patients with GBA1L444P/P415R and GBA1L444P/RecNcil mutations to model nGD brain pathogenesis. These nGD MLOs exhibited GCase deficiencies, reduced enzyme activities, lipids accumulation, transcriptomic alterations, and impaired dopaminergic neuron differentiation, mirroring nGD pathology.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 6
  publication: PMID:42334452
  notes: Identified by GEO DataSets index search for Gaucher Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE150266
  title: Use of mice defective in interferon signaling to distinguish between primary and secondary pathological pathways in a mouse model of neuronal forms of Gaucher disease
  description: The type 1 interferon (IFN) response is part of the innate immune response and best known for its role in viral and bacterial infection. However, this pathway is also induced in sterile inflammation such as occurs in a number of neurodegenerative diseases, including neuronopathic Gaucher disease (nGD), a lysosomal storage disorder (LSD) caused by mutations in Gba1. Mice were injected with conduritol B-epoxide, an irreversible inhibitor of acid-beta glucosidase, the enzyme defective in nGD. Quadrat deficient MyTrMaSt mice, where four adaptors of pathogen recognition receptors (PRRs) are deficient, were used to determine the role of the IFN pathway in nGD pathology.
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: BULK_RNA_SEQ
  sample_count: 14
  publication: PMID:32892753
  notes: Identified by GEO DataSets index search for Gaucher Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE250051
  title: Gene expression profiling of brain tissue from neuronopathic Gaucher disease mouse model of PG9VN, PG9V and wild type mice
  description: To understand the intrinsic link between PGRN and Gba D409V mutation dosage in regulating lysosomal function and disease pathogenesis, we generated nGD model of GbaD409V/D409V and loss of PGRN (Grn-/-), termed PG9V that displayed typical neuronopathic GD (nGD). With decreasing the dose of Gba D409V, i.e., D409V/Null, in Grn KO mice (Grn-/-;GbaD409V/Null, PG9VN) led to much earlier onset and more severe neurodegenerative nGD than PG9V mice.
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: BULK_RNA_SEQ
  sample_count: 9
  publication: PMID:39101473
  notes: Identified by GEO DataSets index search for Gaucher Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: massive:MSV000080786
  title: Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease
  description: Gaucher disease, a recessive inherited metabolic disorder caused by defects in the gene encoding glucosylceramidase (GlcCerase), can be divided into three subtypes according to the appearance of symptoms associated with central nervous system involvement. We now identify a protein, glycoprotein non-metastatic B (GPNMB), that acts as an authentic marker of brain pathology in neurological forms of Gaucher disease.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Gaucher Disease"). Retrieved 2026-08-02.
- accession: massive:MSV000092415
  title: Proteomics analysis of the brain from a Gaucher disease mouse identifies pathological pathways including a possible role for transglutaminase 1
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: PROTEOMICS
  description: Gaucher disease (GD) is caused by the defective activity of acid beta-glucosidase (GCase) which results from mutations in GBA1. Neurological forms of GD (nGD) can be generated in mice by intra-peritoneal injection of conduritol B-epoxide (CBE) which irreversibly inhibits GCase. Using this approach, a number of pathological pathways have been identified in mouse brain by RNAseq analysis. However, unlike transcriptomics, proteomics gives information about protein expression which is more likely to provide insight into which cellular pathways may be impacted in disease.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Gaucher Disease"). Retrieved 2026-08-02.
diagnosis:
- name: Glucocerebrosidase activity and GBA1 testing
  description: >-
    Confirm deficient GCase activity in leukocytes or other nucleated cells and/or biallelic pathogenic GBA1 variants. Dried-blood-spot screening requires appropriate confirmatory evaluation; GBA1 testing must account for its homologous pseudogene and recombinant alleles.
  evidence:
  - reference: PMID:20301446
    reference_title: Gaucher Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The diagnosis of GD relies on demonstration of deficient glucocerebrosidase (glucosylceramidase) enzyme activity in peripheral blood leukocytes or other nucleated cells, or by the identification of biallelic pathogenic variants in GBA1 on molecular genetic testing.
    explanation: >-
      Authoritative diagnostic confirmation strategy.
discussions:
- kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Glucosylsphingosine Accumulation
  - phenotypes#Multiple Myeloma
  - phenotypes#Lung Disease
  - has_subtypes#Perinatal lethal
  - has_subtypes#Cardiovascular
  prompt: Which lipid-dependent and secondary processes determine neuronal, vascular, skin, and malignant complications?
  rationale: >-
    The canonical substrate defect is established, but circulating GlcSph associations do not prove dominant tissue toxicity. Gammopathy and cancer associations do not establish the entire malignant-transformation chain. Perinatal skin/hydrops, valvular calcification, and pulmonary vascular versus infiltrative disease are represented clinically without unsupported mechanistic arrows. Prospective substrate-guided skeletal studies, lipid/ER-stress measurements in cell-resolved models, and longitudinal B-cell clonality studies would discriminate candidate explanations.
  evidence:
  - reference: PMID:37249220
    reference_title: 'Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: There was a significant correlation between GlcSph levels and AVN.
    explanation: >-
      Correlation motivates mechanistic and prospective testing, rather than proving direct mediation.
  - reference: PMID:36054609
    reference_title: Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 10-year cumulative incidence of MM after diagnosis of MGUS was 7.9%, comparable to the general population.
    explanation: >-
      Increased gammopathy prevalence is distinguishable from an increased MGUS-to-myeloma progression rate.
  discussion_id: unresolved_tissue_injury
- discussion_id: selected_alps_like_immune_phenotype
  kind: KNOWLEDGE_GAP
  prompt: How does lipid storage relate to the ALPS-like lymphocyte/apoptosis phenotype in a subset of patients?
  attaches_to:
  - pathophysiology#Lysolipid-Reactive B-Cell Stimulation
  - pathophysiology#Macrophage Inflammatory Mediator Release
  rationale: >-
    In a 41-patient cohort, 10 had ALPS-like immune features and seven of those ten showed defective FAS-induced apoptosis. This selected subgroup supports an additional immune phenotype but does not establish universal FAS dysfunction or the missing lipid-to-apoptosis mechanism.
  evidence:
  - reference: PMID:32702516
    reference_title: Defective FAS-Mediated Apoptosis and Immune Dysregulation in Gaucher Disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: FAS-induced apoptosis and caspase activation were further evaluated in these 10 patients and were found to be defective in 7 of them.
    explanation: >-
      The measured apoptosis defect is conditional on the selected ALPS-like subgroup.
- discussion_id: gap_gd_brain_substrate_in_gba1_parkinson
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Does glucosylceramide or glucosylsphingosine actually accumulate in the
    brains of people with GBA1-associated Parkinson disease, or is that branch
    driven by misfolded GCase protein independently of substrate storage?
  attaches_to:
  - pathophysiology#GBA1-Associated Alpha-Synuclein Proteostasis
  - pathophysiology#Neuronal Glycosphingolipid Accumulation
  rationale: >-
    This entry models the Parkinson disease branch as flowing from reduced GCase
    activity and mutant GCase handling through impaired alpha-synuclein
    turnover, in parallel with the substrate accumulation that drives the other
    branches. Reviewers of the GBA1-Parkinson literature report that substrate
    accumulation has not been convincingly demonstrated in GBA1-Parkinson
    brains, and propose instead that misfolded GCase induces endoplasmic
    reticulum stress and an unfolded protein response that impairs the
    autophagy-lysosomal pathway. If that is right, the branch is a
    gain-of-function proteotoxicity operating alongside rather than downstream
    of the storage chain, and it predicts different therapeutic priorities:
    chaperone stabilization over substrate reduction. The absence is scoped to
    GBA1-Parkinson brains and does not transfer to neuronopathic types 2 and 3,
    where neuronal glucosylsphingosine accumulation is documented. This is the
    ER-stress question left unresolved in the canonical hypothesis notes. The
    stronger reading, that this absence proves gain-of-function predominance, is
    rejected in the codex assessment of the OpenScientist report: bulk-brain
    absence does not prove absence in the relevant cells, and heterozygous
    GBA1-Parkinson disease cannot be conflated with biallelic neuronopathic
    Gaucher disease. What remains is the open question recorded here.
  proposed_experiments:
  - experiment_id: exp_gd_gba1pd_brain_lipidomics
    name: Region-resolved brain lipidomics in GBA1-associated Parkinson disease
    description: >-
      Mass spectrometry imaging of glucosylceramide and glucosylsphingosine in
      post-mortem GBA1-Parkinson brain, stratified by variant severity, region
      (substantia nigra, cortex, cerebellum) and disease stage, with paired
      endoplasmic reticulum stress markers and cell-type-resolved measurement
      separating neurons from glia.
    would_support:
    - pathophysiology#Neuronal Glycosphingolipid Accumulation
    supporting_outcome:
    - >-
        Glucosylceramide and glucosylsphingosine are elevated in affected regions
        and track alpha-synuclein pathology, placing the Parkinson branch
        downstream of substrate accumulation as the storage chain predicts.
    refuting_outcome:
    - >-
        Lipids are normal or minimally raised while endoplasmic reticulum stress
        markers are elevated, which would weaken the substrate-driven reading of
        this branch without by itself establishing that protein misfolding is the
        predominant mechanism.
    notes: >-
      No entity is listed in would_refute. The refuting outcome bears on whether
      neuronal glycosphingolipid accumulation extends to the Parkinson branch,
      which is the node already named in would_support; it does not refute the
      alpha-synuclein proteostasis node, whose description covers mutant GCase
      handling as well as reduced activity and is therefore compatible with an
      endoplasmic reticulum stress result.
  evidence:
  - reference: PMID:37080432
    reference_title: "Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Preclinical evidence also shows that products of GCase activity can promote accumulation of α-synuclein, however there is no convincing evidence of substrate accumulation in GBA1-PD brains."
    explanation: >-
      States the absence directly for GBA1-Parkinson brains, and sets it against
      the preclinical evidence that would predict the opposite.
  - reference: PMID:37080432
    reference_title: "Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Misfolded GCase proteins induce endoplasmic reticulum stress and subsequent unfolded protein response and impair the autophagy-lysosomal pathway."
    explanation: >-
      Names the competing gain-of-function mechanism that would explain the
      branch without substrate storage.
  posed_date: '2026-09-17T00:00:00Z'
experimental_models:
- name: CBE-treated murine macrophage conditioned-medium model
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: >-
    CBE-inhibited murine macrophage/splenocyte conditioned media applied to osteoclast precursors and osteoblast cultures.
  modeled_mechanisms:
  - target: Bone Remodeling Imbalance
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    limitations: Chemical GCase inhibition and conditioned-media transfer do not reproduce human genotype, marrow architecture, perfusion, or clinical osteonecrosis.
    evidence:
    - reference: PMID:24076352
      reference_title: Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In conclusion, these results suggest implication of changes in both bone formation and bone resorption and are consistent with the idea that both sides of the homeostatic balance are affected in GD.
      explanation: >-
        A chemical murine cell model supports a remodeling mechanism, with translation to patient skeletal disease qualified.
    readouts:
    - name: Osteoblast alkaline phosphatase and mineralization
      target: Bone Remodeling Imbalance
      direction: DECREASED
      evidence:
      - reference: PMID:24076352
        reference_title: Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: On the other hand, addition of CM to an osteoblast cell culture resulted in a reduction in expression of alkaline phosphatase and mineralization process.
        explanation: >-
          The reported measurement supports reduced osteoblast function in vitro.
- name: GD1 patient bone marrow stromal cells
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: >-
    Mesenchymal stromal cells from one adult GD1 donor with legacy N370S/L444P genotype, compared with control cells and complemented by chemical inhibition experiments.
  modeled_mechanisms:
  - target: Stromal Inflammatory Secretome
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    limitations: Single patient donor and cell-culture comparison; retained osteogenic differentiation limits claims that intrinsic stromal differentiation failure explains human bone disease.
    evidence:
    - reference: PMID:19587377
      reference_title: Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In conclusion, Gaucher disease MSCs display an altered secretome that could contribute to skeletal disease and immune disease manifestations in a manner distinct and additive to Gaucher macrophages themselves.
      explanation: >-
        The source identifies a distinct stromal inflammatory contribution, with uncertainty about clinical magnitude.
animal_models:
- name: Gba1 D409V with progranulin deficiency
  species: Mouse
  genotype: Grn-null; Gba1 D409V/D409V or D409V/null
  publication: PMID:39101473
  description: >-
    A sensitized neuronopathic model tests interaction between GCase dosage and progranulin loss.
  modeled_mechanisms:
  - target: Neuroinflammation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: The additional Grn-null lesion is an experimental sensitizer; this is not evidence that GRN variants cause ordinary Gaucher disease.
    evidence:
    - reference: PMID:39101473
      reference_title: Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Glycosphingolipid accumulation, inflammatory responses, lysosomal-autophagy dysfunction, microgliosis, retinal gliosis, as well as α-Synuclein increases were much more pronounced in PG9VN mice.
      explanation: >-
        The model links GCase dosage and sensitizing progranulin loss to inflammatory neuropathology.
references:
- reference: PMID:20301446
  title: Gaucher Disease.
  tags:
  - GeneReviews
clinical_trials:
- name: NCT05324943
  phase: PHASE_I
  status: COMPLETED
  description: >-
    GALILEO-1 evaluates single-dose intravenous FLT201 gene therapy in GD1. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT05324943
    reference_title: A Phase 1, Open-label, Safety, Tolerability, and Efficacy Study of FLT201 in Adult Patients With Gaucher Disease Type 1 (GALILEO-1)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This study is a first-in-human, open-label, safety, tolerability, and efficacy study in adult patients with Gaucher disease Type 1.
    explanation: >-
      ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.
- name: NCT07223944
  phase: PHASE_III
  status: RECRUITING
  description: >-
    GALILEO-3 evaluates efficacy and safety of FLT201 in adults with GD1 after ERT/SRT withdrawal. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT07223944
    reference_title: A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients With Gaucher Disease Type 1
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years.
    explanation: >-
      ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.
- name: NCT05487599
  phase: PHASE_I
  status: ACTIVE_NOT_RECRUITING
  description: >-
    PROCEED is a Phase I/II systemic PR001/LY3884961 AAV gene-therapy study for peripheral Gaucher manifestations. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT05487599
    reference_title: An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Study J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD.\n\nUp to 3 dose levels of LY3884961 will be assessed in 3 dose-finding cohorts of 3 patients."
    explanation: >-
      ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.
- name: NCT04145037
  phase: PHASE_I
  status: TERMINATED
  description: >-
    Guard1 is the terminated Phase I/II AVR-RD-02 autologous lentiviral HSC gene-therapy study. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT04145037
    reference_title: The Guard1 Trial, an Open-Label, Multinational Phase 1/2 Study of the Safety and Efficacy of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-02 for Subjects With Type 1 Gaucher Disease
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This was a multinational, open-label study to assess the safety and efficacy of AVR-RD-02 in approximately 8 to 16 subjects (male or female) who are ≥18 and ≤50 years of age and post pubertal at Screening with a confirmed diagnosis of Type 1 Gaucher disease (based on clinical phenotype, genotyping, and deficient GCase enzyme activity in whole blood).
    explanation: >-
      ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.
- name: NCT06272149
  phase: PHASE_I
  status: RECRUITING
  description: >-
    Early Phase I study of intracerebroventricular AAV9-GBA1 VGN-R08b in infants with GD2. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT06272149
    reference_title: An Exploratory Clinical Trial to Evaluate the Tolerability and Safety of VGN-R08b Via Intracerebroventricular Injection in Patients With Type II Gaucher Disease
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This exploratory trial is to prove the tolerability and safety of VGN-R08b to treat infants with type II Gaucher disease.
    explanation: >-
      ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.
- name: NCT02843035
  phase: PHASE_II
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Phase II LEAP investigates venglustat with imiglucerase and subsequent monotherapy extension in GD3. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT02843035
    reference_title: A 4-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic, and Exploratory Efficacy of Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Evaluate short-term (Part 2) and long-term (Part 3) safety and tolerability of venglustat in combination with Cerezyme in adult GD3 participants
    explanation: >-
      The registry specifies the combination intervention and GD3 population; registration is not evidence of benefit.
- name: NCT05222906
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Phase III LEAP2MONO is a randomized active-comparator trial of venglustat versus imiglucerase in GD3. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT05222906
    reference_title: A Phase 3, Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (GD3) Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ERT)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This is a parallel arm, Phase 3, double-blind, double-dummy, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and \<18 years and adult patients with Gaucher disease Type 3 (GD3) who have been treated with Enzyme Replacement Therapy (ERT) for at least 3 years.
    explanation: >-
      ClinicalTrials.gov record verifies the registered intervention and disease population; registration alone is not efficacy evidence.
differential_diagnoses:
- name: Gaucher disease due to saposin C deficiency
  description: >-
    PSAP-related saposin C deficiency can produce Gaucher-like lipid storage despite normal or low activity on artificial-substrate enzyme assays.
  distinguishing_features:
  - Consider PSAP testing when the clinical phenotype and biomarkers suggest Gaucher disease but pathogenic GBA1 variants are absent.
  evidence:
  - reference: PMID:36544230
    reference_title: Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "and normal or low BGLU activity in cells, a Sap C \ndeficiency should be suspected and the PSAP gene \nanalyzed."
    explanation: >-
      The laboratory guideline recommends PSAP analysis in the described GBA1-negative diagnostic context; PSAP deficiency is a separate curated disorder.

📚

References & Deep Research

References

1

PMID:20301446

Gaucher Disease.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Falcon ▸

1. Disease Information

Edison Scientific Literature 41 citations 2026-04-25T22:33:46.418270

1. Disease Information

1.1 Concise overview

Gaucher disease (GD) is a lysosomal storage disorder caused by deficient activity of lysosomal acid β-glucosidase / glucocerebrosidase (GCase), leading to lysosomal accumulation of glucosylceramide (GlcCer) and its deacylated derivative glucosylsphingosine (GlcSph; lyso‑Gb1), particularly in macrophages, resulting in multi-organ disease (visceral, hematologic, skeletal; and sometimes neurologic) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, rossi2023noninvasivedbsbasedapproaches pages 1-2, dardis2022patientcenteredguidelines pages 1-2).

Clinical types (classical): - Type 1 (GD1): non-neuronopathic; accounts for ~90–95% of cases (cojbasicUnknownyeardiagnosisandmanagement pages 5-8, rossi2023noninvasivedbsbasedapproaches pages 1-2). - Type 2 (GD2): acute neuronopathic; rare, often fatal in early childhood (cojbasicUnknownyeardiagnosisandmanagement pages 5-8). - Type 3 (GD3): chronic neuronopathic; less common than GD1 (cojbasicUnknownyeardiagnosisandmanagement pages 5-8).

1.2 Key identifiers and controlled vocabulary

MONDO: MONDO_0018150 (carubbi2026glucosylsphingosine(lysogb1)an pages 1-2)
OMIM (clinical types):
GD1: 230800
GD2: 230900
GD3: 231000 (carubbi2026glucosylsphingosine(lysogb1)an pages 1-2)
MeSH: D005776 (“Gaucher Disease”) (from ClinicalTrials.gov browse module) (NCT07223944 chunk 1, NCT05324943 chunk 1).
Orphanet, ICD‑10, ICD‑11: Not explicitly present in the retrieved full-text excerpts/trial records; therefore not asserted here.

1.3 Common synonyms / alternative names (as used in retrieved sources)

Gaucher disease; GD (rossi2023noninvasivedbsbasedapproaches pages 1-2)
Gaucher disease type 1/2/3; GD1/GD2/GD3 (rossi2023noninvasivedbsbasedapproaches pages 1-2)
“glucocerebrosidase deficiency” / “acid beta‑glucosidase deficiency” (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, dardis2022patientcenteredguidelines pages 1-2)

1.4 Evidence provenance (patient vs aggregated)

The information in this report is primarily derived from aggregated resources: international guideline synthesis (Dardis et al. 2022), narrative reviews (Giuffrida et al. 2023; Rossi et al. 2023), a population screening cohort (Chang et al. 2024), real-world registry analysis (GOS registry; Zimran et al. 2025), mechanistic animal-model work (Lin et al. 2024), and ClinicalTrials.gov trial records (chang2024newbornscreeningfor pages 1-2, dardis2022patientcenteredguidelines pages 8-9, zimran2025evaluationoflysogb1 pages 1-2, lin2024intrinsiclinkbetween pages 1-2, NCT05324943 chunk 1).

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants in GBA1 encoding GCase (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, dardis2022patientcenteredguidelines pages 1-2, dubiela2024longandshortterm pages 1-2).

Important alternative genetic etiology (Gaucher-like biochemistry/phenotype): If clinical/biochemical features are consistent with GD but no pathogenic GBA1 variants are found, international laboratory guidelines recommend considering saposin C deficiency and analyzing PSAP (prosaposin gene) (dardis2022patientcenteredguidelines pages 10-12).

2.2 Risk factors

Genetic: biallelic pathogenic GBA1 variants are causal (dardis2022patientcenteredguidelines pages 1-2). The diagnostic guideline notes extensive allelic heterogeneity; HGMD lists 540 GBA1 variants, with 403 associated with GD (dardis2022patientcenteredguidelines pages 9-10).
Population ancestry: incidence is higher in Ashkenazi Jewish populations (e.g., ~1 in 450–1,000 live births reported by a biomarker review) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2).

2.3 Protective factors

No protective genetic or environmental factors were explicitly identified in the retrieved excerpts.

2.4 Gene–environment interactions

No explicit gene–environment interaction studies were identified in the retrieved excerpts. However, precision-genomics work argues that phenotypic heterogeneity may reflect multi-locus genetic contributions (saith2024concurrentgeneticdisorders pages 1-3, saith2025precisiongenomicprofiling pages 1-2).

3. Phenotypes

3.1 Core phenotype spectrum (with approximate frequencies where available)

From a recent clinical summary excerpt, common clinical findings include: - Splenomegaly: >90% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) - Hepatomegaly: 60–80% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) - Thrombocytopenia: ~90% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) - Anemia: 30–50% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) Skeletal involvement is common and may become irreversible if advanced (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).

Neurologic involvement distinguishes GD2 (acute severe) and GD3 (chronic neuronopathic) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, rossi2023noninvasivedbsbasedapproaches pages 1-2).

3.2 Phenotype characteristics

Onset: ranges from infancy (especially GD2) to adulthood; GD2 typically presents in the first year of life and may be fatal early (cojbasicUnknownyeardiagnosisandmanagement pages 5-8).
Progression: variable; neurologic disease is progressive and generally not improved by current systemic therapies that do not cross the blood–brain barrier (kulkarni2024advancementsinviral pages 10-12, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).

3.3 Quality-of-life impact

The retrieved excerpts do not provide standardized QoL instrument statistics (EQ‑5D/SF‑36). Bone disease and cytopenias plausibly drive morbidity, but such statements require additional QoL-specific sources.

3.4 Suggested HPO terms (examples)

Based on phenotypes explicitly discussed in retrieved sources: - Splenomegaly (HP:0001744) - Hepatomegaly (HP:0002240) - Thrombocytopenia (HP:0001873) - Anemia (HP:0001903) - Bone pain / skeletal dysplasia / osteonecrosis (multiple; skeletal involvement is explicit but granular HPO mapping would require additional phenotype-specific papers) (cojbasicUnknownyeardiagnosisandmanagement pages 5-8, giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2).

4. Genetic / Molecular Information

4.1 Causal genes

GBA1 (glucosylceramidase beta 1; glucocerebrosidase) is causal; located near a highly homologous pseudogene, complicating molecular analysis (dardis2022patientcenteredguidelines pages 1-2, dardis2022patientcenteredguidelines pages 8-9).
PSAP can be involved in saposin C deficiency when GD-like phenotype occurs without GBA1 variants (dardis2022patientcenteredguidelines pages 10-12).

4.2 Pathogenic variant spectrum and genotype–phenotype examples

The laboratory guideline describes extensive allelic diversity and complex alleles arising from recombination with the pseudogene; ~10% may have large deletions/recombinants (dardis2022patientcenteredguidelines pages 9-10, dardis2022patientcenteredguidelines pages 8-9).
Example genotype–phenotype relationships (from biomarker dynamics study):
N370S (c.1226A>G; p.Asn409Ser): common; relatively protective of CNS involvement (dubiela2024longandshortterm pages 1-2).
L444P (c.1448T>C; p.Leu483Pro): associated with neuronopathic disease in some contexts (e.g., GD3) (dubiela2024longandshortterm pages 1-2).

4.3 Modifier genes and “multi-locus” contributions (recent work)

Mechanistic modifier evidence (animal model): - A 2024 mechanistic study reports that progranulin (PGRN; GRN) acts as a modifier of GCase biology and disease severity. In Grn−/− mice with graded Gba1 D409V dosages, higher mutant dosage produced earlier onset/shorter lifespan and more severe inflammation, lysosomal–autophagy dysfunction, gliosis, and α‑synuclein increases, supporting a threshold model for severity (lin2024intrinsiclinkbetween pages 1-2).

Human cohort precision-genomics evidence: - In a deeply phenotyped cohort with WES, ~6–6.5% of GD patients had additional genetic diagnoses contributing to “expanded/atypical” phenotypes, suggesting that some GD presentations behave as multi-locus disorders (saith2024concurrentgeneticdisorders pages 3-5, saith2024concurrentgeneticdisorders pages 1-3). - Example cohort statistics: among 275 patients, 18 (6.5%) had expanded phenotypes (preprint) (saith2024concurrentgeneticdisorders pages 3-5) and 17 (6.2%) had atypical phenotypes (peer-reviewed version) (saith2025precisiongenomicprofiling pages 1-2).

4.4 Epigenetics / chromosomal abnormalities

No epigenetic or chromosomal-abnormality evidence was identified in the retrieved excerpts.

5. Environmental Information

No specific environmental, lifestyle, or infectious triggers were identified in the retrieved excerpts as causal contributors to GD. (GD is primarily genetic.)

6. Mechanism / Pathophysiology

6.1 Causal chain (current understanding)

GBA1 pathogenic variants → reduced/mislocalized GCase activity (dardis2022patientcenteredguidelines pages 1-2).
Impaired lysosomal degradation of GlcCer → ceramide → accumulation of GlcCer and GlcSph (lyso‑Gb1) (dardis2022patientcenteredguidelines pages 1-2, giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2).
Lipid-laden macrophages (“Gaucher cells”) infiltrate liver, spleen, bone marrow → organomegaly, cytopenias, and bone disease (rossi2023noninvasivedbsbasedapproaches pages 1-2, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).
In neuronopathic forms and in modifier contexts, lysosomal dysfunction intersects with neuroinflammation, gliosis, autophagy disruption, and α‑synuclein pathology (lin2024intrinsiclinkbetween pages 1-2).

6.2 Molecular pathways / cellular processes (from retrieved mechanistic sources)

Precision-genomic and mechanistic sources emphasize lipid-driven metabolic inflammation and lysosome-autophagy disruption: - “The accumulation of GlcCer and GlcSph in GD activates a range of pathways, including those involving inflammasomes, iron metabolism, necroptosis, ferroptosis, lysosomal function, autophagy, and reactive oxygen species (ROS).” (Saith et al. 2024 preprint excerpt) (saith2024concurrentgeneticdisorders pages 11-13). - PGRN/GRN modifier work demonstrates dose-dependent substrate accumulation, inflammatory responses, lysosomal–autophagy dysfunction, microgliosis, and α‑synuclein increases in mouse models (lin2024intrinsiclinkbetween pages 1-2).

6.3 Suggested ontology terms

GO Biological Process (examples): lysosomal organization; sphingolipid catabolic process; macrophage activation; autophagy; inflammatory response.
CL (cell types): macrophage (Gaucher cell is macrophage-derived); microglia (in neuronopathic/mechanistic models) (rossi2023noninvasivedbsbasedapproaches pages 1-2, lin2024intrinsiclinkbetween pages 1-2).

7. Anatomical Structures Affected

7.1 Organ level (commonly affected)

Spleen, liver, bone marrow, bone are repeatedly highlighted as key sites of lipid accumulation and clinical disease (rossi2023noninvasivedbsbasedapproaches pages 1-2, cojbasicUnknownyeardiagnosisandmanagement pages 5-8, dardis2022patientcenteredguidelines pages 1-2).
Neurologic involvement (brain) defines GD2/GD3 and is a major unmet-need domain for therapies (kulkarni2024advancementsinviral pages 10-12, NCT06272149 chunk 1).

7.2 Tissue/cell level

Primary disease cell type: macrophages (lipid-laden Gaucher cells) (rossi2023noninvasivedbsbasedapproaches pages 1-2).
In neuronopathic pathology and modifier models: microglia and neurons are implicated through neuroinflammation and neurodegeneration pathways (lin2024intrinsiclinkbetween pages 1-2).

7.3 Subcellular level

Lysosome is the core compartment of dysfunction; impaired lysosomal trafficking/delivery of GCase and lysosomal lipid accumulation are central (dardis2022patientcenteredguidelines pages 1-2, lin2024intrinsiclinkbetween pages 1-2).

7.4 Suggested UBERON terms (examples)

Spleen; liver; bone marrow; brain.

8. Temporal Development

Onset: can be pediatric or adult depending on subtype and genotype (cojbasicUnknownyeardiagnosisandmanagement pages 5-8).
Progression: variable; neurologic forms are progressive and currently poorly addressed by standard ERT/SRT (kulkarni2024advancementsinviral pages 10-12, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).

9. Inheritance and Population

9.1 Inheritance pattern

Autosomal recessive (GD is repeatedly described as such) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, rossi2023noninvasivedbsbasedapproaches pages 1-2, dardis2022patientcenteredguidelines pages 1-2).

9.2 Epidemiology (key recent/reviewed statistics)

Estimates vary across sources and populations: - General population incidence reported as ~1/40,000–1/60,000 (review) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2) and GD1 incidence ~1/40,000–1/86,000 in non-Jewish populations (review) (rossi2023noninvasivedbsbasedapproaches pages 1-2). - In Ashkenazi Jews, incidence reported as ~1/450–1,000 live births (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2) and also ~1 in 850 in one registry-based review excerpt (zimran2025evaluationoflysogb1 pages 1-2). - Reported overall incidence range: 0.4–5.8 per 100,000 births and prevalence 0.7–1.8 per 100,000 (review) (rossi2023noninvasivedbsbasedapproaches pages 1-2).

9.3 Newborn screening (2024 data)

A 2024 Shanghai cohort screened 50,108 newborns for 6 LSDs by MS/MS on DBS and confirmed 2 Gaucher diagnoses among 27 total LSD diagnoses; the combined 6-LSD birth prevalence was 1 in 1,856 live births, with 11.1% early-onset and 88.9% later-onset/subclinical forms among confirmed LSDs (chang2024newbornscreeningfor pages 1-2). This supports real-world feasibility of large-scale screening but Gaucher-specific precision is limited by the small number of Gaucher cases in this combined assay (chang2024newbornscreeningfor pages 1-2).

10. Diagnostics

10.1 Clinical tests and laboratory confirmation

Core principle (guideline-level): GD diagnosis requires biochemical demonstration of deficient GCase/BGLU activity and confirmatory molecular testing where possible (dardis2022patientcenteredguidelines pages 1-2, dardis2022patientcenteredguidelines pages 8-9).

Gold-standard specimens: peripheral blood leukocytes and/or cultured skin fibroblasts (dardis2022patientcenteredguidelines pages 7-8, dardis2022patientcenteredguidelines pages 8-9).

DBS (dried blood spot): recommended as a first-line screen, but any low activity result must be confirmed in leukocytes/fibroblasts; DBS BGLU testing has low positive predictive value and should not be used alone for diagnosis (dardis2022patientcenteredguidelines pages 7-8, dardis2022patientcenteredguidelines pages 10-12).

Diagnostic enzyme-activity threshold: <15% of normal in leukocyte/fibroblast homogenates is diagnostic (dardis2022patientcenteredguidelines pages 7-8, dardis2022patientcenteredguidelines pages 8-9).

Abstract-supported quote (guideline): Dardis et al. emphasize that “Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder due to the deficient activity of the acid beta-glucosidase (GCase) enzyme, resulting in the progressive lysosomal accumulation of glucosylceramide (GlcCer) and its deacylated derivate, glucosylsphingosine (GlcSph).” (dardis2022patientcenteredguidelines pages 1-2).

10.2 Biomarkers

Lyso‑Gb1 (GlcSph): - Widely characterized as a highly sensitive and specific biomarker for diagnosis and treatment monitoring (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, zimran2025evaluationoflysogb1 pages 1-2). - Treatment decision support: a cohort study found a DBS lyso‑Gb1 cutoff >250 ng/mL was associated with initiation of GD-specific therapy (sensitivity 71%, specificity 87.5%), with treated patients showing higher median lyso‑Gb1 than untreated at diagnosis (dinur2023contributionofglucosylsphingosine pages 6-7). - Treatment monitoring dynamics: - Short-term: average 17% decrease 30 minutes after ERT infusion in 20 patients (dubiela2024longandshortterm pages 1-2). - Longitudinal: real-world registry analysis shows median change −8.6 ng/mL in treated vs +25.0 ng/mL untreated, and +19.5 ng/mL in those stopping treatment (zimran2025evaluationoflysogb1 pages 1-2).

Chitotriosidase: useful but lacks specificity and is confounded by common CHIT1 loss-of-function duplication; guideline notes interpretive complications (dardis2022patientcenteredguidelines pages 4-5, dubiela2024longandshortterm pages 1-2).

10.3 Genetic testing strategy (implementation considerations)

Guideline highlights: - GBA1 testing is complicated by a highly homologous pseudogene and recombinant alleles; some methods miss large deletions/recombinants; enzymatic confirmation is mandatory when variants of uncertain significance occur (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 9-10). - If GD phenotype/biochemistry but no GBA1 variants: consider PSAP/saposin C deficiency (dardis2022patientcenteredguidelines pages 10-12).

11. Outcome / Prognosis

The retrieved excerpts do not provide modern, quantitative survival curves stratified by treatment era. They do note that ERT/SRT improved visceral/hematologic disease (especially GD1), while neuronopathic manifestations remain largely unresponsive to standard systemic therapies (kulkarni2024advancementsinviral pages 10-12, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).

12. Treatment

12.1 Standard disease-specific therapy (real-world implementation)

Enzyme replacement therapy (ERT): long-established cornerstone, generally effective for visceral and hematologic manifestations in GD1, but limited for neurologic disease (blood–brain barrier) (kulkarni2024advancementsinviral pages 10-12, giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2). - A review excerpt reports typical dosing 15–120 units/kg every 2 weeks, with most clinical/lab/radiologic improvements within ~6 months (except irreversible skeletal disease) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2).

Substrate reduction therapy (SRT): improves visceral/hematologic manifestations and is used in adults with GD1; does not address CNS disease adequately (kulkarni2024advancementsinviral pages 10-12).

12.2 Biomarker-informed management

Lyso‑Gb1 is increasingly used to guide treatment decisions and monitor therapy response, including identifying when treatment may be indicated among mildly affected patients and detecting response after starting or stopping ERT (dinur2023contributionofglucosylsphingosine pages 6-7, zimran2025evaluationoflysogb1 pages 1-2).

12.3 Emerging/advanced therapeutics (2023–2024 prioritized)

Rationale: current ERT/SRT do not cross the blood–brain barrier and do not improve neuronopathic manifestations, motivating gene therapy strategies (kulkarni2024advancementsinviral pages 10-12).

AAV liver-directed gene therapy (GD1)

FLT201 (GALILEO-1; NCT05324943): Phase 1, completed; single IV infusion of replication-incompetent ssAAV; n=6 adults with GD1; primary outcome TEAEs through Week 38 (ClinicalTrials.gov) (NCT05324943 chunk 1).
FLT201 (GALILEO-3; NCT07223944): Phase 3, recruiting; single IV infusion; n=45 planned; evaluates stable hemoglobin at Week 52 after discontinuation of ERT/SRT (ClinicalTrials.gov) (NCT07223944 chunk 1).

AAV systemic gene therapy targeting peripheral disease (GD/GD1)

LY3884961 / PR001 (PROCEED; NCT05487599): Phase 1/2, recruiting; single IV dose; outcomes include safety, spleen volume, platelets, GCase levels, GlcSph levels, and ability to discontinue/reinitiate ERT/SRT (ClinicalTrials.gov) (NCT05487599 chunk 1).

CNS-directed gene therapy for neuronopathic GD2

VGN-R08b (NCT06272149): Early Phase 1, recruiting; AAV9-human GBA1 delivered intracerebroventricularly in infants ≤24 months; endpoints include safety and survival at 24 months, plus GCase activity and Lyso‑GL1 in blood/CSF (ClinicalTrials.gov) (NCT06272149 chunk 1).

Ex vivo autologous HSC lentiviral gene therapy

AVR‑RD‑02 (Guard1; NCT04145037): Phase 1/2, terminated voluntarily (not for safety/medical reasons). Product is autologous CD34+ HSCs modified ex vivo by lentiviral vector encoding codon-optimized GCase, with busulfan conditioning (ClinicalTrials.gov) (NCT04145037 chunk 1).

Visual evidence note: Kulkarni et al. 2024 summarize multiple current clinical trials and identifiers in a dedicated section; the retrieved cropped images support these program listings (kulkarni2024advancementsinviral media cabb2850, kulkarni2024advancementsinviral media 3ff0cbdf).

12.4 Suggested MAXO terms (examples)

Enzyme replacement therapy
Substrate reduction therapy
Gene therapy
Hematopoietic stem cell transplantation / autologous HSC gene therapy

13. Prevention

13.1 Primary prevention

Not applicable in the classic sense for a Mendelian recessive disorder, but reproductive and carrier-screening strategies are relevant.

13.2 Secondary prevention (early detection)

Newborn screening: MS/MS-based screening with confirmatory biochemical/genetic testing can identify affected newborns, including later-onset forms; 2024 Shanghai data demonstrate implementation at scale (chang2024newbornscreeningfor pages 1-2).

13.3 Genetic counseling

The laboratory guideline emphasizes genetic testing as the most reliable method to identify carriers and recommends pre/post-test genetic counseling (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 9-10).

14. Other Species / Natural Disease

No naturally occurring veterinary Gaucher disease evidence was identified in the retrieved excerpts.

15. Model Organisms

Mechanistic and therapeutic-development work relies heavily on mouse models of GD, including modifier models and neuronopathic models. A 2024 mechanistic study used genetically engineered mouse models combining PGRN deficiency with graded Gba1 D409V dosages to demonstrate threshold-like effects on severity, neuroinflammation, lysosome-autophagy dysfunction, and α‑synuclein accumulation (lin2024intrinsiclinkbetween pages 1-2).

Recent developments (2023–2024 emphasis) and real-world applications (high-yield highlights)

Biomarker maturation into clinical decision support: A 2023 cohort study proposed DBS lyso‑Gb1 >250 ng/mL as associated with initiation of GD-specific therapy among newly diagnosed patients, with ROC-derived 71% sensitivity / 87.5% specificity, while cautioning about inter-laboratory variability (dinur2023contributionofglucosylsphingosine pages 6-7).
Real-world monitoring feasibility: Registry analysis using DBS lyso‑Gb1 showed treatment initiation or withdrawal produced directionally consistent biomarker changes in hundreds of adults, supporting routine monitoring in practice (zimran2025evaluationoflysogb1 pages 1-2).
Population-scale screening implementation (2024): Shanghai MS/MS NBS screened >50k newborns and confirmed 2 Gaucher diagnoses within a 6-LSD panel, while highlighting that most confirmed LSD cases were later-onset/subclinical forms, informing counseling/management (chang2024newbornscreeningfor pages 1-2).
Acceleration of gene therapy pipelines: A 2024 gene-therapy review documents multiple ongoing AAV and lentiviral programs and emphasizes the central limitation of standard therapies for neuronopathic disease due to blood–brain barrier constraints (kulkarni2024advancementsinviral pages 10-12, kulkarni2024advancementsinviral media cabb2850).

Evidence summary table

Topic	Key findings	Evidence type	Source (first author, year, journal or registry)	Publication date	URL	PMID	Notes
Diagnostics / genetics	International Working Group guideline: fluorometric leukocyte/fibroblast GCase assay is gold standard; DBS may be used first-line for screening but must be confirmed in leukocytes or fibroblasts; enzyme activity <15% of normal in leukocyte/fibroblast homogenates is diagnostic; >400 pathogenic GBA1 variants reported in abstract/background and 540 variants (403 GD-associated) noted in guideline text; GBA1 testing is complicated by a highly homologous pseudogene and recombinant alleles; ~10% of patients may carry large deletions/recombinant alleles; two diagnostic algorithms provided (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 9-10, dardis2022patientcenteredguidelines pages 1-2, dardis2022patientcenteredguidelines pages 7-8)	Guideline	Dardis, 2022, Orphanet Journal of Rare Diseases	Dec 2022	https://doi.org/10.1186/s13023-022-02573-6	not in retrieved text	Important limitation: DBS BGLU has poor positive predictive value and cannot stand alone for diagnosis; variants should be ACMG-classified; consider PSAP/saposin C deficiency if phenotype/biochemistry fit but GBA1 is negative (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 10-12)
Biomarkers / epidemiology / treatment	Lyso-Gb1 review: GD incidence estimated ~1/450–1,000 live births in Ashkenazi Jews, ~1/40,000–60,000 in general population; North-East Italy newborn-screening estimate 1/16,063; ERT typically 15–120 U/kg every 2 weeks; lyso-Gb1 described as the most promising biomarker with higher sensitivity/specificity than chitotriosidase (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2)	Review	Giuffrida, 2023, Orphanet Journal of Rare Diseases	Feb 2023	https://doi.org/10.1186/s13023-023-02623-7	not in retrieved text	Narrative review; stresses biomarker utility but exact cross-lab cutoffs vary (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2)
Biomarkers / treatment decision	Retrospective cohort of 97 newly diagnosed patients: 65 started GD-specific therapy; median lyso-Gb1 337 ng/mL in treated vs 153.5 ng/mL in untreated; proposed DBS cutoff >250 ng/mL associated with treatment initiation with 71% sensitivity and 87.5% specificity (dinur2023contributionofglucosylsphingosine pages 6-7)	Cohort study	Dinur, 2023, International Journal of Molecular Sciences	Feb 2023	https://doi.org/10.3390/ijms24043945	not in retrieved text	Authors caution that inter-laboratory methodology/units prevent direct universal adoption of this exact cutoff (dinur2023contributionofglucosylsphingosine pages 6-7)
Diagnostics / epidemiology / newborn screening	DBS-centered review/case-based report: incidence 0.4–5.8 per 100,000 births, prevalence 0.7–1.8 per 100,000; GD1 about 90% of cases; GD1 incidence in non-Jewish populations ~1/40,000–1/86,000, GD2 ~1/150,000, GD3 ~1/200,000; tissue glycolipids may rise 20–100×; illustrates first- and second-tier DBS workflow with low GCase and elevated lyso-Gb1 followed by molecular confirmation (rossi2023noninvasivedbsbasedapproaches pages 1-2)	Review / case-based diagnostic report	Rossi, 2023, Biomedicines	Sep 2023	https://doi.org/10.3390/biomedicines11102672	not in retrieved text	Useful for NBS-style workflows; not a population screening program outcome paper for GD alone (rossi2023noninvasivedbsbasedapproaches pages 1-2, rossi2023noninvasivedbsbasedapproaches pages 10-11)
Biomarkers / treatment monitoring	Eight-year ERT biomarker dynamics: GD1 coefficient of variation 34% vs GD3 23% (p=0.0003); in short-term testing, lyso-Gb1 fell by 17% within 30 min post-ERT (p<0.0001) in 20 patients; prior data summarized in paper show lyso-Gb1 can fall from median ~200 ng/mL pre-ERT to <50 ng/mL after ERT (dubiela2024longandshortterm pages 1-2)	Observational biomarker study	Dubiela, 2024, Biomolecules	Jul 2024	https://doi.org/10.3390/biom14070842	not in retrieved text	Highlights substantial intra-individual/inter-infusion variability; DBS timing relative to infusion matters (dubiela2024longandshortterm pages 1-2)
Newborn screening / epidemiology	Shanghai cohort of 50,108 newborns screened for 6 LSDs by MS/MS on DBS: 353 screened positive; 27 confirmed LSDs (1 in 1,856 live births overall), including 2 Gaucher cases; among all LSD diagnoses, 3/27 (11.1%) early-onset and 24/27 (88.9%) later-onset/subclinical forms (chang2024newbornscreeningfor pages 1-2)	Cohort newborn-screening study	Chang, 2024, JAMA Network Open	May 13, 2024	https://doi.org/10.1001/jamanetworkopen.2024.10754	not in retrieved text	Combined 6-LSD study, so Gaucher-specific prevalence estimate is based on only 2 cases; still highly relevant for real-world NBS implementation (chang2024newbornscreeningfor pages 1-2)
Biomarkers / registry / treatment outcomes	Gaucher Outcome Survey real-world study: of 2,007 registry participants, 435 met inclusion criteria; median lyso-Gb1 change from baseline to last assessment: −8.6 ng/mL in treated, +25.0 ng/mL untreated, +19.5 ng/mL after stopping treatment; treatment-naive had −120.5 ng/mL vs previously treated −3.3 ng/mL; velaglucerase alfa subgroup −32.6 ng/mL (zimran2025evaluationoflysogb1 pages 1-2)	Registry study	Zimran, 2025, Orphanet Journal of Rare Diseases	Jan 2025	https://doi.org/10.1186/s13023-024-03444-y	not in retrieved text	Strong real-world support for lyso-Gb1 as a treatment-response biomarker using DBS; observational, not randomized (zimran2025evaluationoflysogb1 pages 1-2)
Gene therapy / GD1	GALILEO-1 first-in-human study of FLT201: NCT05324943; Phase 1, open-label, single-group; 6 adults with GD1; single intravenous dose of a replication-incompetent ssAAV vector; primary outcome was treatment-emergent adverse events through Week 38; eligibility required stable ERT/SRT for at least 2 years and deficient GCase activity ≤30% of normal at diagnosis (NCT05324943 chunk 1, kulkarni2024advancementsinviral media cabb2850)	Clinical trial record	ClinicalTrials.gov / Spur Therapeutics, NCT05324943	First posted Apr 13, 2022; completed Dec 4, 2024	https://clinicaltrials.gov/study/NCT05324943	not in retrieved text	Focused on safety/tolerability plus GCase augmentation; excludes splenectomy and anti-AAVS3 neutralizing antibodies (NCT05324943 chunk 1)
Gene therapy / GD1 confirmatory study	GALILEO-3 confirmatory FLT201 study: NCT07223944; Phase 3, non-randomized, single-group; estimated 45 adults with GD1 on stable ERT/SRT ≥2 years; single intravenous ssAAV FLT201 infusion; primary endpoint: proportion with stable hemoglobin (decrease no more than 1.5 g/dL) at Week 52 after discontinuing ERT/SRT (NCT07223944 chunk 1)	Clinical trial record	ClinicalTrials.gov / Spur Therapeutics, NCT07223944	First posted Nov 3, 2025; recruiting as of Apr 21, 2026	https://clinicaltrials.gov/study/NCT07223944	not in retrieved text	Outside 2022–2025 publication window but highly relevant as latest implementation trajectory; MeSH term listed as Gaucher Disease D005776 in record (NCT07223944 chunk 1)
Gene therapy / GD peripheral disease	PROCEED: NCT05487599 of LY3884961 (PR001); Phase 1/2, multicenter, open-label, dose-finding; estimated 15 adults; single intravenous dose of replication-incompetent recombinant AAV; outcomes include AEs, spleen volume, platelet count, GCase, GlcSph, and time to discontinuation/re-initiation of ERT/SRT over 5 years (NCT05487599 chunk 1)	Clinical trial record	ClinicalTrials.gov / Prevail Therapeutics, NCT05487599	First posted Aug 4, 2022; recruiting as of Apr 15, 2026	https://clinicaltrials.gov/study/NCT05487599	not in retrieved text	Requires centrally confirmed bi-allelic GBA1 variants and stable therapy; anti-AAV9 antibody titer must be ≤1:40 (NCT05487599 chunk 1)
Gene therapy / ex vivo HSC lentiviral	Guard1: NCT04145037 of AVR-RD-02; Phase 1/2, multinational open-label study; actual enrollment 8; intervention is autologous CD34+ HSCs genetically modified ex vivo with lentiviral vector encoding codon-optimized GCase, with busulfan conditioning; follow-up 52 weeks; sponsor states termination was voluntary and not based on safety or medical reasons (NCT04145037 chunk 1)	Clinical trial record	ClinicalTrials.gov / AVROBIO, NCT04145037	First posted Oct 30, 2019; results posted Jan 18, 2024	https://clinicaltrials.gov/study/NCT04145037	not in retrieved text	Important proof-of-concept for cell-based gene therapy; small sample, early termination limits efficacy interpretation (NCT04145037 chunk 1)
Gene therapy / neuronopathic GD2	VGN-R08b exploratory trial: NCT06272149; Early Phase 1, single-center, open-label, dose-climbing/expansion; estimated 6 infants ≤24 months with GD2; AAV9-human GBA1 delivered by intracerebroventricular injection; primary endpoint AEs/SAEs at Week 52; secondary endpoints include survival at 24 months, GCase activity, GC, and Lyso-GL1 in blood and CSF, plus immunogenicity (NCT06272149 chunk 1)	Clinical trial record	ClinicalTrials.gov / Xinhua Hospital, NCT06272149	First posted Feb 22, 2024	https://clinicaltrials.gov/study/NCT06272149	not in retrieved text	Especially relevant for CNS-targeted therapy where ERT/SRT have limited neurologic benefit; excludes anti-AAV9 neutralizing antibody titer >1:5 (NCT06272149 chunk 1)

Table: This table compiles recent high-yield evidence items for Gaucher disease across diagnostics, biomarkers, epidemiology, newborn screening, and emerging gene therapy. It is structured for direct use in a disease knowledge base and emphasizes quantitative thresholds, trial metadata, and implementation caveats.

Limitations of this report (due to retrieved-source constraints)

ICD‑10/ICD‑11 and Orphanet identifiers were not explicitly present in the retrieved full text excerpts/trial records, and therefore were not asserted.
PMIDs were not provided in the retrieved text chunks for several items (especially MDPI journals and ClinicalTrials.gov records); thus, PMID fields are marked “not in retrieved text” in the summary table.
Some requested elements (e.g., standardized QoL statistics, comprehensive differential diagnosis lists, and detailed epigenetic profiling) require additional targeted retrieval beyond the current evidence set.

References

(carubbi2026glucosylsphingosine(lysogb1)an pages 1-2): Francesca Carubbi, Silvia Linari, and Marco Spada. Glucosylsphingosine (lyso-gb1): an update on its use as a biomarker in gaucher disease. International Journal of Molecular Sciences, 27:1705, Feb 2026. URL: https://doi.org/10.3390/ijms27041705, doi:10.3390/ijms27041705. This article has 2 citations.
(giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2): Gaetano Giuffrida, Uros Markovic, Annalisa Condorelli, Valeria Calafiore, Daniela Nicolosi, Marianna Calagna, Stephanie Grasso, Marco Tindaro Valentino Ragusa, Jennifer Gentile, and Mariasanta Napolitano. Glucosylsphingosine (lyso-gb1) as a reliable biomarker in gaucher disease: a narrative review. Orphanet Journal of Rare Diseases, Feb 2023. URL: https://doi.org/10.1186/s13023-023-02623-7, doi:10.1186/s13023-023-02623-7. This article has 58 citations and is from a peer-reviewed journal.
(rossi2023noninvasivedbsbasedapproaches pages 1-2): Claudia Rossi, Rossella Ferrante, Silvia Valentinuzzi, Mirco Zucchelli, Carlotta Buccolini, Sara Di Rado, Daniela Trotta, Liborio Stuppia, Luca Federici, and Maurizio Aricò. Noninvasive dbs-based approaches to assist clinical diagnosis and treatment monitoring of gaucher disease. Biomedicines, 11:2672, Sep 2023. URL: https://doi.org/10.3390/biomedicines11102672, doi:10.3390/biomedicines11102672. This article has 12 citations.
(dardis2022patientcenteredguidelines pages 1-2): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(cojbasicUnknownyeardiagnosisandmanagement pages 5-8): I Ćojbašić. Diagnosis and management of gaucher disease: current approaches and emerging. Unknown journal, Unknown year.
(NCT07223944 chunk 1): A Gaucher Disease Gene Therapy Trial With FLT201. Spur Therapeutics. 2026. ClinicalTrials.gov Identifier: NCT07223944
(NCT05324943 chunk 1): A Gene Therapy Study in Patients With Gaucher Disease Type 1. Spur Therapeutics. 2022. ClinicalTrials.gov Identifier: NCT05324943
(chang2024newbornscreeningfor pages 1-2): Siyu Chang, Xia Zhan, Yuchao Liu, Huanlei Song, Zizhen Gong, Lianshu Han, Gustavo H. B. Maegawa, Xuefan Gu, and Huiwen Zhang. Newborn screening for 6 lysosomal storage disorders in china. JAMA Network Open, 7:e2410754, May 2024. URL: https://doi.org/10.1001/jamanetworkopen.2024.10754, doi:10.1001/jamanetworkopen.2024.10754. This article has 21 citations and is from a peer-reviewed journal.
(dardis2022patientcenteredguidelines pages 8-9): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(zimran2025evaluationoflysogb1 pages 1-2): Ari Zimran, Shoshana Revel-Vilk, Tama Dinur, Majdolen Istaiti, Jaco Botha, Elena Lukina, Pilar Giraldo, Patrick Deegan, and Stephan vom Dahl. Evaluation of lyso-gb1 as a biomarker for gaucher disease treatment outcomes using data from the gaucher outcome survey. Orphanet Journal of Rare Diseases, Jan 2025. URL: https://doi.org/10.1186/s13023-024-03444-y, doi:10.1186/s13023-024-03444-y. This article has 9 citations and is from a peer-reviewed journal.
(lin2024intrinsiclinkbetween pages 1-2): Yi Lin, Xiangli Zhao, Benjamin Liou, Venette Fannin, Wujuan Zhang, Kenneth D R Setchell, Xiaohong Wang, Dao Pan, Gregory A Grabowski, Chuan-ju Liu, and Ying Sun. Intrinsic link between pgrn and gba1 d409v mutation dosage in potentiating gaucher disease. Human molecular genetics, 33:1771-1788, Aug 2024. URL: https://doi.org/10.1093/hmg/ddae113, doi:10.1093/hmg/ddae113. This article has 6 citations and is from a domain leading peer-reviewed journal.
(dubiela2024longandshortterm pages 1-2): Pawel Dubiela, Paulina Szymanska-Rozek, Piotr Hasinski, Patryk Lipinski, Grazina Kleinotiene, Dorota Giersz, and Anna Tylki-Szymanska. Long- and short-term glucosphingosine (lyso-gb1) dynamics in gaucher patients undergoing enzyme replacement therapy. Biomolecules, 14:842, Jul 2024. URL: https://doi.org/10.3390/biom14070842, doi:10.3390/biom14070842. This article has 5 citations.
(dardis2022patientcenteredguidelines pages 10-12): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(dardis2022patientcenteredguidelines pages 9-10): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(saith2024concurrentgeneticdisorders pages 1-3): Armaan Saith, Jiapeng Ruan, Noor Ul Ain, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Concurrent genetic disorders in gaucher disease: insights into complex phenotypes, genetic modifiers, and targeted therapies. Unknown journal, Dec 2024. URL: https://doi.org/10.20944/preprints202412.1836.v1, doi:10.20944/preprints202412.1836.v1.
(saith2025precisiongenomicprofiling pages 1-2): Armaan Saith, Noor Ul Ain, Jiapeng Ruan, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Precision genomic profiling in gaucher disease: insights from atypical presentations. Frontiers in Genetics, Nov 2025. URL: https://doi.org/10.3389/fgene.2025.1553036, doi:10.3389/fgene.2025.1553036. This article has 0 citations and is from a peer-reviewed journal.
(kulkarni2024advancementsinviral pages 10-12): Akhil Kulkarni, Tiffany Chen, Ellen Sidransky, and Tae-Un Han. Advancements in viral gene therapy for gaucher disease. Genes, 15:364, Mar 2024. URL: https://doi.org/10.3390/genes15030364, doi:10.3390/genes15030364. This article has 16 citations.
(saith2024concurrentgeneticdisorders pages 3-5): Armaan Saith, Jiapeng Ruan, Noor Ul Ain, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Concurrent genetic disorders in gaucher disease: insights into complex phenotypes, genetic modifiers, and targeted therapies. Unknown journal, Dec 2024. URL: https://doi.org/10.20944/preprints202412.1836.v1, doi:10.20944/preprints202412.1836.v1.
(saith2024concurrentgeneticdisorders pages 11-13): Armaan Saith, Jiapeng Ruan, Noor Ul Ain, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Concurrent genetic disorders in gaucher disease: insights into complex phenotypes, genetic modifiers, and targeted therapies. Unknown journal, Dec 2024. URL: https://doi.org/10.20944/preprints202412.1836.v1, doi:10.20944/preprints202412.1836.v1.
(NCT06272149 chunk 1): An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. 2023. ClinicalTrials.gov Identifier: NCT06272149
(dardis2022patientcenteredguidelines pages 7-8): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(dinur2023contributionofglucosylsphingosine pages 6-7): Tama Dinur, Peter Bauer, Christian Beetz, Claudia Cozma, Michal Becker-Cohen, Majdolen Istaiti, Arndt Rolfs, Volha Skrahina, Ari Zimran, and Shoshana Revel-Vilk. Contribution of glucosylsphingosine (lyso-gb1) to treatment decisions in patients with gaucher disease. International Journal of Molecular Sciences, 24:3945, Feb 2023. URL: https://doi.org/10.3390/ijms24043945, doi:10.3390/ijms24043945. This article has 16 citations.
(dardis2022patientcenteredguidelines pages 4-5): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.
(NCT05487599 chunk 1): A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED). Prevail Therapeutics. 2022. ClinicalTrials.gov Identifier: NCT05487599
(NCT04145037 chunk 1): Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease. AVROBIO. 2019. ClinicalTrials.gov Identifier: NCT04145037
(kulkarni2024advancementsinviral media cabb2850): Akhil Kulkarni, Tiffany Chen, Ellen Sidransky, and Tae-Un Han. Advancements in viral gene therapy for gaucher disease. Genes, 15:364, Mar 2024. URL: https://doi.org/10.3390/genes15030364, doi:10.3390/genes15030364. This article has 16 citations.
(kulkarni2024advancementsinviral media 3ff0cbdf): Akhil Kulkarni, Tiffany Chen, Ellen Sidransky, and Tae-Un Han. Advancements in viral gene therapy for gaucher disease. Genes, 15:364, Mar 2024. URL: https://doi.org/10.3390/genes15030364, doi:10.3390/genes15030364. This article has 16 citations.
(rossi2023noninvasivedbsbasedapproaches pages 10-11): Claudia Rossi, Rossella Ferrante, Silvia Valentinuzzi, Mirco Zucchelli, Carlotta Buccolini, Sara Di Rado, Daniela Trotta, Liborio Stuppia, Luca Federici, and Maurizio Aricò. Noninvasive dbs-based approaches to assist clinical diagnosis and treatment monitoring of gaucher disease. Biomedicines, 11:2672, Sep 2023. URL: https://doi.org/10.3390/biomedicines11102672, doi:10.3390/biomedicines11102672. This article has 12 citations.

Ask OpenScientist

OpenScientist Report

Classifications

Definitions

Inheritance

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

External Assertions

Medical Actions

Biochemical Markers

Diagnosis

Progression

Prevalence

Differential Diagnoses

Related Datasets

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 Concise overview

1.2 Key identifiers and controlled vocabulary

1.3 Common synonyms / alternative names (as used in retrieved sources)

1.4 Evidence provenance (patient vs aggregated)

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core phenotype spectrum (with approximate frequencies where available)

3.2 Phenotype characteristics

3.3 Quality-of-life impact

3.4 Suggested HPO terms (examples)

4. Genetic / Molecular Information

4.1 Causal genes

4.2 Pathogenic variant spectrum and genotype–phenotype examples

4.3 Modifier genes and “multi-locus” contributions (recent work)

4.4 Epigenetics / chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Causal chain (current understanding)

6.2 Molecular pathways / cellular processes (from retrieved mechanistic sources)

6.3 Suggested ontology terms

7. Anatomical Structures Affected

7.1 Organ level (commonly affected)

7.2 Tissue/cell level

7.3 Subcellular level

7.4 Suggested UBERON terms (examples)

8. Temporal Development

9. Inheritance and Population

9.1 Inheritance pattern

9.2 Epidemiology (key recent/reviewed statistics)

9.3 Newborn screening (2024 data)

10. Diagnostics

10.1 Clinical tests and laboratory confirmation

10.2 Biomarkers

10.3 Genetic testing strategy (implementation considerations)

11. Outcome / Prognosis

12. Treatment

12.1 Standard disease-specific therapy (real-world implementation)

12.2 Biomarker-informed management

12.3 Emerging/advanced therapeutics (2023–2024 prioritized)

AAV liver-directed gene therapy (GD1)

AAV systemic gene therapy targeting peripheral disease (GD/GD1)

CNS-directed gene therapy for neuronopathic GD2

Ex vivo autologous HSC lentiviral gene therapy

12.4 Suggested MAXO terms (examples)

13. Prevention

13.1 Primary prevention

13.2 Secondary prevention (early detection)

13.3 Genetic counseling